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ABSTRACT 
The outcome of an infection is often determined by the qualitative nature of the immune 
response generated against the infectious agent. Various intracellular pathogens, 
including those that cause leprosy, tuberculosis, leishmaniasis, and most probably malaria 
and AIDS appear to require a predominant cell-mediated, Th1, response for effective 
containment, whereas the generation of a mixed Th1/Th2 or predominantly Th2 response 
is associated with progressive disease. Therefore, any attempt to develop universally 
efficacious vaccination against these pathogens must generate an immunological imprint 
that ensures a strong and stable cell-mediated response upon natural infection with the 
relevant pathogen. We report here critical tests of a strategy designed to achieve such an 
imprint using Bacille-Calmette-Guérin (BCG) vaccine. BCG vaccine is an attenuated 
form of M. bovis, the causative agent of tuberculosis in cattle, and is the most widely 
used vaccine in humans. However, considerable uncertainty still surrounds its efficacy 
against tuberculosis both in man and animals. As the protective dose is not known, BCG 
has been given at the maximum tolerable dose. However, recent studies in mice and other 
animals have shown that the dose of an antigen can be a critical factor in determining the 
type of immune response generated. I tested the general hypothesis that low dose 
vaccination would preferentially induce cell-mediated immune response and generate a 
Th1 imprint that can protect the host against intracellular pathogens in the particular case 
of mycobacteria. To this end, both adult and newborn mice were vaccinated with 
different doses of BCG or saline and cell-mediated and humoral immune responses were 
assessed at different times post-vaccination. Several weeks after vaccination, mice from 
each group were challenged with a dose of BCG that induces a mixed Th1/Th2 response 
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in naïve mice, and the T-cell and antibody responses were assessed using ELISPOT and 
ELISA assays, respectively. The splenic bacterial burden was also determined using 
colony formation on agar plates.  
 
Our results show that the class of immunity induced by BCG depends on the dose 
employed for vaccination, independent of the route of administration and the age and 
strain of mice used. In all cases, lower doses induce an exclusive cell-mediated, Th1, 
response with no antibody production, while higher doses induce either a mixed Th1/Th2 
response or a predominantly Th2, humoral response, with higher titers of both IgG1 and 
IgG2a antibodies. Following intravenous high dose BCG challenge, all mice in the 
vaccinated groups developed a Th1 response associated with a more efficient clearance of 
BCG from the spleen. The greatest clearance of mycobacteria was generated following 
vaccination with lower doses, as low as 33 cfu of BCG. In addition, our findings 
demonstrate that newborn mice are not inherently biased towards generating Th2 
responses, but they can generate Th1 responses and Th1 imprints if appropriate 
vaccination protocols (dose, route and time) are employed. Furthermore, subcutaneous 
exposure of young mice to environmental mycobacteria can induce a mixed Th1/Th2 
response that can abrogate the potential to generate Th1 responses and Th1 imprints upon 
vaccination with low doses of BCG vaccine. Low dose neonatal BCG vaccination can 
circumvent the interference caused by “impingement” of environmental mycobacteria on 
the immune system. Therefore, our observations strongly support a neonatal low dose 
BCG vaccination strategy to provide universally efficacious protection against infections 
by pathogenic mycobacteria. 
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1. General Introduction 
Tuberculosis (TB) has been a major health threat to mankind since prehistoric times. The 
causative agent was isolated and identified more than a century ago, allowing 
tuberculosis to be among the first diseases against which a vaccine was developed. 
Nevertheless, tuberculosis still remains the greatest global cause of human morbidity and 
mortality from a single infectious pathogen. Epidemiological evidence indicates that one 
third of the world’s population is infected with M. tuberculosis; annually, 8-10 million 
people develop clinical disease and of these 2-3 million die (Kaufmann, 2006b). To 
appreciate the enormity of the problem tuberculosis poses to public health, consider that 
an active tuberculosis infection is present in 60 million people at any one time with an 
average of 4 people dying every minute from this disease (Dye et al., 1999).  
 
Tuberculosis is zoonotic, so control of the disease in cattle is important from a public 
health point of view. The economic impact on the cattle industry is an additional concern; 
an estimated 50+ million cattle are infected with M. bovis, resulting in economic losses of 
approximately $3 billion per year due to a reduction in milk production, quality of meat, 
fertility and animal power (Steele, 1995). These facts suggest the urgent need to control 
the disease both in man and animals. However, diagnosis, treatment and control of 
tuberculosis still depends on methods developed between the end of the 19th and middle 
of the 20th century. New cases are still being detected by sputum smear examinations and 
PPD skin tests developed by Robert Koch 125 years ago. These techniques were novel 
and a break-through in the effort to control tuberculosis when developed; however, their 
sensitivity is very poor, detecting only 50% of infected individuals. Differentiating 
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pathogenic from environmental mycobacteria based on these diagnostic tests is also 
difficult. Control of the disease also depends on a 90-year-old vaccine, the Bacille-
Calmette-Guérin (BCG), developed by Albert Calmette and Camille Guérin at the 
Pasteur Institute, France. Similar to the detection techniques, this vaccine was a great 
achievement in its time, but its efficacy remains controversial. 
 
Fortunately, the causative agent of tuberculosis, M. tuberculosis, is sensitive to 
antibiotics. Drugs developed in the 1940s and 1950s can effectively cure the disease. 
Nevertheless, compliance is poor due to the cumbersome and the long lasting nature of 
the treatment regimen that discourages some patients from taking the prescription drugs 
continuously for a year. The high rate of defaulters during this treatment leads to the 
emergence of drug resistant strains of the bacilli. Multi drug resistant (MDR) strains of 
M. tuberculosis that do not respond to first-line drugs (rifampin and isoniazid) have been 
reported from several countries (see section 2.4). What is more worrisome is the 
emergence of extensive drug resistant (XDR) strains that are resistant to both first-line 
and second-line anti-mycobacterial drugs. Several countries are reporting the occurrence 
of these XDR strains of M. tuberculosis among their TB patients, which is further 
complicating the problem, particularly in countries where co-infection with HIV is 
prevalent, resulting in an almost 100% case fatality rate (Gandhi et al., 2006). 
Unfortunately, we find ourselves today in the same position as Koch and others were 
more than 100 years ago as far as control of tuberculosis is concerned. We are trying to 
fight a disease that is threatening to escalate out of control with century-old tools. 
Therefore, much greater effort and investment in terms of knowledge and finance are 
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required in order to respond effectively. Rapid, highly sensitive and specific diagnostic 
techniques, as well as improvements in the efficacy of BCG vaccine or development of a 
new and universally efficacious tuberculosis vaccine, are urgently needed.  
 
Research on tuberculosis slowed during the mid 20th century, largely due to a sharp 
decrease of new cases in developed countries, which practically made tuberculosis a 
disease of the poor. Due to this fact, it seems that very few had interest to work on the 
disease. Without mentioning the pharmaceutical companies, where profit is the driving 
force for research and development, the amount of money spent on tuberculosis research 
by major funding organization was very little, compared to other major infectious 
diseases. For example, the National Institute of Health (NIH) spent 20-fold less money on 
tuberculosis research than on HIV in the late 1990s, even though both diseases claim the 
lives of 2-3 million people every year (Check, 2007). Recently, however, major funding 
organizations, including the Bill and Melinda Gates Foundation, the Rockefeller 
Foundation and the NIH, are transforming TB research as it provides a unique 
opportunity to exploit accumulated knowledge on basic immunology and biology of the 
pathogen (Kaufmann and Parida, 2007). This knowledge may help in developing new, 
fast and efficient diagnostic tools as well as in pinpointing the “tricks” the bacterium uses 
to avoid generating an effective immune response. Clear understanding of the bacterial 
mechanisms used to evade the host’s immune response will aid the development of new 
drugs and vaccines or improve the efficacy of BCG as a vaccine.  
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In any attempt to improve the efficacy of BCG as a vaccine or develop a new one, it is 
imperative to appreciate the general principles of vaccination. Vaccines are administered 
to activate natural and protective immunity to a subsequent infection in order to protect 
the host from the infectious pathogen. Most commercially available vaccines ensure the 
rapid generation of high levels of antibodies upon subsequent infection by the pathogen. 
These antibodies are effective in controlling the growth of extracellular bacteria and 
viruses as well as neutralizing some bacterial toxins. The immunological principle 
underlying successful vaccination in these cases is the ability of the vaccine to increase 
the magnitude and speed of the protective antibody response during natural infections. 
This increase in magnitude and speed of the generated immune response favors the 
vaccinated individual in the race between the multiplication of the infectious agent 
leading to pathology and disease, and containment of the pathogen by host immunity. 
Unfortunately, this strategy does not seem to work against intracellular pathogens that 
induce chronic infections such as tuberculosis, leprosy, leishmaniasis and others. This 
may suggest that the magnitude and speed of the immune response generated following 
infections with chronic intracellular pathogens may not be the only critical factors, but 
the qualitative nature of the immune response generated is also important in the fight 
against intracellular pathogens that cause chronic diseases. The qualitative nature of the 
protective immune response against M. tuberculosis can be elucidated by careful analysis 
of the response generated by healthy contacts, individuals who are able to contain the 
pathogen, and sick individuals who develop progressive disease following natural 
exposure to virulent strains of M. tuberculosis. Such identification is necessary to provide 
a rational basis for vaccine design. 
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M. tuberculosis infects more than 100 million people every year, but only 5-10% of those 
infected develop disease. The remaining, more than 90%, are individuals able to control 
infection, though not able to clear it completely, and remain latently infected for the rest 
of their life (Kaufmann, 2006b). These individuals with latent tuberculosis are commonly 
known as healthy contacts and demonstrate a protective, Th1, type of immune response. 
The key for developing a new vaccine or improving the BCG vaccine, therefore, lies in 
determining the immunological correlates of protection in the healthy contacts and how 
to ensure the generation of such a response through vaccination. In line with this, clinical 
observations show that chronic intracellular infections, including tuberculosis, are best 
contained by an exclusive or predominant cell-mediated, Th1, response. Thus, in addition 
to the speed and magnitude of the immune response, the Th1/Th2 nature of the response 
generated against these chronic pathogens is important in ensuring protection. Therefore, 
vaccination against these chronic infections must generate a Th1 response and Th1 
imprint that can guarantee the generation of an effective cell-mediated response during 
natural infection by the respective pathogens. Having a good understanding of what a 
protective immune response constitutes, the next step will be to look for a means of 
vaccination that can ensure the generation of such a response. Previous results from our 
laboratory in the murine leishmaniasis model have shown that infection with a low dose 
of L. major parasite induces a predominantly cell-mediated, Th1, response that can 
guarantee protection of the prototype “susceptible” BALB/c mice from a challenge dose 
that induces progressive disease in naïve mice (Bretscher et al., 1992). Our laboratory has 
also reported that the Th1/Th2 nature of the BCG specific immune response in adult 
BALB/c mice is dependent on the dose of BCG used for vaccination (Power et al., 1998): 
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lower doses induce Th1 type responses; whereas higher doses induce mixed Th1/Th2 
responses. As BCG is usually administered neonatlly in humans, it is important to 
determine if this dose dependence also works in newborn mice. Besides, it will be 
important to examine if this dose dependence of Th1/Th2 phenotype of the immune 
response also holds true in different strains of mice as well as for different routes of BCG 
administration. The principles of Th1 imprinting and the cellular mechanisms associated 
with it are discussed in detail in section 2.9.  
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2. Literature Review 
The overall purpose of this section is to explain the scientific findings and considerations 
that led to the hypothesis I attempted to test in my thesis. The aim of my study was to test 
critical features of a vaccination strategy designed to be effective in a genetically 
heterogeneous population against intracellular pathogens that cause chronic diseases. 
These diseases include leprosy, tuberculosis, leishmaniasis and AIDS. However, due to 
my personal history, I am particularly interested in strategies to prevent/cure tuberculosis, 
which is the leading cause of human morbidity and mortality from a single infectious 
pathogen. I feel that the potential significance of my work can be best appreciated by 
examining tuberculosis as a public heath problem, so I have attempted to provide a broad 
setting to examine tuberculosis as a public health threat since prehistoric times, and to 
assess the current global burden as well as the socio-economic impact of the disease. This 
section will also cover a review of the current literature on the pathogen, pathogenesis of 
the disease and the host response to the bacilli. The merits and limitations of the control 
measures used in the past to combat the scourge of tuberculosis will also be discussed. In 
view of this, I will propose possible interventions methods, vaccination and 
immunotherapy, that can help in the effort to prevent/cure natural infection with the 
pathogen that causes tuberculosis. I will also discuss the scientific basis for the proposed 
objectives of this study. 
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2.1. History of Tuberculosis 
Tuberculosis was the first infectious disease to be recognized in the history of man. 
Several recorded documents, including the bible, provide a description of a disease that 
resembles tuberculosis. “The Lord will strike you with consumption, with fever, with 
inflammation and with severe burning heat” (Deuteronomy, 28:22). These descriptions 
are more or less identical to the cardinal signs and symptoms of tuberculosis as we define 
tuberculosis today. The word consumption or phthisis in Greek has been used by several 
writers since the time of Hippocrates to indicate the wasting nature of the disease, 
reviewed in (Daniel, 1997). However, the use of written historical documents as evidence 
of tuberculosis is problematic as the symptoms of tuberculosis can easily be confused 
with these of other diseases. Therefore, more reliable evidence of tuberculosis in 
prehistoric times has been obtained from archeological findings. The most compelling 
evidence has been obtained from bones: a mummy of a five year old girl who died 3000 
years ago in Egypt (Zimmerman, 1979), and a 10 year old boy from Peru (Allison et al., 
1973). In both cases, the archeologists were able to microscopically detect the acid-fast 
bacilli in bone samples, confirming tuberculosis in man. However, other reports have 
shown the occurrence of the M. tuberculosis complex group in animals as early as 17,000 
years ago (Rothschild et al., 2001). These findings in animals led to the proposal that 
tuberculosis first occurred in animals as M. bovis and began to infect humans when 
settlements in villages and domestication of animals for farming began several thousand 
years ago. These circumstances are thought to have led to selective adaptation of the 
mycobacteria to human hosts and evolution of the bovine tubercle bacilli into M. 
tuberculosis. However, this view has been challenged by reports that indicate the 
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existence of human tuberculosis long before domestication of animals (Kapur et al., 
1994). Furthermore, analysis of the genomic structure of the bacilli indicates that the 
human specific bacilli, M. tuberculosis, did not evolve from M. bovis (Brosch et al., 
2002). Although one of the oldest known infectious diseases in the history of man, 
tuberculosis remained very rare due to the scattered living conditions of man in ancient 
times. Epidemiological studies indicate that tuberculosis requires a social network of at 
least 180 to 440 persons living in close proximity to become endemic in a community 
(McGrath, 1988). This observation helps to explain why the disease was not a prominent 
public health problem until the first tuberculosis epidemics in Europe, which overlapped 
with the industrial revolution. This historical period saw the development of cities, 
creating perfect conditions for the person-to-person transmission of the bacteria. During 
this time, outbreaks of tuberculosis –“the great white plague”– occurred in the large cities 
of Europe. Almost every European was infected with the bacilli, and one in four deaths 
was due to tuberculosis infection (Bloom and Murray, 1992). In North America, 
outbreaks of tuberculosis that occurred in the 18th century were associated with the 
migration of Europeans into the United States and Canada. Tuberculosis became a public 
health problem in Asia and sub-Saharan Africa in the 19th and 20th centuries, respectively, 
following colonization of the continents by European settlers (Daniel et al., 1994). 
 
2.2. Epidemiology and Global Burden of Tuberculosis 
Even though tuberculosis has affected man since antiquity, the occurrence of outbreaks is 
associated with urbanization and crowding of people in cities that create a perfect 
condition for the person-to-person transmission of the pathogen. An epidemic of 
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tuberculosis in a community follows a predictable pattern: it first attacks the most 
vulnerable (susceptible) members of the society, particularly children, and reaches its 
peak after several years. Infected individuals develop disease and susceptible individuals 
die, leaving the most resistant individuals, who develop protective immunity, to live and 
transfer their genetic material to the next generation. When the pool of susceptible 
individuals is reduced within a community, either due to herd immunity or death, the 
epidemic starts to decline until a new pool of susceptible individuals emerges in the 
community and another wave of disease can occur. In between outbreaks, tuberculosis 
may remain endemic in the area affecting only a few individuals who become susceptible 
for various reasons including age (young or old), concurrent diseases, and malnutrition. 
Tuberculosis is a chronic disease, so patients live several years between infection, disease 
and then death or recovery. Therefore, the time course between epidemics of tuberculosis 
is very long, counted in centuries, in contrast to other more acute infectious diseases, 
which may occur every few years (Grigg, 1958). Defining some epidemiological terms at 
this point will help the reader to understand the words in the right context as the terms are 
going to be used frequently in this section of the thesis. Incidence is defined as number of 
new cases in a population over a given period of time. Prevalence refers to a total number 
of cases in a population at given point in time. Mortality rate refers to the number of 
deaths due to a given disease in a population at risk during a given period of time, while 
case fatality rate refers to the ratio of the number of deaths caused by a given disease to 
the number of diagnosed cases of that disease. These rates are expressed per 100,000 
persons per year in all TB monitoring and control guidelines published by the World 
Heath Organization (WHO). Thus, I will follow a similar way of expression whenever I 
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use these terms. An additional two terms worth mentioning here include: Risk of infection 
that refers to the probability of an individual being infected in a given period of time, and 
case detection rate calculated as the ratio of new smear positive cases to the total number 
of expected new cases estimated for that country in a given year. These two terms are 
usually expressed as percentages. WHO has different formulas to calculate each of these 
rates depending on the nature of the data available.  
 
Epidemics of tuberculosis in Europe reached their peak in the 17th century with an 
incidence rate of around 1000 cases /100,000 persons/year. Almost one fifth of all deaths 
in London were due to tuberculosis, which led the writers of the time to describe 
tuberculosis as the “Captain of all these men of death”, reviewed in (Daniel, 1997). 
Tuberculosis was spread to all corners of the world as a result of emigration of 
Europeans. Tuberculosis epidemics reached their peak in North America in the 19th 
century, resulting in around 1600 deaths /100,000 persons per year (Dutt and Stead, 
1999). The epidemic of tuberculosis is likely reaching its peak in Latin America today, 
and is in an early phase in Africa and Asia. The disease has been in a sharp decline in the 
western world with annual risk of infection dropping from 12% in 1901 to 1.9% in 1950 
(Vynnycky and Fine, 1997). However, in the late 1980s the incidence of tuberculosis 
started to increase at an alarming rate globally, which forced the World Health 
Organization to declare tuberculosis to be a “global emergency” in 1993 in an attempt to 
heighten political and public awareness about the gravity of the disease (Glynn, 1998). 
For example, tuberculosis cases in the United States started to increase in the mid 1980s; 
and around 52,000 excess cases were reported between 1986 and 1992 when compared to 
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the number of anticipated cases based on the previous trend (CDC, 1993). According to 
the WHO annual report, 8.8 million new cases (140 cases/100,000 persons) were reported 
globally in 2005, resulting in an estimated 1.7 million deaths in the same year (WHO, 
2005). In the years 2000-2020, another 200 million people are expected to develop 
tuberculosis, of which 35 million are expected to die. These numbers clearly show the 
public health catastrophe that tuberculosis is expected to cause in the foreseeable future. 
Tuberculosis is a burden not only on public health, but also on the socioeconomics of a 
society, as it affects individuals between the age of 15 to 45 years at the peak of their 
productivity (Dye et al., 1999). South East Asia has the highest number of cases every 
year; however, the per capita incidence is highest in African countries reporting 259-272 
cases per 100,000 individuals every year (Corbett et al., 2003). 
 
2.3. Risk Factors Associated with Tuberculosis Infection 
Of those infected with M. tuberculosis, only 5-10% develop clinical disease. The 
remaining 90-95% are believed to mount an effective immune response that limits the 
multiplication of the bacilli and the development of pathology. These facts demonstrate 
that immunological factors and other circumstances can influence the outcome of 
infection and I will briefly discuss some of the main factors, which may play a role in the 
susceptibility/resistant phenotype of the host.  
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2.3.1. Host Genetics 
The average lifetime risk of developing tuberculosis in infected individuals is around 
10%. However, a very much higher risk of developing the disease is reported in some 
individuals among a population existing under similar circumstances (Raviglione et al., 
1995). A higher concordance rate of tuberculosis also exists among monozygotic versus 
dizygotic twins (Kallmann and Reisener, 1943; Comstock, 1978). Furthermore, racial 
differences in susceptibility upon initial infection have been reported in blacks versus 
whites from nursing homes in the USA (Stead et al., 1990), and aboriginals as compared 
to Caucasians in Canada (Hoeppner and Marciniuk, 2000). These observations suggest 
host genes can affect the outcome of tuberculosis infection. Ample experimental evidence 
from mouse studies also supports the role of host genetic factors in controlling 
susceptibility/resistance to several chronic intracellular pathogens, including 
mycobacteria. Resistance to growth of BCG in mice is under the control of a single, 
dominant autosomal gene named Bcg (Gros et al., 1981). The gene was found to be 
identical to genes that control innate resistance to infections with S. typhimurium (Ity) and 
L. donovani (Lsh) and mapped to the mouse chromosome 1 region (Skamene et al., 
1982). The candidate gene was expressed exclusively in macrophages and subsequently 
named Nramp1, for natural resistance associated macrophage protein 1 (Vidal et al., 
1995). However, the role of Nramp1 gene in controlling mouse resistance to infection 
with the virulent strain of M. tuberculosis has not yet been verified experimentally. The 
human homologue of Nramp1 gene, designated NRAMP1, has been also cloned, and 
mapped to chromosome region 2q35 (Cellier et al., 1994). Association of tuberculosis 
infection with the NRAMP1 gene was reported in Aboriginal Canadians (Greenwood et 
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al., 2000) and tuberculosis patients from Gambia (Bellamy et al., 1998), suggesting that 
the NRAMP1 gene may also play a role in immunity against mycobacterial infections in 
man. Furthermore, several studies show the susceptibility/resistance phenotype to 
tuberculosis is a multi-genetic trait controlled by several genes both within and outside 
the MHC region (Bellamy, 2003).  
 
Despite variations between studies on the particular alleles involved, depending on the 
route and dose of infection, the virulence of the bacilli used, as well as the different 
evaluation criterion used to characterize disease, there is good evidence from mouse 
studies that MHC genes influence the susceptibility/resistance phenotype to tuberculosis. 
For example, Brett and colleagues have reported that H-2k mice died faster and had more 
bacteria in their lung than H-2b mice on both B10 and BALB backgrounds (Brett et al., 
1992). Similarly, studies on H-2 congenic mouse strains have shown that H-2k haplotype 
was able to confer susceptibility on a resistant mouse strain (Medina and North, 1998). In 
all cases, resistance to infection was associated with high level of M. tuberculosis 
antigen-specific IFN-γ production and better DTH expression, suggesting the importance 
of a Th1-type response to resistance. Even though it is hard to find direct evidence for 
how MHC genes play a role in determining the Th1/Th2 nature of an immune response 
against a given antigen, one can speculate on possible mechanisms, based on the fact that 
a combination of antigen dose and number of antigen specific CD4+ T-cells present in 
unprimed animal is believed, at least by some individuals in the field, to determine the 
Th1/Th2 nature of the immune response generated (Bretscher, 1974). More antigen-
mediated CD4+ T-cell interactions are required to generate a response with a substantial 
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Th2 component than to generate a predominant Th1 response (see section 2.9 for details). 
In order to properly explain how MHC genes may play a role in determining the Th1/Th2 
nature of the immune response, and thus resistance/susceptibility to M. tuberculosis 
infection, one must make some assumptions as to what leads to resistance/susceptibility 
phenotype. One view I favor is that susceptibility to M. tuberculosis infection can be 
either due to too weak Th1 response or to a response with a significant Th2 component. If 
susceptibility is due to too weak Th1 response, then we assume that susceptibility is a 
recessive phenotype, as very weak peptide-MHC interaction in all the alleles is required 
for the susceptibility phenotype to be expressed. On the other hand, susceptibility due to a 
response with a significant Th2 component indicates the dominant nature of the 
phenotype, as strong interaction of peptides with one or few alleles within the MHC can 
determine susceptibility regardless of the type of interaction that occurs with the 
remaining alleles. For this discussion, we will assume that susceptibility is due to a 
response with a significant Th2 component and is of a dominant phenotype. It is also a 
well-accepted fact that MHC molecules of different haplotypes differ in their ability to 
bind a given peptide. Therefore, peptides from M. tuberculosis proteins could be well 
presented by H-2 alleles from some mouse strains, and hence favor a response with a 
significant Th2 component, which will make them to be susceptible to M. tuberculosis 
infections. On the other hand, M. tuberculosis derived peptides may not be well presented 
by H-2 alleles from the resistant mouse strains that lead to the induction of Th1 cells as a 
result of weak interaction between cooperating CD4+ T-cells. Another possible 
mechanism as to how MHC genes can determine the Th1/Th2 nature of the immune 
response to mycobacteria is that resistant strains can express relatively low levels of 
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MHC-mycobacterial peptide complexes on the surface of their antigen presenting cells, 
thus leading to less CD4-CD4 T-cell interactions that result in Th1 cell activation, as 
opposed to the high MHC-peptide complex expression on the surface of APCs in the 
susceptible mice. Evidence, which supports this hypothesis comes from challenge studies 
in recombinant mouse strains where lack of the I-E molecule, and thus fewer MHC-
peptide complexes on the surface, was reported to increase resistance to M. tuberculosis 
infections (Brett et al., 1992). 
 
The role of MHC on susceptibility/resistant phenotype against M. tuberculosis infection 
has also been reported in humans. An association between alleles on the HLA-DQ locus 
and pulmonary tuberculosis was reported in Mexican patients (Teran-Escandon et al., 
1999). However, the most compelling evidence comes from studies in some Asian 
populations. Results from different studies, compiled by Hill, have all shown that the 
HLA-DR2 allele on one of the three class II loci is a susceptibility allele for tuberculosis 
and leprosy infection, as well as disease progression (Hill, 1998). The same hypothetical 
mechanism described above for mice may also apply to explain the mechanism as to how 
this particular allele could contribute to susceptibility. This allele, which seems to be 
dominant based on the explanation described above, may bind well with peptides derived 
from mycobacterial protein antigens, resulting in a strong CD4-CD4 T-cell co-operation, 
and hence Th2 cell activation. As discussed elsewhere in this thesis, the generation of 
Th2 response following infection with chronic intracellular pathogens is not only 
ineffective, but can also lead to disease progression by counteracting the effect of Th1 
cells. Finally, it is worth mentioning, that the role of MHC genes in the control of 
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immune responses is not only due to their role in antigen presentation and the activation 
of M. tuberculosis specific T-cells, but also due to the fact that many other important 
genes that are involved in the immune response, including genes that encode for 
complement, TNF and major heat shock proteins are mapped into the MHC region 
(Dunham et al., 1987; Sargent et al., 1989). Genes outside the MHC are also reported to 
play a role in M. tuberculosis immunity. In mice, multiple loci on chromosome 1, 3, and 
7 named as Trl-1, Trl-2 and Trl-3, respectively for tuberculosis resistance loci, are 
reported to greatly influence the pathology and replication rate of the bacilli in the lung 
(Kramnik et al., 2000; Mitsos et al., 2000; Mitsos et al., 2003). In man, case control 
studies during an outbreak have identified several other genes, including the Mannose-
binding protein, Vitamin-D receptor, IFN-γ and IL-1 receptor genes, that can contribute 
to risk of developing disease following infection (Marquet and Schurr, 2001). 
 
2.3.2. Socio-economic Factors 
Socio-economic factors also contribute to the risk of developing tuberculosis. 
Urbanization is recognized as having been a major factor for the change of tuberculosis 
from an endemic to an epidemic disease in Europe. Similarly, overcrowding in settlement 
areas is believed to be the main reason for the high incident rate of tuberculosis in 
Canadian Aboriginals in the late 1800s (Hoeppner and Marciniuk, 2000). Poor socio-
economic conditions, including low household income, frequently lead to poor hygienic 
and housing conditions in urban areas and settlements, which will in turn lead to 
overcrowding that creates a perfect condition for the person-to-person transmission of the 
disease. Deterioration of health care systems due to economic crises in member states of 
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the former Soviet Union is also alleged to be partly responsible for the resurgence of 
tuberculosis in the western world (Shilova, 2001). In addition, homelessness, drug abuse, 
alcoholism and malnutrition are factors that can facilitate the progression of infection into 
clinical disease (Brudney and Dobkin, 1991). The interaction between malnutrition and 
tuberculosis infection is extensively discussed previously (Macallan, 1999). Reports from 
Latin America and Africa show the association of malnutrition with tuberculosis (Harries 
et al., 1988; Scalcini et al., 1991). However, whether malnutrition predisposes humans to 
tuberculosis or whether malnutrition is the consequence of the disease is not clear. On the 
other hand, sufficient experimental evidence from animals studies exists to show protein 
deficiency or deficiency of single nutrients, mainly vitamins (A, C, D) and minerals (iron 
and zinc) can adversely affect cell-mediated immunity (Chandra, 1997). Therefore, it is 
reasonable to propose that malnutrition can predispose people to tuberculosis as 
tuberculosis is best contained by cell-mediated immunity. In addition to the high chance 
of developing tuberculosis, people under poor socio-economic conditions show a high 
rate of noncompliance during treatment, which may further fuel the scourge of 
tuberculosis due to the emergence of multi-drug resistant bacilli (Mishra et al., 2005).  
 
2.3.3. Concurrent Diseases 
Chronic debilitating diseases such as diabetes mellitus, cancer and immunosuppressive 
therapy may increase the risk of developing active tuberculosis. Presently, however, HIV 
infection is the strongest known risk factor for developing active tuberculosis (Styblo 
1991; Daley et al., 1992). The risk of developing tuberculosis upon infection of healthy 
individuals is 0.1-0.2% per year during their life time, assuming that the average life 
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expectancy is 50 years (Bloom and Murray, 1992; Raviglione et al., 1995), whereas the 
risk for HIV infected individuals is as high as 10% per year, which is close to 100-fold 
higher than the risk in HIV negative individuals (Glynn, 1998; Girardi et al., 2000). 
Therefore, in addition to the poor socio-economic conditions prevailing in developing 
countries, the HIV/AIDS pandemic has greatly influenced the epidemiology of 
tuberculosis in South-East Asia and Sub-Saharan Africa. This has also complicated 
control measures to be employed against tuberculosis in these countries. 
 
2.4. Treatment and Control 
Tuberculosis has been the leading cause of death from infectious causes for centuries, 
with a case fatality rate of 40-60% if untreated (Murray et al., 1990; Bloom and Murray, 
1992). In prehistoric times, priests and traditional healers did not even try to heal their 
patients. Knowing that consumption was incurable, they used to tell their patients “All 
the gods have no mercy on it”, reviewed in (Daniel, 1997). During the medieval period, 
newly crowned kings of England and France were believed to have powers to heal by 
touching those suffering from the disease, which was known at that time as “Kings Evil” 
(Bloom and Murray, 1992). However, Robert Koch was the first to attempt a 
scientifically-based therapy in 1890, when he tried to immunize patients with culture 
filtrates to treat tuberculosis (Burke, 1993). Even though Koch’s culture filtrate was soon 
proven to have no therapeutic value, it was found to be useful for diagnosis. Austrian 
physician Clemens von Pirquet showed the allergic reaction to tuberculin could be used 
to detect individuals who had been exposed to tubercle bacilli, reviewed in (Bothamley 
and Grange, 1991). Koch’s “magic bullet”, now known as purified protein derivative 
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(PPD), is widely used in skin testing both in man and animals to assess delayed-type 
hypersensitivity to mycobacterial antigens.  
 
Despite the absence of modern therapy and control measures, tuberculosis was in sharp 
decline in both Europe and North America during Koch’s era. Many factors probably 
contributed to this, including development of genetic resistance to tuberculosis due to 
selection pressure and improved socio-economic conditions. However, the major 
reduction in the incidence rate is attributed to the introduction of sanatoria and other 
control measures in Europe by Herman Brehmer in the 1850’s and into North America by 
Edward Livingston Trudeau in 1884, reviewed in (Snider, 1997). Furthermore, a real 
hope of eradicating tuberculosis arose with the discovery of antibiotics during the late 
1940’s. Streptomycin was first discovered by Seman Waksman in 1943 and was 
successfully used to cure a 21 year old woman with advanced tuberculosis in 1944 
(Pfuetze et al., 1955). Similarly, the administration of isoniazid showed encouraging 
results when clinical signs of tuberculosis subsided in 44 treated patients (Selikoff et al., 
1952). Since then a combination of different antibiotics has been used to treat 
tuberculosis patients, with a good chance of recovery. Even though antibiotics provided 
good reasons for optimism in the control/eradication of tuberculosis, the regular treatment 
regimen was not able to substantially reduce the global burden of the disease, which led 
the WHO to introduce DOTS (Direct Observed Therapy, Short course). DOTS is an 
intensive short-term treatment of patients with multiple anti-mycobacterial drugs, given 
by or taken in the presence of a health care worker to ensure compliance. The DOTS 
program is encouraging, with a 70-80% cure rate in some countries. Despite the 
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introduction of DOTS, and the availability of effective chemotherapy, M. tuberculosis is 
still the number one killer among all infectious pathogens, accounting for about 7% of all 
deaths. Several factors limit the efficacy of chemotherapy in combating tuberculosis. 
First and foremost is the lack of access to treatment by most of the victims. One study 
estimated only one in five tuberculosis patients has access to treatment facilities 
(Raviglione et al., 1995), possibly due to a lack of financial resources required to access 
treatment or a lack of public health infrastructure required to detect and treat new 
tuberculosis cases. The WHO target of reaching a 70% case-detection rate by 2015 does 
not seem achievable as the rate has already reached a plateau at 40% (Dye et al., 2002). 
Another important stumbling block in the control of tuberculosis is the emergence of 
multi-drug resistant (MDR) strains of M. tuberculosis that do not respond to several first-
line anti mycobacterial drugs. In 2005, more than 10% of new tuberculosis cases globally 
were resistant to more than one drug (Kaufmann, 2006a). This is a very serious problem 
in some eastern European countries. For example, as high as 36.9% of new cases in 
Estonia are resistant to one drug, and 14.1% are resistant to more than one drug. The 
problem is also severe in some Asian countries such as Iran and China (Espinal et al., 
2001). In line with this, it is worth mentioning the emergence of the Beijing strain of 
virulent M. tuberculosis, which has a wide epidemiological distribution particularly in 
Asian countries (van Soolingen et al., 1995). This strain is prone to the development of 
resistance to several antibiotics (Anh et al., 2000; Lan et al., 2003). In addition, a recent 
report from South Africa shows the emergence of M. tuberculosis strains resistant to 
several first-line and second-line anti-mycobacterial drugs. These strains, named as 
extensive drug resistant (XDR), are highly fatal, particularly in HIV+ tuberculosis 
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patients where case fatality rates close to 100% were reported (Gandhi et al., 2006). In 
addition to several other reasons not mentioned here, all these inherent problems of 
chemotherapy suggest that vaccination would be the ideal means to control the disease. 
BCG has been used as a vaccine since 1921 and has greatly contributed to the reduction 
of TB meningitis and miliary tuberculosis in children (Trunz et al., 2006). However, as 
discussed in detail below, its efficacy against pulmonary tuberculosis is still 
controversial. 
 
2.5. Etiology of Tuberculosis 
In Europe, tuberculosis was believed for many centuries to be a hereditary disease. Even 
renowned medical professionals did not accept the idea that tuberculosis was an 
infectious disease until Koch isolated the causative agent and identified it as an infectious 
bacillus. Inspired by the discovery of Jean-Antoine Villemin, who first showed the 
infectious nature of tuberculosis by his experiments with rabbits, Robert Koch tried hard 
to identify the etiology of tuberculosis, reviewed in (Daniel, 1997). He successfully 
isolated the organism in culture and was able to stain and see the organism under the 
microscope. He clearly demonstrated in 1882 that it was a rod shaped bacterium and 
hence named it the “Tubercle Bacillus”.  
 
2.5.1. Classification and Morphology of the Tubercle Bacilli 
Today, microbiologists group the bacillus under the genus mycobacterium, which was 
first introduced by Lehman and Neuman in 1896 (Wayne, 1984). The genus typically 
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represents slightly curved rods of about 1-10 μm length and 0.2-0.6 μm width and 
includes a number of pathogenic, opportunistically pathogenic and saprophytic species. 
Some of the classic species of mycobacteria that cause disease in man and animals 
include M. tuberculosis, M. bovis, M. leprae, M. paratuberculosis and M. avium. 
Mycobacteria in general are classified into two broad groups: rapid growers which form 
visible colonies in less than 7 days, and slow growers that require more than 7 days, 
usually weeks, to form visible colonies on solid media. The causative agents of 
tuberculosis in man and animals are slow growers and are grouped under the 
Mycobacterium tuberculosis complex group. This group includes the human pathogens 
M. tuberculosis and M. africanum (native to Africa); the cattle pathogen M. bovis, 
including BCG; and the vole bacillus M. microti. Even though humans are naturally 
susceptible to tuberculosis resulting from infections by the human pathogens and to some 
extent by the bovine type described above, other species of mycobacteria such as the M. 
avium complex (M. avium, M. intracellulare, M. scrofulaceum, and M. asiaticum) can 
also cause tuberculosis in immunocompromised individuals.  
 
The bacilli have high concentrations of lipids in the cell wall, which is around 20-40% of 
the dry weight of the bacillus; due to this, some 30% of the bacterial genome is devoted 
to lipid synthesis and metabolism (Cole et al., 1998). The waxy cell wall is composed of 
mycolic acids, glycolipids, peptidoglycans and several other proteins, lipids and 
carbohydrates. These waxy components of the cell wall are thought to be in part 
responsible for the resistance of the bacilli to host defenses, to inhospitable chemical and 
physical environments, as well as to regular bacterial staining techniques (Russell 2001). 
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The bacilli look violet after gram staining and are grouped as gram-positive rods. 
However, they are better seen after Ziehl-Neelsen staining, which utilizes basic fuchsin 
that binds to the acidic groups on the unsaturated mycolic acid chains within the bacterial 
cell wall. Steaming the carbol fuchsin for a few minutes enhances penetration of the dye 
into the lipid cell wall. Once basic fuchsin has combined with the acid groups in the cell 
wall, the dye complex is stable and very resistant to de-colorization using mineral acids 
(HCl in 95% ethanol), hence the term 'acid-alcohol-fast' is used to describe the bacilli 
(Jenkins et al., 1985).  
 
2.5.2. Growth and Culture Characteristics of Mycobacteria 
The genus mycobacteria in general and the Mycobacterium tuberculosis complex group 
in particular are very difficult to grow in ordinary culture media. They need a special 
medium enriched with serum albumin, glycerol and several other nutrients and trace 
elements. The most commonly used media are either the whole egg-based (Löwenstein-
Jensen and Stone Brink’s) medium or agar-based medium such as the modified 
middlebrook 7H11. Mycobacteria can also grow in a liquid medium such as the 
middlebrook 7H9 broth, which is egg and agar free but enriched with glycerol, albumin 
and trace elements. Glycerol may suppress the growth of M. bovis and probably BCG, 
which are found to grow better in the presence of pyruvate instead of glycerol (Grange, 
1990). Mycobacteria, classified under the Mycobacterium tuberculosis complex group, 
grow very slow in vitro with a generation time of around 18-24 hours. Visible colonies 
from clinical specimens are produced after several weeks of incubation. The slow growth 
of mycobacteria is mainly due to the hydrophobic nature of the cell wall. As a result of 
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the hydrophobic nature of the cell wall, the bacteria clump together and become less 
permeable to nutritious products into the cell (Wayne, 1984). Addition of the surfactant 
Tween 80 to cultures of mycobacteria wets the surface and leads to dispersal of the 
clumps and more rapid growth of the bacilli. Tubercle bacilli are obligate aerobes but 
growth is optimal in a humidified incubator in the presence of 5-10% CO2. The optimal 
growth temperature is 37oC except for the avian type, M. avium, which needs a 
temperature of 40-42oC. The bacilli are facultative intracellular; however, the causative 
agent of human leprosy, M. leprea, is strictly intracellular and cannot grow in artificial 
media or culture. Attempts to grow and isolate it from mice and guinea pigs for large-
scale studies were not successful due to the low temperature requirements for its optimal 
growth. The nine band Armadillo, which has a lower body temperature than most 
mammals, was found to be the perfect animal model to study the course of the disease in 
susceptible individuals (Kirchheimer, 1975). 
 
2.5.3. Biology of Mycobacteria 
The M. tuberculosis genome comprises 4,411,529 base pairs and contains around 4000 
genes. The majority of these genes are devoted to the production of enzymes and lipids 
involved in the biosynthesis of its cell wall (Cole et al., 1998). Among the thousands of 
proteins encoded by these genes, only 52% can be assigned a function, out of which only 
367 are unique to the virulent M. tuberculosis strain (Camus et al., 2002). Some of these 
genes are believed to play a role in the unique biology of the bacilli that enables it to 
survive in one of the most hostile environments of the host’s body. During unfavorable 
conditions, either as a result of lack of oxygen and nutrition or due to the host’s immune 
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response, the bacilli can enter into dormancy by shutting off the transcription of all genes 
required for growth, while up-regulating several other genes known as the latency genes 
controlled by DosR, the dormancy regulon (Boshoff and Barry, 2005). Then, when the 
environment is suitable for the replication of the bacilli, other genes, which encode for 
resuscitation-promoting factors, are up-regulated. This reactivation of dormant bacilli to 
replicate and infect nearby macrophages can lead to reactivation disease (Cohen-Gonsaud 
et al., 2005). Understanding the biology of mycobacteria during the dormant as well as 
the active replicating stages is important for identifying proteins dominant in each stage, 
and this in turn may help in designing an effective vaccine against the pathogen in each 
stage of the disease. In line with this, a strong immune response to a 16-kDa protein 
antigen, encoded by one of the latency genes is reported in healthy individuals with latent 
tuberculosis as compared to those with active tuberculosis who strongly respond to the 
early secretory 6-kDa protein antigen (Demissie et al., 2006).  
 
2.5.4. Diagnosis and Molecular Typing of Mycobacteria 
Effective control and prevention of tuberculosis depends heavily on accurate diagnosis 
and identification of the pathogen. Due to a lack of reliable new techniques, the diagnosis 
of tuberculosis infection still depends mainly on the 100-year-old techniques of direct 
microscopy, bacterial culture and the tuberculin skin test. Direct microscopic examination 
of clinical specimens is an easy, cheap and rapid method; however, it cannot differentiate 
between the pathogenic and the non-pathogenic species of mycobacteria. Further, the 
sensitivity of direct microscopy is very low, as it requires 10,000 - 50,000 bacilli per ml 
of the sputum sample to give a positive diagnosis (Jenkins et al., 1985). Culture 
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examination of clinical specimens, which can detect very few bacteria in a sample, gives 
a definitive diagnosis of tuberculosis infection, but requires 4-8 weeks for results to reach 
the physician. This may be too late for treatment purposes. The skin test is mainly used in 
cattle, but again the specificity is very low, as it cannot differentiate between pathogenic 
and non-pathogenic species as well as between infected and BCG vaccinated individuals. 
The recent development of new techniques based on molecular biology have facilitated 
the development of rapid means to detect the bacilli directly from clinical specimens, 
identify the species/strain involved, provide information for the analysis of transmission 
dynamics, and differentiate between exogenous infection and endogenous reactivation of 
tuberculosis.  
 
Polymerase Chain Reaction (PCR) based amplification of mycobacterial DNA helps to 
rapidly detect the pathogen directly in samples both from man (Butcher et al., 1996) and 
animals (Aranaz et al., 1996), but this may not help in identifying the species/strains 
involved. Fingerprinting of mycobacterial DNA was developed and standardized in 1993 
not only to detect but also identify species/strains of mycobacteria involved in 
tuberculosis outbreaks (van Embden et al., 1993). This technique utilizes restriction 
fragment length polymorphism (RFLP) based on the size and number of repetitive DNA 
elements known as insertion sequences (IS) generated following digestion of the genome 
with specific restriction endonucleases. The most commonly used insertion sequence is 
the IS6110. It is present in almost all species of the mycobacterium tuberculosis complex 
group and is known to be absent in other organisms including the non pathogenic 
environmental mycobacteria (van Soolingen et al., 1991). The number of IS6110 copies 
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varies from 0 to 25; the relative number and position of the fragments within the 
chromosome helps to differentiate between different strains/species of mycobacteria. 
However, the use of IS6110 to study the molecular epidemiology of M. bovis in cattle is 
hampered by the fact that the majority of the strains carry only a single copy of IS6110, 
which is usually present at a single chromosomal location (Collins et al., 1993). DNA 
fingerprinting employing the IS6110 or other short repetitive DNA elements as probes 
has been used in the study of global epidemiology and transmission cycles of M. 
tuberculosis (Kiers et al., 1997), as well as in the distinction of exogenous infection and 
endogenous reactivation of tuberculosis (Small et al., 1993) in man. This technique, by 
using different genetic markers, is also effectively used to study the molecular 
epidemiology of M. bovis (Romano et al., 1996; Fisanotti et al., 1998), to trace the source 
of infection in cattle herds (Perumaalla et al., 1996), as well as in the study of the 
epidemiology and zoonotic importance of M. bovis in man and animals (van Soolingen et 
al., 1994). A serious limitation of DNA fingerprinting is the requirement for culture to 
generate sufficient bacteria for DNA extraction. Weeks if not months may pass before the 
result is available in the clinic to identify species/strains involved for treatment purposes 
and to know whether the bacilli are sensitive to available antibiotics. Recently, several 
other improved molecular techniques, such as spoligotyping and DNA microarrays have 
been developed that can simultaneously detect and type members of the M. tuberculosis 
complex group. Such techniques can be used to differentiate M. bovis from M. 
tuberculosis infections (Kamerbeek et al., 1997), as well as to identify multi-drug 
resistant strains of M. tuberculosis (Dahle et al., 2003). Spoligotyping has been also used 
to detect trans-species transmission of M. bovis in wild and domestic animals (Aranaz et 
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al., 1996; Serraino et al., 1999). Spoligotyping is a more rapid, sensitive and reliable 
technique based on PCR amplification of the mycobacterial DNA, which can be directly 
applied to samples without the need for culture of bacteria. It is based on the 
polymorphism of the direct repeat (DR) locus of the mycobacterial DNA that contains 
multiple 36 base pair repeats (DRs) interspersed by non-repetitive unique spacer 
sequences ranging from 35 to 41 base pairs in size. These unique spacer sequences can be 
used for molecular typing of the M. tuberculosis complex group by their in vitro 
hybridization with synthetic spacer oligonucleotides covalently bound onto a nylon 
membrane in parallel lanes (Groenen et al., 1993). The typing is based on the presence or 
absence of the unique spacer sequence in the PCR amplified DNA as assessed by 
hybridization. In addition to this, information obtained from molecular typing of 
mycobacteria is being used in the development of new diagnostic reagents that can help 
to differentiate BCG vaccination from M. tuberculosis infection. Genetic tools are also 
widely used to differentiate the genetically close relatives of M. bovis and the attenuated 
form of this mycobacterium, the BCG vaccine, as well as in the formulation of new anti-
tuberculosis vaccines (Behr et al., 1999). 
 
2.6. Immunity and Immunopathology  
Every year close to 100 million individuals globally are infected with M. tuberculosis, 
but only 5-10% of these develop clinical disease within a couple of years after infection. 
These data suggest that more than 90% of infected individuals can generate an immune 
response that can contain but may not eliminate the pathogen (Flynn and Chan, 2001; 
North and Jung, 2004). Due to this non-sterile immunity, those individuals are believed to 
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be latently infected and are at risk of developing reactivation disease later in their life 
(Boshoff and Barry, 2005). Moreover, the disease in susceptible individuals is mainly due 
to damage caused by the immune response generated against the bacilli rather than by the 
bacilli itself. Following infection with mycobacteria, the susceptible host may respond 
with a protective type of response to contain the replication of the pathogen. However, as 
the mounted Th1-type response is too little to completely inhibit the multiplication of the 
pathogen, the bacterial population grows progressively and overwhelms the antigen 
specific immune response generated. As a result of this increase in bacterial load, the host 
intensifies its Th1-type response to catch-up with the ever-increasing number of bacteria 
resulting in collateral tissue damage. This indicates that the same immune response 
involved in protection against tuberculosis could also be responsible for the pathology 
associated with M. tuberculosis infection. This appreciation has led to the use of the 
common term “double-edge sword” to describe the immune response generated against 
tuberculosis. Recently, another population of T-cells, the Th17 cells, is reported to play a 
role in the immunopathology of M. tuberculosis infection. Th17 cells produce a pro-
inflammatory cytokine, IL-17, which play a role in the pathogenesis of various infectious, 
autoimmune and inflammatory disease (discussed briefly in section 6.1). As pathology 
during tuberculosis is mainly due to a profound inflammation, Th17 cells and the 
proiflammatory cytokine IL-17 may have previousely unappreciated role in TB 
associated immunopathology. Thus, understanding the pathogenesis of the disease and 
the nature of the immune responses generated against the bacilli both in the resistant and 
susceptible individuals will be critical in developing universally efficacious vaccination 
that can stimulate the generation of protective immunity without inducing pathology. 
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2.6.1. Pathogenesis of Tuberculosis  
Mycobacteria can gain entry to the host body via different routes mainly through 
inhalation as well as oral infection due to ingestion of contaminated food and water. 
Following access to the host body the bacteria establish primary infection at the site of 
entry. Pathogenesis and development of pathological lesions following infection with the 
virulent strains of M. tuberculosis have been discussed in detail in various textbooks and 
review articles. Thus, I will discuss briefly the pathogenesis of tuberculosis only with 
respect to the development of pulmonary tuberculosis following aerosol infection. 
Infection with M. tuberculosis occurs usually as a result of the inhalation of 1-5 bacilli in 
droplet nuclei derived from expelled air arising from a cough of an infected individual. 
These bacilli will lodge in the lung alveoli and will be ingested by alveolar macrophages. 
The macrophages will try to kill the bacteria before they establish an infection. However, 
as alveolar macrophages usually fail to kill the bacilli, blood monocytes are recruited to 
the site where they differentiate into macrophages and try to fight the bacilli. At this stage 
the bacilli replicate at an exponential rate, and monocytes and other inflammatory cells 
will continue to be recruited and accumulate thereby establishing a primary focus of 
infection. This is a symbiotic stage where the bacilli replicate without severe damage to 
the lung tissue. The primary focus of infection can be in any part of the lung but, for the 
infection to progress into clinical disease, the bacilli have to gain access to the most 
vulnerable part, which is the “apex” or upper part of the lung. This area of the lung 
provides the bacillus suitable conditions for its rapid replication (Balasubramanian et al., 
1994). From the primary focus, the bacilli will reach regional lymph nodes and induce 
adaptive immunity, leading to lymphadenopathy and formation of the primary complex 
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known as Ghon’s complex, first described by Ghon in 1912, reviewed in (Ulrichs and 
Kaufmann, 2006). The formation of this primary complex leads to the generation and 
recruitment of activated antigen-specific T-cells that in turn activate macrophages to kill 
the bacilli and inhibit their growth. The accumulation of T-cells, macrophages and other 
inflammatory cells at the site of infection develops into a characteristic microscopic 
tuberculosis lesion, the “granuloma”, which prevents the spread of the bacilli into other 
organs and localizes the lesion to the site of infection. The granuloma is composed of 
alveolar macrophages, epithelioid cells, and multinucleated giant cells (Langhans cells) 
on the periphery and contains a solid necrotic area at the centre. The necrotic area at the 
center of the granuloma is unfavorable for the replication of the mycobacterium and is 
full of dead or dormant bacilli located either inside or outside macrophages. The 
granuloma is also full of infiltrating lymphocytes (T-cells and B-cells) as well as secreted 
cytokines (Ulrichs and Kaufmann, 2006). During mycobacterial infection, activated 
endothelium in the lung tissue expresses the VCAM-1 addressin instead of MadCAM-1, 
which is commonly expressed on mucosal endothelium. Therefore, the lymphocytes that 
infiltrate the granuloma in the lung are found to express the adhesion molecule α4β1 
integrin instead of the α4β7 integrin present on mucosal lymphocytes (Feng et al., 2000). 
Fibroblasts may also contribute to the formation of the granuloma by forming an 
encapsulating wall around the granuloma periphery. This tissue wall in turn helps to limit 
the spread of the bacilli into surrounding tissue. This process of encapsulation is under 
the control of cytokines, mainly TNF-α secreted by macrophages (Kindler et al., 1989; 
Saunders et al., 2005). In several animal studies, treatment of latent tuberculosis with 
anti-TNF-α antibodies resulted in reactivation of disease. The development of fibrosis 
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around the granuloma and surrounding tissues leads to the formation of macroscopic 
nodules known as tubercles. The lung tubercles are the hallmark of tuberculosis infection 
and are used in the diagnosis of human pulmonary tuberculosis when detected by chest x-
rays. Activated macrophages will kill most bacilli within the granuloma in the majority of 
the infected individuals; the granuloma will then regress and eventually calcify. 
However, a few of the bacilli may remain in a dormant state to be activated later, when 
the immune response of the host is compromised, resulting in reactivation tuberculosis. In 
addition to the persistence of dormant mycobacteria inside macrophages within lung 
lesions, the bacilli may also enter other cells that have a limited antigen-presenting 
ability, such as endothelial cells or fibroblasts, and become dormant. Such bacilli may 
avoid immune surveillance, suggesting a new sanctuary for the bacilli during conditions 
unfavorable for its replication (Cassidy, 2006). This conclusion was supported by the 
detection of mycobacterial DNA in cells other than macrophages in lung tissues of people 
from tuberculosis endemic areas who have died of other diseases, and who have no 
visible lesions of tuberculosis in any organ of their body (Hernandez-Pando et al., 2000). 
In susceptible individuals, the bacilli are not well contained within the granuloma and so 
the granuloma will start to increase in size as well as in cellularity, with caseous lesions 
at the center due to necrosis of cells. At this stage, the granuloma may liquefy and rupture 
leading to cavitations in the lung. Patients with this type of lung are highly infectious and 
characteristically have a persistent cough that produces blood-tinged sputum containing 
numerous bacilli. Rupture of the granuloma also results in spread of the bacilli into other 
organs through blood/lymph, producing small millet-seed like lesions throughout the 
body resulting in “Miliary tuberculosis”, which is fatal if not treated.  
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2.6.2. Protective Immunity to Mycobacterium  
Mycobcateria have numerous protein antigens that are highly immunogenic and able to 
induce both humoral and/or cell mediated immunity (Young et al., 1992). Antibodies 
seem to play no role in protective immunity against mycobacteria even though hard 
evidence is difficult to find. Cell-mediated immunity is widely accepted to be effective 
against chronic intracellular pathogens. To this end, several observations with mice 
(Huygen et al., 1992; Hernandez-Pando et al., 1996; Azouaou et al., 1997) as well as 
comparative studies between tuberculosis patients and healthy contacts in man (Sanchez 
et al., 1994; Surcel et al., 1994; Baliko et al., 1998) support the view that cell-mediated 
immunity dominated with Th1 cytokines, mainly IFN-γ, is effective in controlling 
tuberculosis progression. Even though Th1 cytokines are essential for protection their 
mere presence may not indicate protection, as tuberculosis patients are usually reported to 
have high levels of both Th1 and Th2 cytokines in their blood. This may suggest that the 
protective role of Th1 cytokines can be compromised by the presence of cytokines from 
Th2 cells. Furthermore, the presence of high levels of Th1 cytokines in tuberculosis 
patients may suggest that effective control of M. tuberculosis infection needs more 
effector cells other than the Th1-cells. It is also possible that cytokines from cells other 
than Th2 cells, mainly the regulatory T-cells, participate in down-regulating the role of 
Th1 cells during tuberculosis. Even though the role of Th17 cells in down-regulating Th1 
cells is not clear, IL-17 produced by antigen specific Th17 cells may participate in 
orchestrating the immunopathology during M. tuberculosis infection. In this section, I 
will try to review evidence that show the role of different types of cells and analyze the 
relative importance of each cell type during mycobacteria infection. 
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2.6.2.1. T-cells 
SCID mice, deficient in both B and T-cells, succumb to mycobacterial infections even 
including the “non-virulent” BCG strain (Xing et al., 1998). This observation supports 
the conclusion that T-cells play an important role in protective immunity against 
mycobacterial infections. The obvious reason is that the organism lives inside cells, 
mainly in macrophages, and the immune system can only sense what is inside cells when 
antigens derived from the pathogen are presented on appropriate MHC molecules and 
recognized by T-cells. The bacilli are taken up by the macrophages through the process 
of phagocytosis and processed by the exogenous pathway to be presented to CD4+ T-
cells via class II MHC. This line of reasoning indicates that CD4+ T-cells recognizing 
mycobacterial antigens in the context of self-MHC class II are vital in the immune 
response against tuberculosis. This has been shown in various experiments where 
increased susceptibility to M. tuberculosis as well as to BCG infections was reported in 
CD4-/- or MHC class II-/- mice (Boom, 1996; Mogues et al., 2001). Similarly, depletion of 
CD4+ T-cells prior to infection using monoclonal antibodies leads to increased bacterial 
burden and shortened survival in mice infected with virulent strains of M. tuberculosis 
(Muller et al., 1987). In man, the high susceptibility of HIV/AIDS infected individuals to 
tuberculosis is considered to be also explicable on the basis of an important role for 
CD4+ T-cells in protective immunity against mycobacteria. Different CD4+ Th cells 
have different functions depending on the type of cytokines they produce on stimulation. 
There are two extreme types of CD4+ Th cells, Th1 and Th2, based on the profiles of 
cytokines they secrete. Th1 cells need IL-12 for their induction and produce type one 
cytokines, mainly IL-2 and IFN-γ. Th2 cells require IL-4 for their induction and secrete 
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type 2 cytokine, such as IL-4, IL-5, IL-10 and IL-13 (Mosmann, 1991). Recently there is 
compelling evidence in the literature that the main sources of IL-10 are mycobacteria 
infected macrophages and the Treg cells. The Th1, Th2 cells have also been shown to have 
different functions: Th1 cells and their cytokines help the activation of cells effective in 
controlling intracellular pathogens while the Th2 cells and their cytokines are effective 
against extracellular pathogens, reviewed in (Bretscher et al., 2001). In line with this, 
protective immunity against mycobacteria is considered to be mediated by Th1 as 
opposed to Th2 cells. Disruption of genes that code for type one cytokines, such as IFN-γ 
and IL-12 results in uncontrolled multiplication of mycobacteria in the lung of mice, and 
eventual death (Cooper et al., 1993; Cooper et al., 1997). Similarly, TNF-α receptor 
knockout mice or mice depleted of TNF-α by monoclonal antibody have defects in 
granuloma formation and are extremely susceptible to M. tuberculosis infection (Flynn et 
al., 1995). Furthermore, genetic defect in the IFN-γ receptor (IFN-γR1) gene in man 
results in high susceptibility to M. tuberculosis infection as well as to the normally non-
pathogenic BCG vaccine (Jouanguy et al., 1996). On the other hand, recombinant gamma 
interferon administered via aerosol route together with the same anti-mycobacterial 
drugs, given previously under the regular treatment regimen, was reported to clear M. 
tuberculosis from the lung of patients infected with multi-drug resistant (MDR) bacilli 
(Condos et al., 1997). This is thought to be due to the role of rIFN-γ in stimulating the 
expression of the “signal transducer and activator of transcription” (STAT), and the 
“interferon regulatory factor” (IRF) genes in alveolar macrophages, which in turn induce 
the expression of high levels of pro-inflammatory cytokines in the broncho-alveolar fluid 
of the patients (Condos et al., 2003). From all these data, one can safely suggest that the 
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primary effector function of CD4+ Th1 cells is their secretion of type one cytokines, 
which activate macrophages to kill the bacilli. However, activated CD4+ T-cells can also 
directly kill mycobacteria infected macrophages by cytotoxicity (Boom, 1996). 
Macrophage activation plays a crucial role in combating infections with M. tuberculosis; 
it leads to the up-regulation of expression of MHC-I and MHC-II molecules as well as 
the production of reactive nitrogen and oxygen species that are believed to be responsible 
for the killing of the bacilli within the macrophage. This has been illustrated by the 
inducible nitric oxide synthase (iNOS) knockout mouse, which exhibits increased 
susceptibility to infection with the virulent strain of M. tuberculosis (MacMicking et al., 
1997). 
 
The presence of high levels of IFN-γ in M. tuberculosis infected mice and skin test 
sensitivity of tuberculosis patients, believed to be mediated by Th1 cells, suggest that the 
mere presence of Th1 cells and their cytokines may not protect the host from 
tuberculosis. The inability of Th1 cells and their cytokines to protect against tuberculosis 
in susceptible individuals is believed to be due to the simultaneous generation of Th2 
cells and their cytokines that can counteract the effect of Th1 cells on macrophages. This 
has been substantiated by observations in mice and with human tuberculosis patients 
(Hernandez-Pando et al., 1996; Baliko et al., 1998; van Crevel et al., 2000). In contrast, 
an exclusive Th1 response generated upon M. bovis infection, following low dose BCG 
vaccination, is found to be effective in protecting calves from this M. bovis infection 
(Buddle et al., 1995). The implications of these findings are that vaccination should 
ensure the induction of Th1 cells while suppressing the generation of Th2 cells upon a 
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subsequent mycobacterial infection in order to be effective in controlling progression of 
tuberculosis. This is supported by clinical findings in which healthy contacts in 
tuberculosis endemic areas are found to express high levels of mycobacterial antigen-
specific Th1 cytokines and the IL-4 antagonist IL-4δ2 while producing very few or no 
Th2 cytokines (Demissie et al., 2004). IL-4δ2 is a naturally occurring splice variant of 
human IL-4, which has a similar structure to IL-4 except a deletion of a few amino acids. 
It can bind to the alpha chain of the IL-4R as an antagonist blocking the activity of IL-4 
(Vasiliev et al., 2003). 
 
Another subset of T-cells that may be involved in immunity against tuberculosis infection 
is the CD8+ T-cell population. The role of CD8+ T-cells in protecting the host against 
tuberculosis is unclear, mainly due to conflicting observations from different studies with 
mice, and due to the fact that mycobacterial antigens are primarily processed via the 
exogenous antigen-processing pathway and presented on MHC class II to CD4+ T-cells. 
However, a role for CD8+ T-cells in controlling tuberculosis infection has been shown in 
β2 microglobulin KO (β2 m-/-) mice. These mice lack MHC class I expression on the 
membrane of cells that render them more susceptible to infection due to a lack of CD8+ 
T-cell activity. Following high dose iv infection with virulent M. tuberculosis, the β2 m-/- 
mice show increased bacterial burden in all organs examined and quickly succumb to 
infection (Flynn et al., 1992), suggesting the critical role CD8+ T-cells play during 
infection with virulent strains of M. tuberculosis. The high susceptibility of β2 m-/- mice 
in this experiment could not be totally attributed to lack of CD8+ T-cells, as β2 m-/- mice 
are deficient not only in CD8+ T-cells but also CD1 restricted NKT cells (Bendelac et al., 
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1994). However, the dose and route of infection used in this experiment does not 
resemble natural infection, which is aerosol with 1-5 bacilli. Another study that employed 
low dose M. tuberculosis aerosol infection found that the effect of β2 m-/- is not as 
dramatic as reported previously (Mogues et al., 2001). This study reported that CD8+ T-
cells play a marginal role during immunity against natural infections with virulent strains 
of M. tuberculosis, as the consequence of the absence of CD8+ T-cells was very minimal 
on the survival time of the mice. Furthermore, both the above studies reported that the 
KO mice were not any different than control mice in controlling BCG infection, 
suggesting CD8+ T-cells are not important in controlling the non-virulent strains of 
mycobacteria. This is in agreement with previous studies that reported only a marginal or 
no role for CD8+ T-cells in controlling BCG infections in mice (Pedrazzini et al., 1987; 
Ladel et al., 1995; Xing et al., 1998). This might be due to the inability of the non-
virulent BCG to escape from the phagolysosome into the cytoplasm, which is probably a 
requirement for antigens to be presented to CD8+ T-cells on class I MHC molecule. The 
effector function of activated CD8+ T-cells against the virulent strains of M. tuberculosis 
may depend on their ability to secrete type 1 cytokines, mainly IFN-γ, that can activate 
macrophages to kill the bacteria. However, the main mechanism by which CD8+ T-cells 
can protect against tuberculosis infection is their ability to directly kill infected 
macrophages via two different mechanisms:  
(i) Receptor mediated killing, where the FasL is up regulated on cytotoxic CD8+ T-cells 
(CTL) upon antigen recognition to bind to the Fas molecule, which is constitutively 
expressed on target cells. This mechanism is good at killing the infected cells by 
apoptosis, but reports indicate this may not kill the intracellular pathogen, and may thus 
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contribute to the pathology by further spreading the pathogen if no activated 
macrophages are available to take up and kill the bacilli (Santucci et al., 2000). (ii) 
Exocytosis of granules, whereby CTL cells release their granular contents onto target 
cells to kill both the cell and the pathogen. Perforin is believed to insert itself into the 
surface of the target cell thereby forming a pore or hole on the surface of the infected cell 
through which Granzyme B can gain access to induce cell death by activating a cascade 
of caspases (Cooper et al., 1997). Even though Granzyme B is effective in killing the 
target cell by apoptosis, which may also lead to the killing of the pathogen, this 
mechanism is believed to be less effective in killing mycobacteria due to the high lipid 
content of their cell wall. This cytotoxicity may release viable mycobacteria to the 
extracellular environment, which, as stated above, will be beneficial only if activated 
macrophages are present to take up and kill the released bacilli. Granulysin, another 
protein isolated from the granular content of human CTL cells, interacts very well with 
lipid membranes and can activate lipid-degrading enzymes on the cell wall of the 
bacteria. The release of granulycin by CTL may thus result in the direct killing of 
mycobacteria inside infected macrophage (Stenger 2001).  
 
In summary, a number of studies illustrate that mice depleted of CD4+ T-cells show a 
higher degree of susceptibility than those lacking CD8+ T-cells, suggesting the primary 
role of CD4+ T-cells in tuberculosis immunity. However, depletion of both cells further 
increases susceptibility, indicating that CD8+ T-cells may also play a role in protecting 
against M. tuberculosis infection. On the other hand, the absence of protection in CD4-/- 
mice with intact CD8+ T-cell population might mean that CD4+ T-cells are very 
important for the activation and maintenance of CD8+ T-cells during tuberculosis 
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infection. These observations may suggest a hierarchy that may exist among these T-cells 
in protecting against M. tuberculosis infection, the primary role being played by CD+ T-
cells. However, the relative importance of each cell type may vary depending on the 
tissue involved. For example, CD8+ T-cells must play a great role if the bacilli are inside 
cells that do not express MHC class II molecules such as endothelial cells fibroblasts and 
epithelial cells. How the mycobacterial antigens are processed and how the peptides are 
loaded onto the MHC class I molecule so they can be presented to CTL is yet to be 
determined. Various studies have tried to address this problem (Grotzke and Lewinsohn, 
2005). The most prominent mechanism is referred to as the cytosolic model, according to 
which microbial products from live mycobacteria form pores on the surface of the 
phagosome through which protein and lipid antigens and/or the bacilli escape into the 
cytosol. These proteins or/and bacteria in the cytosol will be processed via the 
endogenous antigen-processing pathway and presented on MHC class I. This is reported 
only from macrophages infected with live and virulent bacilli suggesting that it is 
probably the effect of their virulence factors (Mazzaccaro et al., 1996). On the other 
hand, Schaible and colleagues suggest mycobacteria or their antigens may not penetrate 
the phagosomal membrane to access the cytosolic antigen processing pathway, but rather 
live virulent bacilli induce apoptosis resulting in apoptotic vesicles that contain 
mycobacterial lipid and protein antigens. These apoptotic blebs will be taken up by 
bystander APCs, mainly DC, from the extracellular milieu and will be presented on MHC 
class I and CD1 molecules to CD8+ and CD1 restricted T-cells, respectively, by 
mechanisms that are as yet unclear (Schaible et al., 2003). These contrasting reports 
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suggest the various possibilities by which mycobacterial antigens can be processed and 
presented on MHC class I to activate cytotoxic T-cells.  
 
Unconventional populations of T-cells – the CD1 restricted T-cells and the gamma delta 
(γδ) T-cells – are also believed to have a role in protective immunity against tuberculosis 
(Kaufmann, 2002). The CD1 restricted T-cells are phenotypically CD4+CD8- or double 
negative T-cells bearing the αβ T-cell receptor (Brigl and Brenner 2004), which are most 
probably the NKT cells. The CD1 restricted T-cells recognize glycolipids abundant on 
the cell wall of the bacilli, such as mycolic acid and lipoarabinomannon, in the context of 
the CD1 restriction element. Functionally, they are reported to produce IFN-γ as well as 
to lyse target cells (Stenger, 2001). However, the pertinence of this is not clear, as 
macrophages, the main habitat of the bacilli, are believed to be devoid of CD1 molecules 
on their surface and hence cannot present glycolipid antigens to CD1 restricted T-cells 
(Naeim, 1996; Kaufmann, 2002). The γδ T-cells directly recognize unusual antigenic 
elements of the bacilli, such as phospholipids and heat shock proteins, either in the 
context of CD1 molecule or independent of any restriction element. Due to their ability to 
recognize antigens independent of MHC class I and II molecules, they are believed to be 
less specific as compared to the αβ TCR T-cells (Janis et al., 1989). These lymphocytes 
represent a small proportion of the T-cells in the mouse, on average 5% of those that 
express CD3. In man, most of the γδ T-cells are CD2+, CD4 and CD8 double negative; 
however, some activated γδ T-cells may express CD8 marker (Groh et al., 1989). The γδ 
T-cells are considerably more prominent in cattle, and are CD3+, CD2-, CD4-, CD8-, and 
express a unique 215 kD MW cell surface antigen called WC1 (Clevers et al., 1990; 
  
43 
 
 
 
Machugh et al., 1997). The level of γδ T-cells is higher in peripheral blood from 
tuberculosis healthy contacts and tuberculoid leprosy patients as compared to patients 
with sever pulmonary tuberculosis and lepromatous leprosy (Barnes et al., 1992), leading 
to the suggestion that these cells may play a role during protective immunity. In addition, 
the distribution of γδ T-cells in the body and their early appearance during tuberculosis 
infection in mice (Griffin et al., 1991), in cattle (Pollock et al., 1996; Cassidy et al., 
2001), and in man (Barnes et al., 1992) have led to the conclusion that γδ T-cells may 
play a role as a primary line of defense during mycobacterial infections. The protective 
role of γδ T-cells, as described above for CD1 restricted T-cells, would likely be due to 
their ability to secrete type 1 cytokines that can activate macrophages in response to 
mycobacterial antigens. In addition, CD1 restricted and γδ T-cells can secrete perforin 
and granulysin that can directly kill the bacilli within the macrophages in a way similar to 
that mediated by CD8+ T-cells (Kaufmann, 2002). Activated NK cells that secrete high 
levels of IFN-γ and perforin were also observed to increase in number within the lung in 
the first three weeks of infection, suggesting these cells may be involved in protecting 
against tuberculosis. Despite this, depletion of NK cells had no influence on the 
pulmonary bacterial load, indicating these cells may not be an essential component of the 
protective mechanism (Junqueira-Kipnis et al., 2003).  
 
Another subset of T-cells gaining attention in the recent literature is the regulatory T-cell 
subset. The role of regulatory T-cells in ensuring a fine balance between the host and the 
pathogen, thereby ensuring survival of the pathogen without inducing severe 
immunopathology to the host during chronic infection, is discussed in detail in a recent 
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review article (Belkaid and Rouse, 2005). Briefly, regulatory cells limit the magnitude of 
antigen specific immune responses and result in the failure of the host to clear infections. 
However, the regulatory cells also help to minimize collateral damage of host tissues, 
which would otherwise occur as a result of the strong immune response generated against 
the pathogen. Therefore, the host has to compromise and allow persistent chronic 
infection in order to avoid tissue damage and to maintain protective immunity against re-
infection. In line with this, the level of T-regulatory cells is reported to increase during 
tuberculosis infection. The finding of increased level of CD4+CD25hi T-cells (Ribeiro-
Rodrigues et al., 2006) and the cytokines they secrete, IL-10 and TGF-β (Olobo et al., 
2001) during active tuberculosis infection in man, may suggest that these T-regulatory 
cells inhibit tissue destruction that would be caused by profoundly activated Th1. 
Paradoxically, suppression of Th1 cells by T-regulatory cells that inhibit the destructive 
process that leads to pathology, may allow the pathogen to replicate without check, 
leading to a clinical illness of the host due to a shift on the fine balance in the host-
parasite relationship towards the pathogen. Whether this increase in T-regulatory cells 
during active M. tuberculosis infection is a natural host reaction to a very large 
inflammatory response, or a response to a bacterial product released to evade the 
immunity generated against the mycobacteria, is not yet clear.  
 
Another subset of T-cells recently reported to play a role in immunity and pathogenesis 
of mycobacterial infections is the Th17 cells. These cells produce IL-17 under the 
influence of IL-23 (Harrington et al., 2005). TGFβ in combination with IL-6 is also 
reported to induce the differentiation of IL-17-secreting Th17 cells from naïve CD4+ T-
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cells in mice (Bettelli et al., 2006). Although IL-17 is widely considered to be a product 
of CD4+ Th17 cells, γδ T-cells were the main source of IL-17 during experimental 
infection of mice with virulent M. tuberculosis (Lockhart et al., 2006), as well as BCG 
(Umemura et al., 2007). IL-17 is a pro-inflammatory cytokine that stimulates the 
induction of inflammatory cytokines and chemokines responsible for the recruitment and 
activation of neutrophils, and was reported to play a role in several autoimmune and 
inflammatory diseases, reviewed in (Steinman, 2007). Furthermore, reports from 
infectious mouse model have suggested that Th17 cells may play a role in mediating 
protection against extracellular bacteria and fungi, including Candida albicans (Huang et 
al., 2004), Klebsiella pneumoniae (Happel et al., 2003), and Bordetella pertussis (Higgins 
et al., 2006). On the other hand, the exact role of IL-17 in immunity against intracellular 
pathogens, including M. tuberculosis is not yet clear. However, its pro-inflammatory 
nature suggests that IL-17 may play a role in pathogenesis and lesion development during 
mycobacterial infections. Evidence, which supports this view, comes from mouse 
experimental studies in which IFN-γ deficient mice were reported to have increased 
numbers of IL-17-producing T-cells that induced tissue damage due to a profound 
inflammation following BCG infection (Cruz et al., 2006). The immunopathology was 
not severe in normal mice; furthermore, exogenous IFN-γ was able to reduce the 
frequency of BCG-specific IL-17-producing T-cells in vitro, suggesting that IFN-γ 
counter-regulates the secretion of IL-17 to limit tissue damage during mycobacterial 
infections. In contrast to this, recent studies in mice have shown that IL-17 may play a 
role in early immunity during M. tuberculosis infections by recruiting IFN-γ producing T-
cells into the lung and enhancing granuloma formation, as IL-17 deficient mice were 
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reported to produce less IFN-γ and show impaired granuloma formation (Umemura et al., 
2007). These data suggest that IL-17 may play a protective role during the early phase of 
infection, but can also contribute to the immunopathology during the chronic stage of the 
disease if not counter-regulated by Th1 cells. 
 
2.6.2.2. Macrophages 
It has been repeatedly reported that macrophages activated with IFN-γ and other type 1 
cytokines have anti-mycobacterial activity in vitro (Rook et al., 1986). This anti-
mycobacterial activity is due to the ability of activated macrophages to produce reactive 
oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI) (Ding et al., 
1988). ROI, generated by the transfer of an electron from NADPH to molecular oxygen 
in the presence of NADPH-oxidase, may play a role in controlling the multiplication of 
mycobacteria in macrophages. However, the most potent anti-mycobacterial activity of 
macrophages is their ability to produce RNI, mainly nitric oxide (NO), from L-arginine 
via the action of inducible nitric oxide synthase, iNOS2 (Chan et al., 1995). This has been 
shown experimentally in mice in which deletion of the gene that codes for NOS2 was 
found to be lethal for mice infected with M. tuberculosis (MacMicking et al., 1997), 
while mice unable to produce ROI were only slightly affected in their ability to control 
tuberculosis infection (Cooper et al., 2000). The central role of IFN-γ in the activation of 
macrophages and in the control of infections with M. tuberculosis has been shown in vivo 
both in mouse and human studies. As discussed in section 2.6.2.1, mice with a targeted 
disruption of IFN-γ genes (Cooper et al., 1993; Flynn et al., 1993) as well as human 
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individuals genetically deficient in IFN-γ receptor (Jouanguy et al., 1996; Sasaki et al., 
2002) were found to be highly susceptible to mycobacterial infection including the non-
virulent BCG. 
 
2.6.2.3. Innate Immunity 
Mycobacteria can attach themselves to macrophages for phagocytosis by binding to 
various receptors, including Toll-like receptors on the surface of macrophages. 
Immediately after ingestion by macrophages, the mycobacteria trigger the transcription of 
genes that code for various pro-inflammatory cytokines via the NF-κB pathway (Ragno 
et al., 2001). Engagement of Toll-like receptors, mainly TLR2 and TLR4, on alveolar 
macrophages is believed to be the mechanism by which mycobacteria induce 
transcription of pro-inflammatory cytokines during the early stage of infection. Most 
Toll-like receptors use myeloid differentiation factor 88 (MyD88) as an adaptor molecule 
to activate the NF-κB pathway and act as a bridge between the innate and the adaptive 
immune system. This has been shown experimentally in which MyD88-/- mice failed to 
control M. tuberculosis infection and rapidly succumbed to the disease, as compared to 
control mice, due to failure of both the innate and adaptive immune response  (Scanga et 
al., 2004). On the other hand, there is a recent report, which claims that MyD88 signaling 
is dispensable in generating an acquired immune response to mycobacteria as there were 
equal amounts of activated T-cells and cytokines of the adaptive immune response both 
in Myd88-/- and control mice following infection with virulent M. tuberculosis (Fremond 
et al., 2004). In this case, both the Myd88-/- and control mice were comparable in their 
ability to resist infection. How can one reconcile these contrasting findings? The findings 
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from the later group can be explained by the fact that TLRs may use adaptor molecules 
other than MyD88 to induce signal transduction. For example, TLR4 uses CD14 surface 
protein as a co-receptor to signal via TIRAP/MyD88 or via TIR domain-containing 
adapter inducing interferon beta (TRIF), which is attached to TRIF-related adaptor 
protein (TRAM). TLR3 solely induces signal transduction via TRIF independent of 
MyD88 (Akira and Takeda, 2004). Furthermore, the commonly accepted concept that 
innate immunity is a springboard to orchestrate the adaptive immune response is being 
challenged. Some well-known personalities in the field suggest that innate immunity may 
not be a prerequisite for the generation of antigen specific adaptive immune response. 
There are observations from more recent studies, which support this idea. Immunization 
of MyD88/TRIF double KO mice with protein antigens in the presence of Complete 
Freund’s Adjuvant (CFA) was reported to induce a robust antigen specific, T-cell 
dependent, antibody response in the absence of Toll-like receptor signaling (Gavin et al., 
2006). However, there is ample evidence both from in vitro (Underhill et al., 1999; 
Thoma-Uszynski et al., 2001) and in vivo (Sugawara et al., 2003) experiments that TLR2 
signaling via the MyD88 dependent pathway has an important role in controlling 
mycobacterial infection. On the other hand, the role of TLR4 signaling during 
mycobacterial infection is still controversial, as TLR2-/- mice were found to be more 
susceptible than TLR4-/- mice when exposed to high dose of virulent strains of M. 
tuberculosis under similar conditions (Reiling et al., 2002). In addition, studies with 
C3H/HeJ mice, which have a single amino acid mutation on TLR4 that make them LPS 
hypo-responsive, suggests that TLR4 may not play a significant role in tuberculosis 
immunity, as there was no difference in pathology and immune responses between the 
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TLR4 deficient C3H/HeJ and control mice, of the same background (C3H), following 
aerosol exposure to a low dose of M. tuberculosis (Kamath et al., 2003; Shim et al., 
2003). It is also reported that most mycobacterial cell wall components and culture 
filtrates are agonists of the TLR2 (Underhill et al., 1999), strengthening the notion that 
TLR2 is important for signal transduction during mycobacterial infections. However, 
results from in vitro studies suggest that different mycobacterial components may interact 
with different members of the toll like receptor family and that both TLR2 and TLR4 can 
be used for signaling. In a recent study, it was reported that the HSP65 signals 
exclusively through TLR4 while HSP70 signals through both TLR2 and TLR4 (Bulut et 
al., 2005). Similarly, soluble heat stable factors from virulent M. tuberculosis strains were 
found to induce TLR2 mediated signaling while a heat labile, cell wall associated 
mycobacterial factor, mediates TLR4 dependent signaling (Means et al., 1999; Means et 
al., 2001). In addition, there are reports from in vivo experiments where TLR4-/- 
(C3H/HeJ) mice were found to succumb to the disease earlier than the corresponding 
wild type mice following low dose aerosol infection with virulent M. tuberculosis. These 
experiments show that TLR4 signaling can be involved in protecting against tuberculosis 
in contrast to a previous experiment done under similar conditions, dose and route, of 
infection (Abel et al., 2002; Branger et al., 2004). These contradictory reports show that 
our knowledge regarding the signal transduction mechanisms during M. tuberculosis 
infection is far from sufficient and needs further investigation.  
 
The role of other TLRs, other than TLR2 and TLR4, during immune responses against 
mycobacterial infection does not seem to be clear. As M. tuberculosis is intracellular, 
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TLRs expressed in intracellular organelles may play a role in recognizing mycobacterium 
specific ligands. One such receptor is TLR9, which recognizes un-methylated CpG 
motifs in bacterial and viral DNA, and is known to be localized in the endosomes and 
phogolysosomes of the cell (McCluskie and Krieg, 2006). This implies that 
mycobacteria, rich in CpG and residing in the phogolysosomes, can be easily recognized 
by TLR9 for signal transduction. There is a recent report that supports this hypothesis 
(Bafica et al., 2005). According to this study, TLR9-/- mice displayed defective 
mycobacterial induced IL-12 and IFN-γ response in vivo, and were found to be more 
susceptible than wild type mice to low dose aerosol challenge with M. tuberculosis. 
There was also a decreased production of pro-inflammatory cytokines by macrophages 
and dendritic cells in response to live mycobacteria in vitro. Susceptibility to infection 
was markedly enhanced in TLR2/9-/- (double knockout) mice when compared to TLR2-/- 
or TLR9-/- mice, showing that signaling via TLR9 in cooperation with TLR2 was able to 
induce a better Th1 type response against M. tuberculosis infection in vivo. Another 
intracellular pattern recognition receptor (PRR) that may play a role in immunity against 
intracellular pathogens is the nucleotide-binding oligomerization domain 2 (NOD2) 
receptors. The NOD2 receptor is a cytoplasmic protein that can recognize bacterial 
peptidoglycans from both gram-positive and gram-negative bacteria through interaction 
with muramyl dipeptide (MDP) (Girardin et al., 2003). M. tuberculosis, with a cell wall 
rich in peptidoglycans, makes NOD2 a highly suitable candidate for the recognition of 
mycobacteria inside macrophages. Even though NOD2 is located in the cytosol and not 
inside the phagolysosome, it is possible that mycobacterial antigens escaping into the 
cytosol can be easily recognized by NOD2 for signal transduction. In line with this, there 
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is a recent report from an in vitro study showing that mycobacteria can induce signal 
transduction and transcription of pro-inflammatory cytokines via NOD2. The recognition 
of M. tuberculosis via NOD2 is non-redundant with other TLRs, but synergizes for the 
induction of pro-inflammatory cytokines (Ferwerda et al., 2005).  
 
2.6.2.4. Immune Evasion Mechanisms in Mycobacteria 
There are a lot of review articles in the literature discussing in great detail mechanisms 
utilized by mycobacteria to evade the host immune response and to induce disease. The 
aim of this section is not to discuss all the details of immune evasion mechanisms utilized 
by mycobacteria; however, I will briefly discuss these mechanisms as it might help the 
reader to understand the host-pathogen relationship, particularly in susceptible 
individuals. Mycobacteria live within macrophages, which are believed to be able to kill 
the bacilli if properly activated. To gain entry into host macrophages, mycobacteria use 
various receptors such as the complement receptors, mannose binding receptors, lectin 
binding receptors, Fc receptors, scavenger receptors and Toll-like receptors on the 
surface of macrophages. However, they may use some receptors more frequently than 
others to avoid the activation of macrophages and thereby to ensure their survival within 
the macrophages. To this end, the pathogen looks for “surreptitious entry” to gain access 
to the macrophages by a mechanism that avoids activating the oxidative burst of the host 
cell. Therefore, it is to their advantage if the mycobacteria gain entry via complement 
receptors and/or the mannose binding receptors on the surface of macrophages, which are 
not linked to MyD88. Activation of the NF-κB pathway in the absence of MyD88 is 
believed to induce transcription of Th2 cytokines (IL-4, IL-10, IL-13) that do not 
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activate, but inhibit activation of macrophages against mycobacteria (Doherty and Arditi, 
2004). It is also reported that MyD88-/- mice failed to make antigen specific IgG2a, while 
producing high level of IgG1 and IgE antibodies against the same antigen (Schnare et al., 
2001). Furthermore, MyD88/TRIF double KO mice showed higher levels of IgG1 and 
IgE antibodies in their pre-immune sera as well as in response to antigens administered 
with CFA adjuvant, at least in some time points after vaccination, than IgG2a antibodies 
as compared to wild type mice (Gavin et al., 2006). These observations further strengthen 
the notion that entry of mycobacteria into macrophages via receptors, which are not 
attached to the TLR signaling pathway, may induce a Th2 type response, which is not 
effective in controlling their intracellular replication. Mycobacteria have also developed 
mechanisms to circumvent the host immune response so that they can live in one of the 
most hostile organelles of the activated macrophages. They are able to do this by using 
host molecules to their advantage in addition to proteins and glycolipids of the 
mycobacterium’s cell wall. A host protein molecule known as the tryptophan-aspartate-
containing coat protein (TACO) is recruited by pathogenic bacilli and retained in the 
phagosome thereby inhibiting phagolysosome formation and bacterial killing. This was 
observed in phagosomes containing live bacilli but not by those containing heat killed 
bacilli (Ferrari et al., 1999). Similarly, virulent mycobacteria can inhibit phagolysosome 
fusion by utilizing other host molecules involved in the biosynthesis of molecules 
required for the biogenesis of the phagolysosome (Flynn and Chan, 2003). In addition to 
host molecules, microbial proteins, specifically the mycobacterial protein kinase G, 
pknG, secreted only by pathogenic mycobacteria, are also found to inhibit 
phagolysosome fusion (Nguyen and Pieters, 2005). Glycolipid components of the 
  
53 
 
 
 
mycobacterial cell wall, such as the lipoarabinomanan (LAM) and sulfatides/sulfolipids 
(ST), are also reported to contribute to the immune-evasion mechanisms of mycobacteria, 
either by scavenging the ROI produced during the oxidative burst or by inhibiting the 
generation of the highly lethal RNI compounds (Chan et al., 1989; Chan et al., 1991). 
Moreover, the sulfatides appear to promote the survival of the bacilli within the 
macrophages by inhibiting phagolysosome formation (Zhang et al., 1988). On the other 
hand, LAM can either induce or inhibit activation of macrophages depending on their 
structural configuration. Mannose-capped Lipoglycans (ManLAM) are believed to be 
anti-inflammatory as they suppress production of IL-12 and TNF-α and induce IL-10 
production independent of the TLR2 and MyD88 pathway (Nigou et al., 2001), whereas 
those capped with phosphoinositide residues (PILAM) and uncapped LAM are pro-
inflammatory as they stimulate secretion of type 1 cytokines via a TLR2 dependent NF-
κB pathway (Means et al., 2001). The anti-inflammatory effect of ManLAM is believed 
to be due to their preferential binding to mannose receptors, the lectin-binding receptors 
or other macrophages surface receptors that are not linked to MyD88 and hence do not 
lead to induction of the NF-κB pathway (Nigou et al., 2001; Quesniaux et al., 2004). 
Besides, the 19kDa mycobacterial lipoprotein is reported to have immunosuppressive 
effects as it can interfere with antigen processing, presentation and cytokine secretion as 
well as expression of MHC II by antigen presenting cells (Noss et al., 2001; Flynn and 
Chan, 2003). It is also reported that mycobacteria produce significant amounts of 
ammonia that inhibits acidification of lysosomes, which is a requirement for 
phagolysosome maturation (Armstrong and Hart, 1971; Gordon et al., 1980). The ability 
of virulent strains of mycobacteria to escape from the phagolysosome into the cytoplasm 
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may also help the bacilli to avoid the highly acidic environment of the vesicle (Ladel et 
al., 1995). The mycolic acid of the cell wall can also offer some sort of physical 
protection and helps the bacterium to be resistant to the proteolytic effect of the acidic 
phagolysosome (Glickman et al., 2000). Even though virulent strains of mycobacteria are 
endowed with these all evasion mechanisms, epidemiological data show that 90% of 
individuals infected with M. tuberculosis are able to overcome all these “tricks” by the 
bacteria and contain disease progression. This may suggest that evasion mechanisms are 
phenomenon associated with susceptible individuals. 
 
In summary, all the data discussed in this section suggest to me that a good understanding 
of diseases pathogenesis, the host response to the pathogen, including the type of immune 
response generated in healthy contacts and tuberculosis patients, are the key for the 
development of effective intervention methods. Understanding the role of innate 
immunity in combating the disease in the healthy contacts may also help to reveal the 
role of innate immunity in the overall fight by the host against the pathogen. 
Manipulation of innate immune responses may help to contain/decrease the replication of 
the bacteria during the first few weeks before the host mounts adaptive immunity. This in 
turn may have an effect on the type of adaptive immunity generated by decreasing the 
dose of the bacteria and paving the way for the generation of an effective Th1 type 
response. Similarly, knowledge on how the pathogen dampens the generation of effective 
immunity or/and evades an otherwise effective host response may help in designing 
targets for the development of new drugs, immunotherapy or vaccines, as well as to 
improve the efficacy of the existing one. 
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2.7. Tuberculosis in Laboratory Animals 
Laboratory animals are very important for the study of the host-pathogen relationship 
during tuberculosis infection, including studies aimed at understanding virulence, 
pathogenesis and the significance of the host immune response. It was Villemin, a French 
military surgeon, who first used laboratory animals to prove that tuberculosis is an 
infectious disease, reviewed in (Daniel, 1997). In his study he infected two rabbits with 
an extract from material obtained from lesions of tuberculosis patients and observed the 
rabbits for about four months. The rabbits did not show severe signs of illness, but on 
postmortem, lesions similar to those in the lungs of human patients were found in the 
lung of one rabbit. No lesions could be seen in the second rabbit. This difference might 
have been due to the susceptible and resistant phenotype of the two rabbits to the virulent 
M. tuberculosis infection, as described by Lurie several years later (Lurie et al., 1952). 
The story might well have been different had he infected guinea pigs as discussed later in 
this section. Max Bernard Lurie in the early 1900s performed an extensive study to 
examine the fate of M. bovis and M. tuberculosis in various organs, namely spleen, liver, 
bone marrow, kidney and lung (Lurie, 1928), and the histological lesion the bacilli 
induced in those organs (Lurie, 1932) following low and high dose intravenous injection 
of the these bacteria. One of his remarkable findings from these studies was that rabbits 
are relatively resistant to the human form of tuberculosis and behaved in a similar manner 
upon infection with the less virulent BCG or the virulent M. tuberculosis. Following 
infection with either of these bacilli, the burden of the bacilli increased exponentially in 
the first few weeks, followed by effective control of bacterial growth in all organs, albeit 
at different times after infection. However, Lurie showed the same rabbits to be highly 
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susceptible to the bovine type of tuberculosis, with the development of lesions in the lung 
similar to those seen in human tuberculosis patients. Rabbits infected with M. bovis died 
within a short period of time due to the unabated replication of the bacilli in the lung and 
kidney, despite the ability of the rabbits to control growth of the bacilli in liver, spleen 
and bone marrow. In general, both M. bovis and M. tuberculosis replicate in rabbits 
without hindrance for the first few weeks; then, at about 3-4 weeks post-infection M. 
tuberculosis is destroyed in most organs but merely contained in the lung and kidney. 
However, M. bovis still replicates progressively in the lung and kidney, while it is 
contained in other organs. Another remarkable observation made during this study was 
that, even though rabbits are more susceptible to bovine tuberculosis than to the human 
type of tuberculosis, M. bovis grows at a much slower rate than M. tuberculosis in vivo 
(Lurie, 1928; Lurie, 1932). Lurie was also a pioneer in describing the role of genetics in 
susceptibility/resistance of laboratory animals to tuberculosis infection. He categorized 
rabbits as being of susceptible or resistant phenotype depending on their survival time 
when infected with M. bovis and whether infection resulted in post-mortem lung 
pathology following infection with M. tuberculosis (Lurie et al., 1952). Resistant rabbits 
infected with M. tuberculosis show no signs of tuberculosis lesion in their lung and no 
bacteria were isolated from their organs, as the animals were able to destroy the bacilli in 
all organs, including those in the lung, following the generation of an adaptive immune 
response. In susceptible rabbits, replication of the bacilli is controlled but not completely 
inhibited in the lung and kidney, resulting in a variable degree of pathology in the lung. 
All descriptions of tuberculosis in rabbits refer to the disease model in susceptible rabbits.  
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Another animal extensively used in the study of tuberculosis is the guinea pig. It was 
shown to be highly susceptible to M. tuberculosis infections. The growth of the bacilli, as 
well as the course of the disease, was found to follow the same trend as observed for 
bovine tuberculosis in rabbits. The bacilli replicate exponentially for the first three weeks 
and then remain at a stationary level until the end of the experiment or the death of the 
animal (Smith et al., 1970; Alsaadi and Smith, 1973). The pathology induced in the lung 
of guinea pigs infected with M. tuberculosis, including the histological structure of the 
granuloma, is more or less identical to the lung lesion observed in susceptible human 
tuberculosis patients and rabbits infected with M. bovis (Smith and Wiegeshaus, 1989). 
These observations led to the suggestion that guinea pigs are a good model for 
tuberculosis in man in the same way as rabbits are a good model for bovine tuberculosis. 
However, the disease in susceptible humans and cattle is mainly confined to the lung, 
unlike in guinea pigs and rabbits, which show tuberculosis lesions outside the lung, 
mainly in the spleen of M. tuberculosis infected guinea pigs and in the kidney of M. bovis 
infected rabbits. Similarly, many studies during the 1950s analyzed how the course of the 
disease and the burden of the bacilli varied in various organs of the mouse following 
intravenous infection with virulent strains of M. tuberculosis (Pierce et al., 1953; 
McCune et al., 1956; Sever and Youmans, 1957). More recently, North and colleagues 
have investigated the fate of the bacilli and the course of the disease in mice following 
infection with 105 cfu given intravenously or 102 cfu administered intranasally. 
Accordingly mouse strains were categorized as susceptible and resistant based on median 
survival time after infection with 102 cfu of BCG aerosol or 105 cfu iv (Medina and 
North, 1998). One can conclude, from all these mouse studies that the course of the 
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disease in the lung of resistant mice is more or less identical to the course of the disease 
in the lung of guinea pigs and susceptible rabbits infected with the virulent strain of M. 
tuberculosis. As summarized by North and Jung in their recent review article, M. 
tuberculosis grows progressively at a linear log scale with a generation time of about 28 
hours for the first three weeks in the lung of all three laboratory animal species (guinea 
pigs, susceptible rabbit strains and resistant mouse strains). At around day 21 post 
infection, bacterial replication is contained at a stationary level due the generation of an 
adaptive immune response, which inhibits a further increase in the burden of the bacilli 
and slows the course of the disease (North and Jung, 2004). Even though replication of 
the bacilli is stabilized at a stationary level in the lung, the disease in all the laboratory 
animal species is not resolved and ultimately leads to the death of the animals at different 
times after infection. In general, lesions in the lung of guinea pigs, susceptible rabbits and 
resistant mice infected with M. tuberculosis displayed pathology more or less similar to 
that seen in human tuberculosis patients, except for the less organized nature of the 
granuloma in mice. This indicates that all the laboratory animals can be used equally well 
as models of tuberculosis in man. However, for logistical reasons, including cost of 
handling, availability of laboratory reagents, mouse is the preferred model to study 
human tuberculosis. Although there are similarities in the immune response generated 
against M. tuberculosis in man and mouse, there are still quite considerable differences in 
the pathology of the disease. The granulomas that develop in resistant mouse strains are 
not well developed with all the organized structures seen in man but are simply an 
aggregate of lymphocytes and macrophages distributed among intact air sacs (Boshoff 
and Barry, 2005). Some even argue that there is no such thing as a granuloma in the lung 
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of mice and granuloma in mice refers to those formations seen in the spleen and liver of 
resistant mice. Besides, lesions in organs of susceptible mice are diffused, necrotic, 
contain few lymphocytes and are dominated by neutrophils, which are more or less 
similar to tuberculosis lesions in organs of AIDS patients (Chaisson et al., 1987). One 
important point worth mentioning here, that might contribute to the difference in 
pathology when comparing M. tuberculosis infection in mice and humans, is the dose and 
route of infection in all mouse studies, which are very different from the natural route and 
dose of infection that occurs in man. Even though mice are frequently used as an animal 
model of tuberculosis in man for reasons mentioned above, none of these animal models 
are able to exhibit the latent form of tuberculosis seen in more than 90% of tuberculosis 
infected individuals, making these animal models deficient to study all aspects of human 
tuberculosis. One of the reasons for the failure of these laboratory animals to develop the 
latent form of the infection could be the high dose of mycobacteria used to challenge the 
animals in all the studies. If it were not for cost and ethical reasons, the best animal 
model to study human tuberculosis would be a non-human primate. Infection of these 
animals with a low number of viable bacteria of M. tuberculosis results in a disease 
course more or less similar to the course observed in man, in the sense that only a small 
percentage of the infected monkeys develop disease in a short period of time, whilst 
others develop chronic infection and then succumb to the disease after some time. The 
granuloma in the lung of chronically infected primates is identical to the granuloma seen 
in the lung of human tuberculosis patients both in terms of gross lesion and microscopic 
structures. What is surprising is that more than 40% of the monkeys did not develop 
disease at all during the study period, and were believed to have the latent form of the 
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disease as different diagnostic tests have confirmed that they were all infected with the 
bacilli (Capuano et al., 2003). There is also some evidence that M. bovis infection in 
cattle can develop a form of latency which is similar to the latent type of TB seen in man 
(Cassidy, 2006). 
 
2.8. The BCG Vaccine 
Tuberculosis in man is a curable disease, which can be effectively treated with 
antibiotics. However, effective antibiotic treatment is undermined by a number of factors. 
As it is a disease of poverty, only 1 in 5 tuberculosis victims are estimated to have access 
to treatment (Raviglione et al., 1995). This could be mainly due to individual financial 
means of the patients, but there is often a failure to detect and hence treat new cases due 
to poor health delivery systems in most countries. One study estimated the detection rate 
worldwide to be as low as 27% for the years 1980 to 2000 (Dye et al., 2002). Even for 
those who have access to chemotherapy, effective treatment requires a long course of 
antibiotic administration and there is often low compliance. This favors the appearance of 
multi-drug resistant strains of the bacilli. According to one study, 3.2% of the new 
tuberculosis cases diagnosed in 2000 were caused by multi-drug resistant bacilli (Dye et 
al., 2002). The number was even higher in 2005: around 10% of global tuberculosis cases 
were found to be resistant to more than one drug (Kaufmann, 2006a). All these intrinsic 
limitations of chemotherapy speak to the fact that vaccination, should this be possible, is 
a more viable option for controlling tuberculosis, particularly in developing countries, 
where poor socio-economic conditions and less organized health care systems greatly 
limit the success of chemotherapy in combating the scourge of tuberculosis. Bacille-
  
61 
 
 
 
Calmette-Guérin (BCG) is the only registered vaccine against tuberculosis both in man 
and animals. It is the most widely used vaccine globally; however, there is still 
controversy as to its efficacy in protecting against the highly contagious form of 
pulmonary tuberculosis. In this section, I will discuss the history of BCG as a vaccine, 
some experimental evidence pertinent to its efficacy, as well as some advantages and side 
effects of the BCG vaccine. This will eventually lead to our hypothesis on how we think 
the efficacy of the BCG vaccine can be improved. 
 
2.8.1. History of BCG 
In addition to his major discovery of the causative agent of tuberculosis, Robert Koch 
was the first to experimentally prove that immunity exists against tuberculosis. When he 
inoculated guinea pigs already ill with tuberculosis, with a few mycobacteria, killed or 
live, or with a culture filtrate, he found that the lesion on the skin becomes dark, necrotic, 
eventually sloughed off, and this resulted in healing of the wound. This unique type of 
immune reaction has come to be known as Koch’s Phenomenon (Bothamley and Grange, 
1991). Koch was trying to develop an immunotherapeutic treatment of tuberculosis by 
administering the substance in filtrates from mycobacterial culture. He is, therefore, 
considered to be the pioneer in subunit vaccine development. However, this was a great 
failure for Koch as the administration of his magic protein failed to treat tuberculosis in 
man (Kaufmann, 2006a). Despite its failure to cure against tuberculosis, Koch’s culture 
filtrate, now known as PPD for purified protein derivative, was the basis for the 
development of the skin test that has been used for the last 100 years and is still in use to 
differentiate between those infected/exposed to M. tuberculosis from uninfected healthy 
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individuals. Knowing of the earlier work of Jenner and Pasteur on vaccination and 
inspired by the attempt of Koch to cure tuberculosis, Albert Calmette and Camille Guérin 
started their work on tuberculosis in 1900 in France. The ultimate goal of their research, 
conducted in the Pasteur Institute, was to develop a vaccine against tuberculosis. It was 
prudent of them to look for an equivalent of cowpox (Jenner’s vaccine for small pox) and 
they found the etiological agent of tuberculosis in cattle, M. bovis, to be the appropriate 
candidate. They grew the bacilli on culture media containing ox bile and after ~213 
passages on this media, for over a period of 13 years, the bacillus was no longer virulent 
in a variety of experimental animal models. To their surprise, the vaccine was not only 
safe to use but also was able to protect animals from challenge with virulent M. 
tuberculosis and M. bovis (Calmette and Plotz, 1929). After assessing its safety in various 
laboratory animals, including monkeys, they decided to explore its efficacy in man. It 
must have been ethically tough to get an appropriate human subject to try their new 
vaccine. In 1921, they chose a newborn baby whose mother had died of tuberculosis and 
who was going to be looked after by his grandmother, who also had tuberculosis. The 
assumption was that the baby would develop tuberculosis and might die; but to the 
amazement of all he grew up healthy with no tuberculosis, reviewed in (Daniel, 1997). In 
a short period of time, hundreds of thousands of infants were vaccinated in Europe with 
no serious side effects. This fact encouraged the then League of Nations to recognize, in 
1929, BCG as a safe vaccine for human use following the approval of the vaccine by the 
microbiologists who were attending an international conference organized by the medical 
section of the League of Nations and held in Paris, France, in October 1928 (Calmette 
and Plotz, 1929). However, BCG received only a lukewarm reception in North America, 
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mainly due to reports of a low rate of protection (14%) in school children in the southern 
United States (Comstock and Palmer, 1966). It was also clear that the Lübeck catastrophe 
in Germany, resulting from the injection of children with mislabeled M. tuberculosis 
instead of BCG, had a widely negative impact on the popularity of BCG. Out of the 251 
infants vaccinated, 212 developed active tuberculosis and 77 died (Kaufmann, 2006a).  
 
2.8.2. Efficacy of BCG Vaccination 
Since its introduction in 1921, BCG has been administered to almost three billion people 
globally (Kaufmann, 2006a). However, there is still considerable uncertainty as to its 
efficacy against tuberculosis. Several controlled clinical trials have been conducted in 
several countries to evaluate the protective efficacy of BCG vaccination. Unfortunately, 
those trials, as summarized in various review articles (ten Dam, 1984; Fine, 1995) led to 
disparate conclusions, with the assessed protection rate against pulmonary tuberculosis 
ranging between 0% to 80%. The last World Health Organization-sponsored trial, called 
the Madras trial, involving over a quarter million subjects, was carried out between 1968 
and 1971 in the Madras province of India. The study led to the conclusion that BCG 
vaccination had no overall protective effect against tuberculosis (Baily, 1980; ten Dam, 
1984). This conclusion has been the cause of considerable pessimism. However, it must 
be pointed out that some BCG trials in children gave incontrovertible evidence that BCG 
vaccination was protective with an efficacy of 84% in one case (Hart and Sutherland, 
1977). In addition to this, a meta-analysis of all the published literature has shown that 
BCG vaccination can have an overall protective effect of 50% (Colditz et al., 1994). The 
variables, which might have contributed to this discrepancy in efficacy of BCG 
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vaccination, will be discussed in detail in section 2.8.3. Generally, it is agreed that BCG 
vaccination is effective in protecting children against TB meningitis and disseminated TB 
with close to 80% efficacy. These facts have led to the inclusion of the BCG vaccine into 
the Expanded Program on Immunization (EPI) in 1974 and currently around 118 million 
doses are delivered each year (Fine et al., 1999).  
 
2.8.3. Factors Which May Affect Efficacy of BCG Vaccination 
There has been no extensive and systematic research to evaluate how the efficacy of BCG 
vaccination depends on various parameters of vaccination. All the observations come 
from different trials, which usually differ in more than one parameter of vaccination. It is 
clear that there are many variables that differed between each vaccination program, and 
these variables might have resulted in the disparity in the level of protection achieved in 
different trials. The most obvious variables are those directly or indirectly associated with 
the host, the BCG vaccine itself, and the environment under which the vaccination 
programs were carried. 
 
2.8.3.1. Host Factors 
Host genetics plays a role in determining susceptibility/resistance to tuberculosis 
infection, in part by affecting the nature of the immune response generated against the 
tubercle bacilli, discussed in detail in section 2.3.1. By the same token, host genetics may 
also play a role in the type of immune response generated after BCG vaccination. In mice 
the Nramp1 gene plays a role in determining the replication rate of the BCG in the 
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animal’s body in the first few weeks after infection before immunity is evident. Mice 
have been categorized as resistant or susceptible at the level of innate resistance 
depending on whether their macrophages fail to support or support rapid growth of BCG. 
In the susceptible strains, BCG replicates at an exponential rate without any opposition 
from the host for the first few weeks, until it is held in check by adaptive immunity. 
However, in the resistant mouse strains, replication of the bacilli is much slower and 
never exceeds the number employed for infection. The BCG burden is reduced in both 
strains by the generation of an adaptive immune response at around three weeks post-
infection (Gros et al., 1981). Even though the effect of the Nramp1 gene is in the early 
stage of infection (innate immunity), its effect in controlling bacterial multiplication at 
the early days of infection may have an effect in determining the nature of the BCG-
specific adaptive immune response generated. Many experiments demonstrated that 
antigen dose is important in determining the Th1/Th2 nature of the ensuing immune 
response, with lower doses favoring the generation of a predominantly Th1 response. 
Therefore, mice with Nramp1 resistant allele will harbor lower levels of BCG than 
susceptible mice, which will favor the long-term generation of Th1 cells during the 
generation of an adaptive immune response. Furthermore, there are reports which show 
differences between blacks and their white counterparts in the level of protection against 
M. tuberculosis following BCG vaccination (Comstock and Palmer, 1966), further 
suggesting an influence of host genetics on BCG-specific adaptive immune response and 
hence on the efficacy of BCG vaccination. In addition to host genetics, host age at the 
time of vaccination and nutritional status of the host may also have an influence on the 
type of response generated following BCG vaccination. The effect of age on the efficacy 
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of BCG vaccination can be seen in the context of exposure of the host to cross-reacting 
environmental antigens that induce an immune response that can easily interfere with the 
BCG vaccine. This has been mentioned several times in other sections of this thesis, and 
is briefly discussed in the next section, (section 2.8.3.2). There is well documented 
evidence from animal studies which shows the effect of nutrition, mainly minerals, 
vitamins and protein nutrients on cell-mediated immunity (Chandra, 1997). This may 
suggest that deficiency of these nutrients due to malnutrition of the host can negatively 
influence the generation of effective cell-mediated immunity against mycobacteria 
following BCG vaccination. Evidence both from humans studies (Adeiga et al., 1994) 
and experimental animal studies (McMurray and Yetley, 1982) support the possibility 
that malnutrition can adversely affect the efficacy of BCG vaccination. Finally, there is a 
theoretical possibility that maternal antibody may interfere with ability of BCG vaccine 
to induce effective immunity against tuberculosis; however there is no hard evidence, 
either from human vaccination studies or animal experimental studies, to support this 
possibility.  
 
2.8.3.2. The Environment 
Exposure of the host to cross-reacting environmental microbes can induce an immune 
response, which may well interfere with BCG vaccination. In order to discuss this 
interference in a comprehensible fashion, we will have to define some immunological 
phenomenon, which may help us to understand the cellular mechanisms that govern this 
immunological interference. Animals exposed to antigen in a manner that induces 
humoral immunity are unable to generate a cell-mediated response to the same antigen, a 
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phenomenon known as humoral immune deviation, as the immune response is already 
locked into a Th2, humoral mode. Animals immunized in a manner to express a 
predominant cell-mediated, Th1, response can become unresponsive for the induction of 
an antibody, Th2, response. The response has become locked into a cell-mediated, Th1 
mode. This phenomenon is referred to as cell-mediated immune deviation. We can 
respectively refer to cell-mediated and humoral immune deviation as due to Th1 and Th2 
imprinting. These findings have direct implication for the design of the studies described 
here as will be discussed in great detail later in section 2.9. In line with this, neonates 
were found to readily respond immunologically to environmental mycobacteria in the 
first few weeks of their life, as reported both in man (Marchant et al., 1999) and cattle 
(Buddle et al., 2002). This exposure may result either in Th2 imprinting, which would 
inhibit the generation of a protective, Th1, type response upon BCG vaccination, or in 
weak immunity that is effective against BCG undermining its ability to generate a 
protective type of response following vaccination. One of the compelling explanations 
given as contributing to the failure of the Madras trial is the interference or masking of 
BCG specific immune response by prior infection with environmental mycobacteria (Fine 
1995; Smith et al., 2000). There is evidence in the literature, which supports this 
explanation from human studies in Malawi and Gambia. Vaccination of PPD reactive 
adults with BCG resulted in very low BCG-specific IFN-γ production (Black et al., 
2001), whereas BCG vaccination at birth induced strong BCG- specific IFN-γ response 
with no or a very low IL-4 response (Vekemans et al., 2001). To minimize the potential 
interference by environmental mycobacteria on BCG vaccination, it might be sensible to 
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give the BCG vaccine early, at birth, as is done in most tropical countries, where 
infection by cross-reacting environmental mycobacterium is high. 
 
2.8.3.3. Factors Associated with the Genotype of the BCG Vaccine  
Different vaccine trials often used different strains of BCG for vaccination, which may 
also contribute to the observed disparity in efficacy of protection. There is experimental 
evidence that shows different strains of BCG differ in their ability to persist and replicate 
in vivo, in their ability to stimulate the generation of CD4+ T-cells, as well as in their 
ability to protect against secondary challenge (Lagranderie et al., 1996). In addition, 
genotypic differences among different strains of BCG have been demonstrated by DNA 
fingerprinting using copy number of IS6110 and presence or absence of the mpt64 gene 
as molecular markers (Behr and Small, 1999). Genetic disparity is not only significant 
among BCG strains, but also extends to differences between BCG and virulent strains of 
M. bovis and M. tuberculosis. This may have implications for the efficacy of BCG 
vaccination, as it is possible that BCG may lack some of the immunodominant antigens 
expressed in virulent strains of mycobacteria. There is evidence in the literature that 
supports this argument. Mahairas and colleagues have reported that the BCG strains 
currently in use lack genetic regions that are present in virulent strains of M. tuberculosis 
and M. bovis. The genetic regions which are deleted from BCG, as a result of mutations 
occurring during the process of attenuation, are designated as regions deleted (RD1, RD2 
RD3) (Mahairas et al., 1996). More extensive genomic studies, using microarrays to 
compare BCG with M. tuberculosis, have identified more deleted genes in BCG 
extending the number of RDs to 16 (Behr et al., 1999). However, the RD1 region is 
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thought to be the most important, as it is confirmed to be present in all members of the 
virulent strains of the M. tuberculosis complex group but missing from all BCG vaccine 
strains and other non-virulent species of environmental mycobacteria. Proteins encoded 
by RD1 genes, mainly the early secretory antigen, ESAT-6 (6-kDa), and a culture filtrate 
protein CFP-10 (10-kDa), have been considered to be useful candidate antigens for the 
development of improved vaccines effective against infections with the virulent strains of 
M. tuberculosis complex group. These antigens may also be useful in the development of 
new diagnostic reagents to detect and differentiate infections with the virulent strains 
from exposure to the non- virulent species of mycobacteria (Cockle et al., 2002; Mustafa, 
2002). In line with this, it has been possible to differentiate M. bovis infected from BCG 
vaccinated cattle using these protein antigens (Vordermeier et al., 2000; Vordermeier et 
al., 2001). It is also reported that ESAT-6 and CFP-10 are useful antigens to differentiate 
people with latent or active tuberculosis from those vaccinated with BCG or exposed to 
environmental mycobacteria (Lalvani et al., 2001). The CFP-10 and ESAT-6 proteins are 
the immunodominant antigens within virulent species of mycobacteria and were 
immunologically recognized by more than 70% of human TB patients (Skjot et al., 2000) 
and by more than 50% of cattle infected with virulent M. bovis (Mustafa et al., 2002). In 
addition to their immunodominance and ability to trigger the generation of immune cells 
able to mediate protective immunity, the expression of these proteins by virulent species 
of mycobacteria has led to the suggestion that these proteins may have an important role 
in virulence (Guinn et al., 2004). Deletion of the RD1 gene region from M. tuberculosis 
resulted in a decrease virulence to the same level as the non-virulent BCG strain, as 
assessed by infection of mice and human cell lines (Lewis et al., 2003). In addition to 
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this, ESAT-6 and CFP-10 may participate in the immune-evasion mechanism of 
mycobacteria by down regulating production of NO and inhibiting the up-regulation of 
the B7 family co-stimulatory molecules in infected macrophages (Trajkovic et al., 2004).  
 
2.8.3.4. Variables Associated with BCG Vaccination Protocols  
The efficacy of BCG vaccination may also vary depending on other factors associated 
with the vaccination protocols used, such as the route of vaccination and dose of vaccine 
administered. Originally, Calmette and Guérin administered the vaccine orally but this 
route of administration was abandoned for various reasons, including the high dose 
required to induce effective immunity and the reaction in cervical and pharyngeal lymph-
nodes (Lotte et al., 1984). Various studies in mice have evaluated different routes of 
administration (Falero-Diaz et al., 2000; Lagranderie et al., 2000; Chen et al., 2004; Giri 
et al., 2005). However, for safety reasons, the intradermal route is used today to vaccinate 
infants immediately after birth with 0.1mg of BCG in 0.05ml volume. The dose is 
doubled in children and adults. Another factor worth mentioning here is the dose of BCG 
given. As the relationship between the dose of BCG and the protective effect achieved 
was not known, the highest tolerable dose of BCG was used in most studies (ten Dam, 
1984). However, there is ample evidence in the literature, to be discussed in detail in 
section 2.9, that the dose of antigen administered determines the type of immune 
response generated after vaccination. Moreover, the culture methods used for the growth 
of BCG, the freeze-drying and thawing process of BCG, as well as handling of the 
vaccine, for example exposure to high temperature and to UV light, may result in 
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considerable differences in the numbers and proportions of viable to dead organisms per 
dose of vaccine (Fine et al., 1999). 
 
2.8.4. Additional Merits of BCG Vaccine 
Despite its reported low efficacy to protect against pulmonary tuberculosis, the BCG 
vaccine is the most extensively produced and widely used vaccine today. One of the main 
reasons for its wide use in infant immunization is its high efficacy against miliary 
tuberculosis and TB meningitis in children (Colditz et al., 1995). However, there are also 
other qualities, which other vaccines lack that make BCG a highly popular and widely 
used vaccine. Firstly, BCG is the safest vaccine, with no or very little adverse reactions, 
and can be administered safely to neonates. This feature of BCG encouraged some 
countries in tuberculosis endemic areas to recommend BCG vaccination of HIV positive 
children with no symptoms of AIDS. In addition, there is good evidence that BCG 
vaccination can protect with an efficacy as high as 85% against diseases caused by 
atypical mycobacterium (Romanus et al., 1995) as well as with 20-80% efficacy in 
protecting against leprosy in Africa (Ponnighaus et al., 1992; Orege et al., 1993). It is also 
believed that BCG can be used in the treatment of bladder cancer due to its ability to 
promote the Th1 nature of a response to another antigen when present during the 
response to this second antigen (Meyer et al., 2002). This property of BCG has 
encouraged many researches to use it as an adjuvant or as a vaccine delivery vehicle, to 
induce a Th1 type response against intracellular pathogens. Complete Freund's adjuvant 
(CFA) is a water-in-oil emulsion containing killed mycobacteria and is the most widely 
used adjuvant in vaccines that are intended to induce strong cell-mediated immunity. 
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However, due to the severe reaction it causes, it is not licensed for use in human 
vaccination protocols. Following the successful introduction of foreign DNA and its 
stable expression in mycobacteria (Jacobs et al., 1987; Snapper et al., 1988), several 
attempts have been made to use BCG as a recombinant vaccine delivery vehicle (Jacobs 
et al., 1990; Stover et al., 1991). Accordingly, the gene encoding the leishmania surface 
protein, gp63, was cloned and expressed in BCG and this recombinant BCG vaccine was 
able to induce protective immunity against L. mexicana (Connell et al., 1993) but not 
against L. major in BALB/c mice. However, another expression system was found to 
induce protective immune response against L. major infections in susceptible BALB/c 
mice (Abdelhak et al., 1995). Recently, BCG was also used to express genes that code for 
immunodominant antigens of pathogenic mycobacteria, thereby improving its efficacy in 
preventing infection by the virulent M. tuberculosis strains (Horwitz et al., 2006a; 
Horwitz et al., 2006b). Finally, BCG is a very cheap and easy to produce, making it 
easily accessible to people in developing countries, which are the prime targets as far as 
BCG vaccination and control of tuberculosis is concerned. 
 
2.8.5. Limitations of BCG as Vaccine 
Even though the advantages outweigh the disadvantages of BCG vaccination, there are 
some limitations of the BCG vaccine in addition to its low efficacy against pulmonary 
tuberculosis. The most obvious one is its interference with the skin test, which makes it 
very difficult to differentiate between DTH due to M. tuberculosis infection or BCG 
vaccination. This is of particular interest in veterinary medicine in which the skin test is 
employed for detecting and controlling bovine tuberculosis in the test and slaughter 
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policy. One can imagine the considerable economical loss that would be incurred from 
the slaughter of false positive reactors if BCG vaccination of animals were a standard 
practice in tuberculosis endemic areas. With the advance in knowledge of the genome of 
different mycobacteria, this problem is being solved by using diagnostic tests that can 
detect immunity to proteins that are expressed by pathogenic mycobacteria but not by 
attenuated or non-pathogenic mycobacteria (Kumar et al., 1996; Cockle et al., 2002). 
Another limitation of BCG is the adverse reactions that BCG can cause under certain 
circumstances. The most extensive report comes from Lotte and co-workers who have 
analyzed and classified complications associated with BCG vaccination based on clinical, 
bacteriological, histological and biological information they obtained from articles 
published between 1921 and 1982. According to their findings, life threatening 
complications are very rare, 1-3 per million vaccinated individuals (Lotte et al., 1984). 
However, mild reaction at the injection site, with or without involvement of regional 
lymph nodes, is not unusual, particularly when an inexperienced health care worker 
administers the vaccine. In one study, around 5% of vaccinated individuals complained of 
side effects following BCG vaccination (Turnbull et al., 2002). A more sever case was 
reported from Israel when BCG was given by mistake, instead of PPD, during a skin test 
survey in school children. Adverse reactions at the injection site, with or without 
involvement of regional lymph nodes, was reported in 50% of the cases (Gross et al., 
2004).  
 
Similarly, I have experienced the adverse effect of BCG injection, with abscess formation 
at the injection site, as a result of the accidental injection of BCG into the wrist of my left 
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hand while injecting mice in the tail vein. All the signs and nature of the lesion I observed 
at the injection site were more or less identical to what is described by Gross et al on the 
school children, except there was no involvement of draining lymph nodes in my case, as 
diagnosed by a physician. As shown in Figure 1, a papule like lesion started to form on 
day 3 after injection, with erythema at the injection site (Fig 1A). The lesion was itchy 
but there was no pain. Between 2-3 weeks post injection (Fig 1B), the lesion started to be 
painful, with increased swelling and visible necrosis of the skin, which started to slough. 
Around week 5 after injection, the lesion was big enough (Fig 1C) that I sought medical 
attention. The lesion was drained by incision, and took a couple of weeks to heal, without 
any other treatment. However, there was still a visible lesion/scar more than 6 months 
after the incident (Fig 1D). It is also worth mentioning that the scar left at the injection 
site that may develop into a keloid, as one of the adverse reactions of BCG vaccination. 
This scar is also considered advantageous, as one can easily differentiate vaccinated 
children from those that did not receive the vaccine during childhood immunization 
programs.  
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Figure 1. Pictures showing adverse reaction to BCG resulting from accidental 
injection of BCG during vaccination of mice.  
BCG strain Montreal was prepared and re-suspended at 2x108 cfu per ml in saline 
containing 0.05% Tween 80 to vaccinate mice. While injecting 100 μl of this preparation 
iv in the tail vein of a mouse the investigator, distracted by a mouse jumping out of the 
cage, accidentally injected his hand on the wrist. It is not clear how many CFU of BCG 
were inoculated, but it is easy to estimate close to a million based on the assumption that 
at least one drop (10 μl) of the preparation had been injected; a microliter of the 
preparation contained 105 cfu of BCG. The pictures show lesion development at 3 days 
(A), 3 weeks (B), 5 weeks (C) and 6 months (D) post-injection. The lesion completely 
healed with a scar visible at the injection site as shown in (D). Mycobacteria were grown 
from samples taken from the lesion and were sensitive to all antibiotics tested. 
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2.9. Pertinent Observations on the Regulation of the Immune 
Response: The Basis of Our Working Hypothesis 
 
Our working hypothesis is based on three hypothetical generalizations from the literature, 
already briefly alluded to but explicitly stated and justified here. I will discuss the 
evidence supporting these three generalizations one at a time. First of all, it is prudent to 
assume that any rational approach to vaccination must be based upon knowledge of how 
the immune response differs in people infected by the pathogen but who remain healthy, 
presumably due to an effective immune response, and in those who develop the disease, 
respectively designated as “healthy contacts” and “patients”. There is considerable 
controversy over what immunological parameters discriminate the immune state of 
healthy contacts and patients during mycobacterial infections. The difficulty can be 
illustrated by noting that both healthy contacts and patients usually express delayed type 
hypersensitivity (DTH) used for diagnosis of M. tuberculosis infection. Evidence from 
other chronic diseases shows that predominant cell-mediated, Th1, responses correlate 
with protection against intracellular pathogens causing chronic diseases. Therefore, I will 
discuss evidence from less complex systems before embarking on discussing issues in the 
context of tuberculosis, which is admittedly complicated. 
 
In the murine model of cutaneous leishmaniasis, it has been repeatedly shown that the 
nature of the immune response generated following infection with L. major parasite 
determines disease outcome. Resistant mouse strains mount predominantly cell-mediated, 
Th1, responses with little or no antibody and contain the infection, while susceptible 
mouse strains which suffer progressive disease, generate Th2 or mixed Th1/Th2 
responses with a substantial levels of serum antibodies. Furthermore, it has been shown 
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that the relative ratio of the amount of L. major-specific IgG1/IgG2a antibodies give a 
good indication of the relative sizes of the Th2 and Th1 components of the response, as 
reflected in the number of parasite-specific IL-4 and IFN-γ-producing CD4+ T cells in the 
spleen (Bretscher, 1992; Menon and Bretscher, 1998). Previously, studies in mice have 
also clearly shown a correlation between the presence of certain subclasses of antibodies 
and the Th1/Th2 nature of the associated response to another parasite, Trichinella 
spiralis. In resistant mice a predominant Th1 response with IFN-γ production was 
associated with high serum levels of antigen-specific IgG2a antibody whereas a Th2 
response with IL-4 production was associated with predominant IgG1 antibody (Pond et 
al., 1989). Similarly, a correlation between subclasses of Babesia bigemina-specific IgG 
antibodies and antigen specific Th1/Th2 cytokines was reported in cattle (Brown et al., 
1999). These results, coming from various animal species infected with different 
parasites led us to explore the use of the IgG1/IgG2 ratio in indirectly assessing the 
Th1/Th2 phenotype of the response generated following infection with various pathogens 
in man. The use of serum antibodies as immunological markers to distinguish between 
the immune states of patients and healthy contacts has a practical significance in humans, 
as serum is easily accessible and may better reflect the systemic immune response than 
peripheral blood lymphocytes. The utility of this approach has been demonstrated in 
human visceral leishmaniasis where a distinction of immune responses between healthy 
contacts and patients was reported based on the IG1/IgG2 ratio of parasite-specific 
antibodies (Hailu et al., 2001). Disease was associated with a poor expression of DTH 
and higher titer of antibodies, mainly of the IgG1 but also the IgG3 and IgG4 isotypes, 
while healthy contacts show antigen specific DTH with only significant levels of IgG2 
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serum antibody, indicating a mixed Th1/Th2 and Th1 type of responses, respectively. 
Furthermore, this study has shown that chemotherapy can modulate the immune response 
of patients from a non-protective mixed Th1/Th2 type of response to a protective Th1 
mode, as the immune responses of treated patients become indistinguishable from that of 
healthy contacts. 
 
The qualitative nature of the immunity generated against M. tuberculosis and M. leprae 
may also determine disease outcome. However, unlike visceral leishmaniasis, there is no 
a clear distinction between the anti-mycobacteria immune state of all healthy contacts and 
all patients. In leprosy, patients with tuberculoid form of the disease exhibit a strong M. 
leprae-specific DTH responses that can restrict the growth of bacilli in the lesion site, 
whereas patients with lepromatous leprosy are characterized by strong humoral, Th2- 
type, responses with no or little M. leprae-specific T cells that mediate DTH. In addition 
to these two polar groups, leprosy patients can be categorized as borderline, falling 
somewhere between these two immunologicaly defined polar groups. These borderline 
leprosy patients show immunological characteristics of the neighbouring polar groups 
and are further classified as borderline tuberculoid, mid-borderline, or borderline 
lepromatous (Verhagen et al., 1998). Similarly, observations in the old literature have 
been interpreted as indicating the existence of spectrum of immune responses during 
tuberculosis infection. On one end of the spectrum are healthy contacts that express a 
strong antigen-specific DTH response with no or little serum antibodies. At the other 
extreme are patients with miliary tuberculosis that generate a predominant Th2 type 
response associated with high level of serum antibodies and no detectable DTH. The 
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immune response of the majority of the patients with active pulmonary tuberculosis may 
lie somewhere between these two polar groups (Bhatnagar et al., 1977; Lenzini et al., 
1977). In view of these observations, it seems difficult to correctly discriminate healthy 
contacts from patients based on the immune parameters at the individual patient level. 
However, other observations have reported that the immune response in patients has, on 
average, a significant Th2 component (Sanchez et al., 1994; Surcel et al., 1994). Based on 
these observations it is safe to state that at the population level, there are statistically 
significant differences between the immune parameters of patients and healthy contacts, 
the latter having a predominant Th1 response. Nevertheless, the spread of the spectrum of 
the immune response in individual patients, anywhere between the two polar groups, may 
suggest that the immune system can fail in various ways in different tuberculosis patients. 
For example, an exclusive cell-mediated, Th1 response may be protective, and 
tuberculosis may arise if either the immunity is of the right kind but not strong enough, or 
if it is not of the right kind, having a significant Th2 component. There is unpublished 
data from our laboratory, which support this view. In this study, almost all healthy 
contacts and around 71% of the patients showed an IgG1/IgG2 ratio in the range of 0.001 
to 2, while the ratio ranges from 3 to 100 for the remaining 29% patients. Based on these 
data, it was hypothesized that there may be two distinct types of tuberculosis: Type I 
tuberculosis is envisage to occur as a result of too weak Th1 response, with the patients 
showing immune parameters identical to healthy contacts. Patients with type II 
tuberculosis have a high IgG1/IgG2 ratio, reflecting a mixed Th1/Th2 or polarized Th2 
response. The identification of immunological parameters that discriminate between the 
immune response of healthy contacts and tuberculosis patients sets the stage for 
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considerations of how to guarantee, by means of vaccination, an effective response upon 
natural infection by the pathogen. Based on the evidence discussed above, we can 
hypothesise that a strong and exclusive Th1 response is protective against tuberculosis, 
whereas a weak Th1 response or a response with a significant Th2 component is less 
protective or insufficient. This viewpoint naturally leads to the question of how to 
guarantee a strong Th1 response on natural infection. Given the phenomenon of Th1 
imprinting, it seems essential to a successful vaccination that we examine how to 
guarantee a Th1 response upon primary vaccination. We therefore now address what is 
currently known about the factors/circumstances that determine the Th1/Th2 phenotype 
of a primary immune response. This will take us to the second hypothetical generalization 
referred to at the beginning of this section.  
 
The recognition of a tendency for exclusivity between the induction of DTH and IgG 
antibody came from the finding that different conditions of antigen administration induce 
different classes of immunity. Guinea pigs immunized to produce only antibody were 
rendered specifically unresponsive for the induction of DTH, a phenomenon termed as 
‘humoral immune deviation’ (Asherson and Stone, 1965). On the other hand, some 
animals immunized to only express cell-mediated immunity were found to be specifically 
unresponsive for the induction of antibody (Parish, 1972), a phenomenon that can be 
referred to  as cell-mediated immune deviation. The aim of a series of experiments in the 
mid 1970s was to explore the cellular basis of the exclusivity of cell-mediated and 
humoral response. It was shown that the inverse relationship between cell-mediated and 
humoral immunity is due to the presence of different type of suppressor T-cells, which 
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need different requirements for their induction. Accordingly, mice immunized to produce 
only humoral immunity to horse red blood cells (HRBC) were reported to harbor T-cells 
that suppress the induction of DTH (Ramshaw et al., 1976). Conversely, mice immunized 
to express potent cell-mediated immunity and rendered unresponsive for the induction of 
antibody to the same antigen harbor T-cells that specifically inhibit antibody production 
(Ramshaw et al., 1977). These T-cells were later referred to as TsDTH and TsAb cells, 
respectively, and differed from each other in the surface markers they express. The 
former T-cell population are Ly1+ Ly2- (CD4+) cells whereas the latter are reported to 
be Ly1-Ly2+ (CD8+) T-cells (Ramshaw et al., 1977). They are induced under different 
conditions and they inhibit the induction of the opposing class of response, leading to the 
exclusive nature of the DTH and antibody responses. This will again lead to the question 
of what variables of immunization determine whether TsDTH and hence a humoral 
response, or TsAb cells and hence a cell-mediated response is generated? Our attempt to 
address this question, based on experimental evidence from the literature, will lead us to 
the third generalization. There is ample evidence in the old literature that shows a direct 
relationship between dose of antigen used for vaccination and the type of immune 
response generated. It was Salvin who first showed that administration of very low doses 
of antigen induce an exclusive cell-mediated response, while immunization with higher 
doses result in a more rapid cell-mediated response that is transient and decays as a 
strong antibody/humoral response is generated (Salvin, 1958). Several subsequent 
observations supported the generality of this finding for many different kinds of antigens 
be they proteins, bacteria, parasites, or particulate antigens in the form of RBC. These 
studies employed different species, strains and ages of animals as hosts as well as various 
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routes of immunization, including iv, id, and sc, reviewed in (Bretscher et al., 2001). 
What can be the potential mechanism underlying this dose dependence? Bretscher 
proposed a mechanism that may help to explain the differential expression of cell-
mediated and humoral immunity following antigen administration (Bretscher, 1974). This 
hypothesis, known as the “Threshold Hypothesis”, is based on some critical scientific 
assumptions and postulates:  
(i) The activation of naïve precursor T helper (pTh) CD4+ cells into effector cells 
requires antigen-mediated cooperation of CD4+ T-cells. 
(ii) More antigen-mediated CD4+ T-cell cooperation is required to generate Th2 
cells than Th1 cells.  
(iii) Antigen presented on the surface of APC mediates the interaction between 
these helper CD4+ T-cells.  
These three postulates are the basis of the Threshold Hypothesis and based on these, the 
hypothesis states that less CD4+/CD4+ T-cell interactions (or less help) are required for 
the induction of Th1 cells than is needed for the generation of Th2 cells. Accordingly, 
antigens with low foreign sites – either due to small molecular size, or because most 
epitopes are shared with self, as in skin bearing minor hstocompatibility antigens, for 
there are only a few Th cells in the periphery – bring very few antigen-specific CD4+ T-
cells into the field of cooperation and hence induce the differentiation of Th1 cells from 
precursor T-helper (pTh) cells. On the other hand, there are many T-helper cells specific 
for very foreign antigens or for the foreign peptides generated on processing these 
antigens and the high level of cooperation between these helper CD4+ cells, mediated by 
optimal doses of antigen, leads to the induction of pTh cells to generate Th2 cells. Once 
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these pTh cells are differentiated, they start to produce cytokines which amplify their 
further differentiation while inhibiting both the differentiation of the opposite CD4+ T-
cell subsets and most of their important effector functions (Mosmann, 1991). Various in 
vitro and in vivo experiments conducted over the years in our laboratory support the 
Threshold Hypothesis and its critical assumptions (Bretscher, 1983a; Bretscher, 1983b; 
Ismail and Bretscher, 2001; Ismail et al., 2005; McKinstry et al., 2005). The role of 
antigen in this interaction is to bring the cooperating CD4+ T-cells together so an 
interaction between CD4+ T-cells will be possible only in the presence of antigen. Non-
optimal and low doses of antigen limit the CD4+ T-cell interaction and thus can favor the 
generation and differentiation of Th1 cells even by a very foreign antigen for which there 
are many CD4+ T-cells in the periphery. Therefore, a low dose of antigen induces the 
generation of Th1 cells that play a role in cell-mediated immunity and can hypothetically 
establish a state of cell-mediated immune deviation, as assessed, for example by a 
subsequent challenge of the host with a dose that generates a mixed Th1/Th2 or 
predominant Th2 response in unexposed animal. This phenomenon is commonly 
described as Th1 imprinting. By the same token, a high dose of antigen induces Th2 cells, 
which result in an antibody response and can limit the induction of cell-mediated 
immunity against the respective pathogen upon natural infection (Ogunremi and 
Bretscher, unpublished data). This phenomenon is referred to as Th2 imprinting. This has 
practical implications for our low dose BCG vaccination study, as the possibility of Th2 
imprinting, due to exposure of the host to cross-reacting environmental mycobacteria, 
may have a deleterious effect on the ability of the BCG vaccine to generate a Th1 
response and Th1 imprint. 
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In summary, the three hypothetical generalizations referred to are (i) that healthy contacts 
have a strong, predominant cell-mediated response, whereas patients have either a similar 
response but too weak to contain the infection, or one with a Th2 component, that also 
cannot contain the infection; (ii) that the generation of Th1, cell-mediated, and Th2, 
antibody, responses tend to be exclusive and (iii) that the dose of antigen can determine 
the Th1/Th2 phenotype of the response, with low dose favoring predominant Th1 
responses. Furthermore, as discussed in previous sections, clinical observations have 
shown that a strong and predominant Th1-type response is protective against chronic 
intracellular pathogens. Moreover, it would appear from the old literature employing non-
living antigens (Parish, 1972) that this type of response can be guaranteed by exposing an 
animal in a manner that generates an exclusive Th1 response over a period of time. Such 
an exposure can result in cell-mediated immune deviation, i.e. a state where the animal 
produces a strong and predominant cell-mediated, Th1-type, response to a challenge that 
generates an antibody response with at least a substantial Th2 component in naïve mice. 
One means of establishing cell-mediated immune deviation is to ensure prolonged 
stimulation with a dose of antigen that is sub-immunogenic for an antibody response and 
that leads to a substantial cell-mediated response (Parish, 1972). 
 
Experiments in our laboratory have explored whether it was possible to similarly 
establish a state of cell-mediated immune deviation to a replicating agent by infecting 
with low number of organisms that were too few to induce specific antibody and Th2 
cells. The mouse model of cutaneous leishmaniasis, involving infection with L. major 
parasite, was chosen for the experiments, as it had been so extensively developed. 
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Infection of BALB/c mice, the susceptible prototype, with very low numbers of L. major 
parasites, 1000 fold lower than the dose that induces progressive disease, is found to 
induce a stable cell-mediated/Th1 response exclusive of Th2 cell generation and antibody 
production. Over time these mice become resistant to a high dose challenge that causes 
progressive infection in naive mice of the same strain (Bretscher et al., 1992; Menon and 
Bretscher, 1998). It is also reported that BCG doses 100,000 fold lower than previously 
used provide dramatic protection in calves against a normally lethal M. bovis challenge 
(Buddle et al., 1995). In addition, recent studies in deer (Griffin et al., 1999) show that 
low doses of BCG induce exclusive cell-mediated, Th1, responses that can protect the 
host against challenge with virulent mycobacteria. The higher doses used induced mixed 
Th1/Th2 responses and were inferior in reducing the bacterial burden from the organs of 
the infected host. In summary, low dose BCG vaccination that induces a Th1 type 
response and Th1 imprint may constitute effective vaccination against virulent M. 
tuberculosis.  
 
All these facts speak to the possibility that one of the reasons for the failure of BCG 
vaccination to reliably protect against pulmonary tuberculosis is the high dose of BCG 
used in all the previous human vaccination trials. In some studies, 1.6 x108 cfu has been 
considered the standard dose (Lowry et al., 1998) and 100 fold higher doses were used 
for oral vaccination of infants (Lagranderie et al., 2000). Cattle have been vaccinated in 
the past with 50-100 mg of BCG, which is about 1010 cfu (Buddle et al., 2003). 
Therefore, the possibility that vaccination with relatively low doses of BCG provides 
better protection against tuberculosis than vaccination with the standard dose is 
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intriguing, particularly in view of the use of the largest acceptable dose of BCG in most if 
not all previous vaccine trials. Moreover, dramatic protection in calves against bovine 
tuberculosis has been achieved by lowering the BCG dose to either 104 or 106 cfu, about 
a hundred thousand fold lower than the previously employed dose (Buddle et al., 1995). 
Based on these general facts, we propose here a hypothetical low dose BCG vaccination 
strategy that can guarantee the correct type of response upon exposure of the host to 
natural infection by mycobacteria.  
 
I have discussed in detail the variables that may affect the efficacy of BCG vaccination in 
section 2.8.3; however, there are two important issues, pertinent to our low dose BCG 
vaccination strategy, which I want to mention here and discuss briefly how these issues 
will be addressed in this study. Firstly, genetic diversity of the target population, whether 
in animals or people, can be a stumbling block for the development of a universally 
efficacious vaccination protocol, as genetically distinct individuals in a population may 
respond differently to a standard dose of BCG vaccine. A low dose that induces an 
exclusive cell-mediated, Th1, response in one individual can be high enough to induce a 
mixed Th1/Th2 or a predominant Th2 response in another individual of the same 
population. Therefore, the standard dose of BCG vaccine may generate an effective 
immune response in some individuals and fail to induce a protective response in others. I 
believe the way out of this impasse may be to use an ultra-low dose vaccination strategy 
whereby a dose that will not induce any antibody response in any member of the 
population is employed. This dose will either induce an exclusive cell-mediated response 
and Th1 imprint or will be too low to induce any kind of response. In the later case, BCG, 
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a live attenuated vaccine, can easily replicate and reach a threshold level where it can 
induce a cell-mediated response and Th1 imprint in all individuals. The ultimate goal of 
this study is to find an effective BCG vaccination strategy in the mouse model that can be 
applied in the control of tuberculosis in the genetically heterogeneous population of 
humans and animals. Therefore, it is important to test the low dose BCG vaccination 
strategy in mice with different genetic backgrounds. The choice of mouse strains will be 
based on previous reports which classify inbred strains of mice into two broad categories 
based on their ability to reduce bacterial burden from organs of their body (Gros et al., 
1981) and their survival time following exposure to virulent M. tuberculosis (Medina and 
North, 1998). The second problem pertinent to our low dose BCG vaccination strategy is, 
that exposure of the host to cross-reacting environmental mycobacteria can possibly 
interfere with the type of immune response generated following vaccination with BCG 
and prevent Th1 imprinting. This interference could be due to the generation of mixed 
Th1/Th2 or Th2-type response following exposure to environmental mycobacteria before 
the host is vaccinated with BCG. Low dose BCG vaccination of individuals with an 
established Th2-type response, due to prior exposure to environmental mycobacteria, 
may not induce a Th1-type response and Th1 imprint, as the immune response might 
have been already locked into a Th2 mode (Asherson and Stone, 1965). It is important to 
examine whether this problem can be overcome by administering the vaccine 
immediately after birth, before the newborn animals or humans are exposed to 
environmental mycobacteria. Another consideration, which may have relevance to our 
neonatal low dose BCG vaccination strategy, is whether the vaccine is able to protect the 
two billion people already infected with M. tuberculosis against reactivation disease. In 
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circumstances where vaccination cannot provide the desired level of protection, 
immunotherapy would be an alternative approach in the fight against chronic disease 
caused by intracellular pathogens, particularly when there is no effective chemotherapy to 
cure the disease. 
 
The identification of discriminating immunological parameters between healthy contacts 
and patients is also essential for the rational design of immunotherapy. The ultimate goal 
of immunotherapy will be to modify the ongoing immune response from the non-
protective Th2 or mixed Th1/Th2 into a protective Th1 mode. In line with this, a number 
of maneuvers, such as administration of IL-12 (Heinzel et al., 1993; Nabors et al., 1995), 
treatment with neutralizing anti-IL-4 monoclonal antibody (Sadick et al., 1990; Nabors 
and Farrell, 1994), or partial depletion of CD4+ T-cells (Titus et al., 1985; Heinzel and 
Rerko, 1999) have been used to protect susceptible BALB/c mice from infection with the 
L. major parasite. In all cases, treatment was able to help establish a Th1 type response 
and Th1 imprint – at the expense of Th2 cells – that helps the mice to withstand an 
otherwise lethal challenge with L. major parasite. To me, there seems to be a caveat in all 
these maneuvers to be used as a model for human chronic disease. All the interventions 
were done either prior to or immediately after infection, which suggests they influence 
the decision making process to generate either a Th1 or Th2 type response rather than 
modifying an on-going response from a mixed Th1/Th2 or predominant Th2 into a Th1 
mode and were shown to be ineffective if given a few days later after infection. In man, 
chronic diseases like tuberculosis and leishmaniasis are diagnosed several months after 
infection when the response is already established as mixed Th1/Th2 or Th2 type. 
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However, anti-IL-4 therapy or partial depletion of CD4+ T-cells is reported to cure mice 
with a stable borderline leishmaniasis associated with mixed Th1/Th2 response several 
months after infection of BALB/c mice with L. major parasite by modulating the 
response into a Th1 mode (Uzonna and Bretscher, 2001). These reports encouraged me to 
examine whether the same maneuvers will induce similar outcomes in modifying an 
ongoing mixed Th1/Th2 response in BCG infected mice into a Th1 type response, and if 
this switch in response is associated with a more rapid and efficient clearance of the 
bacilli from the spleen. 
 
2.10. Hypothesis 
 
Ultra-low dose neonatal BCG vaccination will provide universal protection against 
tuberculosis in a genetically heterogeneous population. 
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3. Study Objectives 
 
I. To determine if low dose BCG vaccination generates a stable, predominantly cell-
mediated/Th1 response against mycobacteria in naïve adult and newborn mice. 
 
II. To determine whether the generation of cell-mediated responses following low 
dose BCG vaccination results in a Th1 imprint that can persist following high 
dose BCG iv challenge, and whether such an imprint results in a decreased 
mycobacterial burden. 
 
III. To examine the low dose vaccination strategy in different strains of mice, to 
explore whether it is applicable in genetically heterogeneous populations. 
 
IV. To determine whether different methods of immunotherapy to modulate an 
ongoing mixed Th1/Th2 response into a Th1 mode are effective in the 
mycobacterial system and to evaluate whether such modulation is associated with 
a reduction in bacterial burden. 
 
V. To test the hypothesis that incorrect priming, due to pre-exposure to 
environmental mycobacteria, can negatively affect the efficacy of low dose BCG 
vaccination and, if so, to explore ways of overcoming this problem. 
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4. Materials and Methods 
 
4.1. Mice 
Adult, female BALB/c mice were obtained from Charles River, Wilmington, 
Massachusetts and were at least 6 weeks of age when first used. Adult CD1 mice were 
obtained from Animal Resource Center, University of Saskatchewan and adult CBA mice 
were obtained from the breeding colony of the animal care facility, College of Medicine. 
Newborn mice were obtained by mating 10 BALB/c breeding pairs, obtained from the 
above source, in the College of Medicine animal care facility and newborn mice were 
used at around 5-7 days of age. Mice were tagged by piercing the ear when necessary to 
identify individual mice in longitudinal studies. All mice were housed at the College of 
Medicine animal care facility. Mice were handled and experiments performed in 
accordance with the guidelines approved by Canadian Council on Animal Care and the 
University Committee on Animal Care and Supply, UCACS. 
 
4.2. BCG Growth and Enumeration 
Mycobacteria, BCG strain Montreal, was kindly provided by Dr. Emil Skamene, of 
McGill University. BCG stocks were propagated in Dubos broth base (DIFCO, BD 
Biosciences, Sparks, MD 21152, USA) enriched with Dubos medium albumin 
supplement containing 5% bovine serum albumin (BSA) in saline. The supplement was 
added into the Dubos medium to a final concentration of 0.5% and finally Tween-80 was 
added to a final concentration of 0.05% to avoid clumping of bacteria. The bacteria were 
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then incubated at 37oC in a humidified incubator with 5% CO2 for 14-21 days. To 
quantify the number of mycobacteria growing in the broth media, bacteria were 
enumerated based on their ability to form colonies as previously described (Gros et al., 
1981). Briefly, bacterial stock culture was sonicated for few seconds in a Branson 
Sonifier (Model 450) to disrupt clumps and bacteria was serially diluted, by 10 fold 
dilutions in PBS containing 0.05% Tween-80. From each dilution, 5-7 drops of 10 μl 
each were seeded as a spot on plates containing Dubose-Oleic agar base (DIFCO, BD 
Biosciences, Sparks, MD 21152, USA) supplemented with 5% BSA in saline and oleic 
acid at a final concentration of 0.5%. Plates were incubated in a humidified, 5% Co2 
incubator set at 37oC. Colonies in each spot were counted 10-14 days after plating, the 
average number calculated and the number of bacteria consequently expressed as cfu/ml. 
Bacterial suspension was then stored in saline-Tween 80 at -70oC until used for injection. 
 
4.3. BCG Vaccination and Challenge 
For injection, BCG stock of known cfu content was pelleted by centrifugation at 8000xg 
for 30 minutes, and subsequently washed three times in saline containing 0.05% Tween-
80 by pelleting bacteria at the same speed for 20 minutes. The pellet was re-suspended in 
a given volume of 0.05%Tween-saline and briefly sonicated for 10 seconds in a Branson 
Sonifier, Model 450, to disrupt clumps. The homogenous suspension of BCG was serially 
diluted in PBS to get the appropriate number of bacterial required for injection. Adult 
mice were vaccinated intravenously (iv) in the tail vein. Newborn mice were vaccinated 
intradermaly (id) or subcutaneously (sc) on the back around the base of the tail. All BCG 
challenges were done intravenously.  
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4.4. BCG Antigen Preparation 
Bacteria were grown in Dubos broth base, as described in section 4.2. They were then 
pelleted by spinning for 30 minutes at 8000xg, re-suspended in saline containing 0.05% 
Tween-80 and washed two more times in this solution. The bacteria were then re-
suspended in 5 ml of ice-cold 0.05% Tween-80-saline and sonicated for 14 cycles of one 
minute each in a Branson Sonifier, Model 450, according to the manufacturer's 
instructions to disrupt the mycobacteria. The suspension was in some cases spun for 20 
minutes at 8000xg to remove particulate matter and the supernatant collected. The 
concentration of the protein antigen was determined using the Bicinchronic acid (BCA) 
protein assay reagent (Pierce, Rockford, Illinois), according to the manufacturer’s 
protocol. Briefly, a BSA standard (2 mg/ml) was serially diluted in the diluent used to 
prepare the antigen in a low binding ELISA plate. The BCG antigen was also similarly 
diluted and 10 μl of each dilution from the standard and the unknowns transferred into a 
Maxisorp ELISA plate. 200 μl of working reagent that contains 50 parts reagent A 
(Na2CO3, NaHCO3 and Sodium tartrate in 0.1N NaOH) and 1 part reagent B (4% Copper 
sulfate solution) was added to each well and the plate incubated at 37oC for 30 minutes. 
Plates were read with EmaxTM microplate reader (Molecular Devices Corporation, 
Sunnyvale, CA) wavelength 540–590 nm, the standard curve drawn and the amount of 
protein in the BCG sample was assessed by extrapolation. Antigens was stored at -70oC 
until used to stimulate the production of cytokines by spleen cells of BCG immunized 
mice in the ELISPOT assay (section 4.7) or in the measurement of BCG-specific IgG1 
and IgG2a antibodies in an ELISA assay (section 4.8). 
 
  
94 
 
 
 
4.5. Media 
RPMI 1640 and DMEM media supplemented with L-glutamine, as well as the Leibovitz 
medium were prepared from powdered stocks (Gibco Laboratories, Grand Island, NY) as 
per the manufacturer’s instructions by dissolving the powder in de-ionized and distilled 
water (ddHO2). Media were sterilized by filtration through 0.22 μm filters (Millipore, 
Molsheim, France) and assessed for sterility by overnight incubation at 37oC.  
 
4.6. Preparation of Single Cell Suspensions 
Experimental and control mice were sacrificed by cervical dislocation and their spleens 
taken aseptically into a test tube containing 10 ml of Leibovitz media. Each spleen was 
gently disrupted by teasing into small fragments using sterile forceps and/or scissors and 
by crushing using a blunt glass rod. Single cell suspensions were obtained by passage 
through a stainless steel wire mesh and then the suspension was put into a 15 ml tube. 
Suspension were left to stand for around 2 minutes to allow debris to settle and the 
supernatant collected from each tube leaving around 0.5 ml debris on the bottom. Single 
cell suspensions were then washed twice in the same media by spinning at 300xg for 10 
minutes and finally pellets re-suspended in RPMI 1640 media supplemented with L-
glutamine containing, 10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 100 
μg/ml streptomycin, 0.8mM sodium pyruvate, and 5x10-5M β-mercaptoethanol, here after 
called as complete RPMI 1640 media. Viable white cells were counted on a 
haematocytometer employing the trypan blue exclusion technique and re-suspended at 
107 viable cells/ml of RPMI media. Cells were kept on ice until used.  
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4.7. ELISPOT Assay to Detect Antigen Specific Cytokine 
Secreting Single Cells 
 
This assay was used to quantify the number of antigen-specific spleen cells producing 
IFN-γ or IL-4 and was conducted as described (Power et al., 1999). Briefly 96 well 
nitrocellulose-bottom culture plates (Whatman-Polyfiltronics, Clifton, New Jersy, USA) 
were coated with purified 1.25 μg/ml anti-IFN-γ (R4-6A2) or anti-IL-4 (11B11) 
antibodies (Pharmingen, San Diego, CA) in 1M bicarbonate buffer (pH 9.6) at 100 μl per 
well and incubated at 4oC overnight. The next morning, plates were rinsed with 150 μl of 
RPMI 1640 and blocked with 200 μl of complete RPMI 1640 medium for at least two 
hour prior to addition of cells. Spleen cells from experimental and control mice were 
prepared as single cell suspensions as described in section 4.6 and re-suspended at 107 
cells/ml in RPMI 1640 complete medium. Finally, cells were plated in 100 μl RPMI 1640 
complete medium at one of the following three densities 106, 5 x 105, or 2.5 x 105 per 
well. Whenever less than a million sensitized cells per well were used, additional spleen 
cells from un-immunized mice were added to bring the total number of cells in each well 
to 106. The number of antigen-dependent spots observed was directly proportional to the 
number of immunized spleen cells plated (Figure 2) and was not affected by the number 
of naïve spleen cells added to each well. The average number of spots detected with cells 
from a naïve mouse was around 5-10 for IL-4 and 10-15 for IFN-γ. When peripheral 
blood lymphocyte (PBL) cells were used, blood was collected by nipping the tail vein of 
mice after exposure of the mouse to a heat lamp and 10-15 drops of whole blood 
collected into 2 ml screw cap tubes containing 2 drops of Heparin Sodium Injection B.P 
anticoagulant (LEO Pharma. inc, Thornhill, Ontario). The whole blood was re-suspended 
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in 1ml Liebovtiz media, gently layered on top of 0.7 ml ficoll and centrifuged for 20 
minutes at 750xg to separate the peripheral blood mononuclear cells (PBMNCs) from 
dead cells, granulocytes and RBC which pass through the ficoll and pelleted at the 
bottom of the tube. Finally, the buffy layer was carefully collected from the interface. 
These cells, were washed 2-3 times in Leibovitz media, re-suspended in 1 ml complete 
RPMI 1640 media, counted and finally dispensed into a 96 well nitrocellulose plates as 
described above. The number of peripheral blood mononuclear cells harvested from 
individual mouse blood was always less than 106 per ml when we re-suspend it in one ml 
complete RPMI 1640 media. Thus, even though the number varies among individual 
mice, the average number of PBL cells added into each well was close to 105. Therefore, 
spleen cells from naïve mice were added to bring the total number of cell per well to 106. 
Antigen was added to provide a final concentration of 3.33 μg of BCG protein per ml of 
complete media in a final volume to 200 μl per well. The number of spot-forming cells 
generated in the presence and absence of antigen by the spleen cells of each experimental 
mouse was assessed in triplicate. The seeded plates were placed in a 37oC incubator 
undisturbed for eight hours and then washed thoroughly twice with ddH2O, waiting for 
five minutes between each wash, to lyse any remaining cells, and then six times with 
phosphate buffered saline containing 0.05% Tween-20 (PBST). Biotinylated anti-IFN-γ 
(XMG1.2) or anti-IL-4 (BVD6-24G2) antibodies (Pharmingen) were added at a 
concentration of 1.25 μg/ml in 100 μl of PBST and the plates incubated overnight at 4oC. 
The next morning, plates were again thoroughly washed with PBST and 100 μl of PBST 
containing 0.2 μg/ml of alkaline phosphatase strepavidin (Jackson Immunoresearch 
Laboratories Inc., West Grove, PA) added to each well and incubated at room 
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temperature for 1.5 to 2 hours. The plates were then thoroughly washed with ddH2O and 
spots developed by addition of a 1 in 50 dilution in 0.1M Tris, 0.1M NaCl, 0.05M MgCl2 
buffer, pH 9.5, of 18.75 mg/ml nitro blue tetrazolium chloride (NBT) and 9.4 mg/ml 5-
bromo-4-chloro-3-indolyl phosphate, toluidine in 67% DMSO (v/v), commonly referred 
to as BCIP/NBT substrate, according to the manufacturers instructions (Boehringer 
Mannheim, Germany). Spots were counted using a dissecting microscope after the plates 
had dried and antigen specific spots expressed by subtracting spots in antigen negative 
wells from antigen positive wells and expressed as mycobacterium-specific spots per 
million spleen cells. As mentioned in the previous paragraph the number of antigen 
specific spots per 106 spleen cells from naïve mice is around 5-10 spots for IL-4 and 10-
15 for IFN-γ. 
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Figure 2. The number of antigen-dependent spots observed in the ELISPOT assay 
was directly proportional to the number of immunized spleen cells plated.  
Spleen cells from BALB/c mice vaccinated with either saline (A) or 102 cfu (B) of BCG 
sc and challenged 12 weeks after vaccination with ~3.3x107 cfu iv were processed for 
ELISPOT assay. Pooled splenocytes from 3 mice in each group were plated at different 
concentrations per well as indicated on the abscissa. Whenever cells less than 106 were 
used, spleen cells from naïve mice were added to bring the total number of cells per well 
to 106. The number of antigen-specific spots is determined by subtracting the number of 
spots in wells without from the number of spots with antigen. Each point represents the 
number of antigen-specific spots in 3 assay wells +/- SE. 
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4.8. Detection of Mycobacteria Specific IgG1 and IgG2a 
Antibodies in Serum  
 
Blood was collected into MICROTAINER brand tubes by nipping the tail vein of mice 
after their exposure to a heat lamp, and serum from individual mice separated by spinning 
the tubes at 12,000 rpm for 3-5 minutes in a Microspin centrifuge (Sorvall® instruments). 
Serum was harvested carefully into eppendorf tubes and stored at -700C until assayed for 
antibody content. The IgG1 and IgG2a serum antibody titers were determined using 
ELISA as follows. NuncTM Maxisorp 96 well polystyrene plates were coated with BCG 
antigen at a concentration of 1 μg/well in 100 μl of 0.1M NaHCO3 and incubated 
overnight at 4oC. Plates were washed 2-3 times with PBS containing 0.05% Tween-80 
and blocked at 37 0C for at least one hour with PBS containing 10% calf sera. Serum 
samples were diluted 1/100 in PBS containing 10% calf serum and then two-fold serial 
dilutions were prepared in low protein binding dilution plates. From this 100 μl of diluted 
sera were transferred into the corresponding wells on the Maxisorp ELISA plates.  The 
plates were incubated at 37oC for 2 hours or at 4oC overnight and washed thoroughly 
with PBS containing 0.05% Tween 20. Horseradish peroxidase labeled rat anti-mouse 
monoclonal antibodies against mouse IgG1 or IgG2a (Southern Biotechnology Associates, 
Birmingham, AL) were added to the wells at a dilution of 1/5000 in 100 μl per well in 
assay diluents, 10% calf sera in PBS. Plates were incubated again at 37oC for two hours.  
After washing, stock ABTS® peroxidase substrate solution (KPL, Gaithersburg, MA) that 
contains 2.2'-azino-di (3-ethyl-benzthiazoline-6-sulphonate) was added in 100 μl per well 
to all wells and incubated for 10-20 minutes at room temperature in a dark place. Plates 
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were read using EmaxTM microplate reader (Molecular Devices Corporation, Sunnyvale, 
CA) at 405nm. Readings were corrected for background by subtracting OD values of 
wells with no serum added (conjugate control) from the corresponding wells of 
vaccinated and non-vaccinated control mice. The positive cutoff value was then set at 2x 
the mean plus 2x the standard deviation of the value for pooled non-vaccinated mice sera. 
The titer was considered to be the reciprocal of the last serum dilution to give a positive 
result.  
 
4.9. Assessment of Bacterial Burden in the Spleen of BCG 
Challenged Mice 
 
At different time points after iv challenge of vaccinated or unvaccinated age-matched 
control (AMC) mice, spleen cells were processed for assessment of bacterial burden 
(Gros et al., 1981). Briefly, single cell suspensions were prepared from each spleen in 
saline containing 0.05% Tween-80 and 0.05% bovine albumin, fraction V (Sigma 
chemicals Co.) and washed 2-3 times by spinning for 20 minutes at 800xg in this 
solution.  Pellets were re-suspended in 5 ml of the same solution and lysed by sonication 
(Branson Sonifer, Model 450) over a period of 10 seconds, according to the 
manufacturer’s instructions. Then, 5-7, 10 μl drops of each sonicates were placed onto 
Dubos oleic agar plate and incubated in 5% CO2 incubator at 37oC for 10-14 days. When 
bacterial colonies could be enumerated, colonies arising from each drop were counted 
under a dissecting microscope and results calculated and expressed as cfu per spleen. 
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4.10. Magnetic Cell Sorting and Flow Cytometric Analysis 
Single cell suspension were prepared from BALB/c spleen cells as described in section 
4.6 and red blood cells were separated by density gradient separation using ficoll as 
described in section 4.7. Then, CD4+, CD8+ and Thy1.2+ cells were sorted by magnetic 
cell sorting with MACS MicroBeads (Miltenyi Biothech GmbH, Germany) as per the 
manufacturer’s instructions. Briefly, cells were washed once in complete RPMI 1640 
medium and pellets re-suspended in MACS buffer (5% fetal calf sera in PBS). Cell debris 
was removed by passing the cell suspension through a 30 μm nylon mesh and cells 
pelleted by spinning at 300xg for 10 minutes. Pellets were re-suspended at 107 cells/ 90 
μl of MACS buffer and 10 μl of the respective microbeads were added per 107 cells. 
After thorough mixing, cells were incubated at 4-8oC for 15 minutes and then washed in 
3 ml MACS buffer by spinning at 300xg for 10 minutes. Pellets were re-suspended in 500 
μl buffer per108 cells and applied onto an MS selection column (Miltenyi Biothech 
GmbH, Germany) placed in a magnetic field and prepared according to the 
manufacturer’s instructions. Unlabeled cells were collected when they passed through the 
column as a negative fraction and the labeled cells, the positive fraction, were harvested 
after removing the column from the magnetic field and flushing with an appropriate 
volume of buffer by firmly applying the plunger into the column. Cells were washed once 
in complete RMPI 1640 medium, re-suspended in the original (pre-depletion) volume of 
the same media, counted and adjusted to 107 cell/ml by adding APC from naïve mice. 
Cells were kept on ice until used in the ELISPOT assay and 100 μl of these cells were 
added per well so that each well of the ELISPOT assay will have equal number (106) of 
spleen cells. 
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For flow cytometric analysis, a 100 μl aliquot containing around 106 cells in complete 
RPMI media were taken from each test tube into a screw cap 2 ml tube. Tubes were 
centrifuged at 300xg for 10 minutes, supernatant removed gently and pellets re-
suspended in 100 μl FACS buffer (5% FCS in PBS). Cells were stained for expression of 
CD4(L3/T4, Ly4) and CD8(Ly2) by adding 5 μl of FITC conjugated rat anti mouse CD4 
(Clone YTS 191.1.2) and PE conjugated rat anti-mouse CD8 (Clone YTS 169 AG 
101HL) antibodies (Cedarlane Laboratories Ltd) to each tube and incubating in the dark 
for 30-45 minutes at 4-8 OC. Cells were again washed as above in 1 ml FACS buffer and 
pellets re-suspended in 1ml buffer and analyzed by flow cytometry using a Beckman 
Coulter Epics Flow Cytometer and Expo32 v1.2 analysis software (Beckman Coulter, 
Mississauga, ON, Canada). If flow cytometry was not to be done on the same day, cells 
were fixed by adding equal volume of 2% formaldehyde in PBS and stored in the dark 
until next day. 
 
4.11. Anti-IL-4 Antibody Production  
The protocol for ascites production was described in detail previously (Coligan et al., 
1992). Briefly, adult BALB/c or CD1 mice, age 8-10 weeks, were injected with 0.5 ml of 
incomplete Freund’s adjuvant (IFA) or 0.5 to 1 ml pristane ip to induce nonspecific 
inflammation. As the hybridoma cells are of rat origin, mice were treated ip with 4 
mg/mouse of cyclophosphamide and/or gamma irradiated with ~750 rads to suppress the 
immune response seven days after pristane or IFA treatment. Then, on the same day or 
the next morning, the mice were injected, using a 20 or 22 gauge needle, with 0.2 ml 
saline containing ~108 11B11 hybridoma cells (ATCC # HB-188). Starting from day 7 
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after injection, mice were checked for the development of ascites and ascites fluid was 
collected into a test tube using an 18-gauge needle. Collected fluid was purified by 
thiophilic adsorption chromatography using the T-GelTM purification Kit (Pierce, 
Rockford, IL, USA) according to the manufacturers protocol and its biological activity 
was tested using the CT4S (IL-4 dependent cell line) assay as previously described (Hu-
Li et al., 1989). Briefly, cells were counted, washed, and re-suspended in RPMI complete 
medium at a concentration of 1x105 cells/ml. Standard and sample (ascites fluid) to be 
tested were titrated onto 96-well flat bottom plates at 50 µl/well. The range of the rIL-4 
standard was 4 units/ml to 0.5 units/ml without or with 30 µl anti-IL-4 antibodies/well. 
To the test wells, 50 µl media was added to the first row and the sample (ascites fluid) 
was serially diluted from 1/25 to 1/3200 in triplicates starting from the second row. Then, 
100 units rIL-4/ml was added to all the test wells. Finally, 100 µl culture medium 
containing the CT4S cells was added to all wells at a concentration of 104 cells/well. 
Plates were incubated overnight at 37°C in a humidified atmosphere containing 5% CO2. 
At the end of the incubation period, 0.5 µCi of tritiated thymidine in 50 µl medium was 
added to each well and plates were again incubated for 4hrs at 37°C. After final 
incubation, cells were harvested onto a filter paper and placed into scintillation tubes. 
Finally, each tube was filled with 4 ml of scintillation cocktail and cell proliferation 
counted using Beckman LS 5000TD liquid scintillation system (Beckman Instruments 
Inc, Fullerton, CA, USA). The BCA protein assay (Pierce, Rockford, Illinois) was used, 
as described in section 4.4, to determine the concentration of anti-IL-4 antibody and mice 
were treated with this antibody as described in section 4.12. 
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4.12. Treatment of Mice with Anti-IL-4 Antibody 
Mice previously vaccinated with a dose of BCG that induced a mixed Th1/Th2 response 
were divided into two groups and treated ip either with 1 mg/week anti IL-4 antibody for 
4 weeks or an equal amount of control antibody. This dose was chosen based on previous 
results from the mouse model of leishmaniasis in our laboratory (Uzonna and Bretscher, 
2001). ELISPOT and ELISA assays were done between 6 to 18 weeks after the last 
treatment to determine if anti-IL4 antibody treatment is able to alter the immune response 
from a mixed Th1/Th2, humoral, type of response into a cell-mediated, Th1, response.  
 
4.13. Exposure of Mice to Mycobacterium gordonea 
M. gordonea stock was obtained from the TB laboratory of the Royal University 
Hospital, University of Saskatchewan, Saskatoon. Bacterial stock was propagated in 
Middlebrook 7H9 broth supplemented with 10% Middlebrook ADC enrichment and the 
number of bacteria subsequently enumerated by plating on Mycobacteria 7H11 agar 
supplemented with Middlebrook OADC enrichment (BD Biosciences, Sparks, MD 
21152, USA). For infection, bacteria were washed three times in PBS by centrifuging at 
8000xg and re-suspended at the required concentration in the same buffer. Mice were 
exposed orally to M. gordonea (~5x106 cfu/ml) in the drinking water for 2-3 weeks in a 
attempt to cause immunological priming, as assessed by seroconversion. Our results were 
not consistent and so we decided to prime mice by exposing them to the same 
mycobacteria by sc injection with different doses of the bacteria. This was to determine a 
dose that can induce a mixed Th1/Th2 response as assessed by seroconversion. 
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4.14. Nitric Oxide Assay 
This assay was done to measure the total level of nitric oxide (NO) secreted by activated 
macrophages. Isolation and culture of mouse macrophages was carried out as described 
elsewhere (Coligan et al., 1998). Briefly, adult BALB/c mice were injected ip with 1ml of 
3% Brewer’s thioglycolate medium prepared by the Glassware and Media Preparation 
Unit of the Department of Vet. Microbiology, University of Saskatchewan. Four days 
later, mice were killed by cervical dislocation and laid on their back. The abdomen was 
disinfected with 70% ethanol and a midline incision made with sterile scissors. After 
reflecting the abdominal skin with forceps, the abdomen was penetrated with a 19G 
needle attached to a 10 ml syringe that contained 6-8 ml Delbucco’s tissue culture 
medium, DMEM-0%, (DMEM media with no serum but supplemented with 100 U/ml 
penicillin, 100 μg/ml streptomycin, 0.8mM sodium pyruvate, and 5x10-5 M β-
mercaptoethanol). The peritoneum was flushed with the medium and the lavage harvested 
with the same syringe and needle into a 15 ml centrifuge tube. Cells were washed in the 
same media by spinning at 300xg for ten minutes, counted and re-suspended in DMEM-
10%, (DMEM media supplemented with 10% heat inactivated fetal bovine serum, 100 
U/ml penicillin, 100 μg/ml streptomycin, 0.8 mM sodium pyruvate, and 5x10-5 M β-
mercaptoethanol) at 106 cells/ml. Cells were added into a 24 well polystyrene tissue 
culture plate (Corning Glass Works, Corning, NY) at 1 ml/per well and incubated in a 
humidified, 5% CO2 incubator set at 37oC. After 2-3 hours of incubation, non-adherent 
cells were removed by careful aspiration and the adherent cells were further incubated for 
another 48 hours by adding 1 ml DMEM-10% media containing nylon wool-purified T-
cells in the presence or absence of BCG antigen.  
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To separate T-cells using nylon wool columns, spleen cells from mice vaccinated with 
either low dose or high dose of BCG or saline were prepared into single cell suspension 
as described above, and then red blood cells were lysed using the hypotonic lysis method 
(Gordon 2002). Briefly, 9 ml ddH2O was added into 1 ml cells and lysis stopped after 20 
seconds by adding 1 ml of 10x Hank’s Balanced Salt solution, HBSS (GIBCO). Cells 
were washed by centrifuging at 300xg, re-suspended in DMEM-10% at 108 cells/ml and 
purified using nylon wool fiber columns (Polysciences Inc, Warrington, PA) according to 
the manufacturer’s instructions. Cells collected from the column were again washed in 
DMEM-0% and re-suspended at 5x106 cells/ml in DMEM-10% and added into the wells 
containing the adherent cells at 1 ml per well. After 48 hours incubation, the supernatant 
was collected from each well into test tubes and stored at -20 oC until the NO level was 
measured in the Griess reaction using the ParameterTM NO assay kit (R&D Systems, Inc. 
Minneapolis, USA), as per the manufacturer’s protocols.  
 
4.15. Statistical Analysis 
 
Analysis of variance was carried out on the estimated number of antigen-dependent 
cytokine secreting cells from mice within each vaccination groups using the SAS 
statistical package PROC GLM (SAS, 1999) and the number of IL-4 and IFN-γ secreting 
cells as well as their ratios were compared in mice among groups using the Fisher’s 
protected least significant difference (FLSD) test. P values <0.05 were considered to be 
significant.  
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5. Results 
 
5.1. Low Dose BCG Vaccination in Newborn Mice 
 
5.1.1. Introduction 
In humans, vaccination with BCG against tuberculosis is usually done on newborn 
infants immediately after birth. Moreover, neonatal BCG specific Th1 imprinting may be 
important in the prevention of Th2 imprinting caused by exposure to environmental 
mycobacteria, which may interfere with the efficacy of vaccination (Fine, 1995; Black et 
al., 2001). Studies outlined in the Introduction and carried out with both animals and 
humans indicate that the neonatal immune system can be easily primed following 
exposure to environmental mycobacteria. Hence, our objective in this experiment was to 
determine an appropriate low dose vaccination strategy in newborn mice to establish a 
Th1 imprint as early as possible and thus prevent possible interference by environmental 
mycobacteria. Mice, unlike man and cattle, are less immunocompetent at birth. 
Observations from our laboratory (unpublished data) and from others (Piguet et al., 1981; 
Ridge et al., 1996) show that the total number of peripheral T-cells (LN plus spleen) at 
birth are more than 1000 fold lower than in adult mice. Similarly, the number of 
thymocytes at birth is more than 100 fold lower than in mice 7-14 days after birth (Piguet 
et al., 1981; Xiao et al., 2003). Therefore, 7-14 day old mice may arguably best represent 
the immunocompetence of newborn humans (Siegrist, 2000) and mice of about this age 
can be used as an animal model for our envisaged strategy for tuberculosis vaccination in 
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humans. In preliminary studies, neonatal BCG vaccination of 2-day-old mice gave results 
that could not be interpreted due to high variability within mice of the same group (data 
not presented). This variability could be due to the immune-incompetence of mice at 
birth, as discussed above, or could be also due to technical problems in vaccine delivery. 
It was very difficult to reliably inject the required dose of BCG intradermally into 2-day-
old mice. Therefore, we decided to use “very young mice” instead of neonates. We use 
the terms “very young” or “newborn” to refer to mice between the ages of 5 and 7 days. 
 
5.1.2. Results 
 
5.1.2.1. Dose of BCG Administered to Newborn Mice Determines the 
Th1/Th2 Nature of the Ensuing Immune Response  
 
We wished to determine if the cell-mediated/humoral nature of the immune response to 
BCG in newborn BALB/c mice was dependent upon the dose of BCG administered. As 
explained in section 5.1.1, such a study is a required first step in developing a mouse 
model to examine the potential efficacy for a neonatal low dose BCG vaccination 
strategy against tuberculosis in humans. We therefore chose to examine the responses of 
newborn BALB/c mice vaccinated with a range of BCG doses. We chose a highest dose 
that can induce a mixed Th1/Th2 response in naïve mice on the basis of previous studies 
from our laboratory in adult mice. We then chose different doses, which are several logs 
lower than the highest dose to look for the lowest possible dose that can induce an 
exclusive Th1-type response with no significant Th2 component. Accordingly, mice were 
vaccinated with 33, 330, 3300, 3.3x107 cfu of BCG or saline sc in a 20 μl volume. Mice 
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were sacrificed at different times after vaccination and ELISPOT assays were employed 
to enumerate the number of BCG-specific IFN-γ and IL-4-producing T-cells per million 
spleen cells (Figure 3). Each sample was analyzed in triplicate and the average of the 
three wells was used to determine antigen-dependent spots by subtracting spots in antigen 
negative wells from those counted in antigen positive wells. Figures 4A and B show 
observations obtained from mice sacrificed 12 and 16 weeks post-vaccination, 
respectively. Individual rather than pooled responses are shown to demonstrate the 
consistency of the observed responses. In general, responses much greater than 
background (seen in age-matched control mice) are generated in mice vaccinated with 33, 
330, 3300 and 3.3x107 cfu of BCG. Statistical analysis of the overall result shows that all 
vaccinated mice have significantly (P<0.05) higher numbers of IFN-γ-secreting cells in 
their spleen than non-vaccinated mice, but no significant differences were observed 
among vaccinated groups. This reflects the level of IFN-γ production at a relatively long 
time after vaccination when the Th1-type response is stabilized. We chose to assess the 
immune response at this time, as we were interested in the long-term response following 
immunization of newborn mice. The level of the IFN-γ response might well differ 
significantly between mice given different doses of BCG during the early course of the 
infection, as the lower doses need time to replicate and induce an immune response 
comparable to the high dose vaccinated group. On the other hand, no significant numbers 
of IL-4-secreting cells were found in any of the low dose vaccinated groups (33, 330, 
3300 cfu); however, mice in the high dose group (3.3x107 cfu) displayed a significantly 
higher (p<0.05) number of IL-4-secreting cells than both the control mice and low dose 
vaccinated groups. 
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Figure 3. Picture of a 96 well plate showing BCG-specific IFN-γ and IL-4 spots as 
detected in the ELISPOT assay.  
Spleen cells from BALB/c mice vaccinated with different doses of BCG were assessed 
for the number of antigen-dependent cytokine producing cells by ELISPOT assay. The 
picture above shows the number of spots seen in mice immunized when very young, with 
either saline or the indicated number of BCG given sc. Mice were sacrificed around 12 
weeks post-vaccination and spleen cells processed for ELISPOT assay. The spots shown 
in the picture were produced by culturing 5x105 sensitized spleen cells per well.  
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Figure 4. Low doses, but not a high dose of BCG, administered to newborn BALB/c 
mice generate predominant Th1 responses.  
Newborn BALB/c mice were vaccinated with different doses of BCG subcutaneously as 
shown on the abscissa and were sacrificed at 12 (A) and 16 (B) weeks post-vaccination. 
Spleen cells were assessed for the number of antigen-dependent cytokine secreting cells. 
These two sets of observations are representative of more than 4 replicate experiments 
with 3-5 mice per group in each experiment. Data represent values for individual mice in 
each group. 
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In summary, the three lowest doses of BCG employed generated predominantly Th1-type 
responses with an “indeterminate” value for the ratio of the number of antigen specific 
IFN-γ to IL-4-producing cells due to an insignificant or barely detectable number of 
antigen-specific IL-4-producing cells, usually < 10 per million spleen cells. The possible 
detectable numbers of spots were used for analysis purposes. The highest dose of BCG 
generated a mixed Th1/Th2 response with an IFN-γ/IL-4 ratio less than or close to 1, 
which is significantly (p<0.05) lower than the ratio in the mice belonging to low dose 
vaccinated groups. Mice were also bled and their peripheral blood leucocytes isolated to 
assess, by ELISPOT assay, the number of antigen-dependent cytokine producing cells. 
Serum collected from whole blood was also used to measure, by ELISA, the levels of 
mycobacterium-specific IgG1 and IgG2a antibodies. The nature of the response seen in the 
peripheral blood reflected a trend similar to that observed in the spleen: all low dose 
vaccinated groups had a high number of IFN-γ-secreting cells but an inconsistent and low 
number of IL-4 producing cells in their peripheral blood, while the high dose vaccinated 
group had a substantial number of IL-4-producing cells (Table 1). Again, no significant 
difference in the level of IFN-γ production was observed among all vaccinated groups, 
but the level of IL-4 was significantly higher (p< 0.05) in the high dose (3.3x107 cfu) 
vaccinated group. Our observations in the BCG model as well as results from the 
leishmania model (unpublished data) show relatively more IL-4-secreting cells are found 
in the peripheral blood than in the spleen when compared to the number of IFN-γ 
producing cells. This general finding is reflected in the ratio of IL-4/IFN-γ-producing 
cells, which is >2 in peripheral blood but <1 in the spleen of the high dose vaccinated 
group.  
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Table 1. Low dose BCG vaccination in 5-7 day old BALB/c mice induces a 
predominantly cell-mediated response with a high level of IFN-γ-secreting cells in 
the peripheral blood.  
Blood taken from the tail vein was processed to isolate peripheral blood mononuclear 
cells, and the PBMNCs cells were dispensed into ELISPOT plates to determine antigen-
specific cytokine secreting cells in blood. Mice in each group were injected with the 
indicated number of bacteria in cfu, while control mice were injected with an equal 
volume of saline. Results represent the mean values from 3-4 mice per group with the 
standard deviation of the mean (SD).  
 
 
Antigen-specific cytokine secreting cells per 
million PBMNCs as detected in the 
ELISPOT assay 
 
 
 IFN-γ IL-4 IL-4/IFN-γc
 
BCG dose (cfu) Mean SDb Mean SDb  
33 145.0 28.3 24.5 0.7 0.17‡ 
330 117.5 20.5 66.3 7.1 0.56‡ 
3300  202.0 12.7 20.0 1.4 0.10‡ 
3.3x107 114.5 48.8 231.0 43.8 2.02* 
Salinea 13.3 NA 18.3 NA NA 
a Control mice injected with equal volume of saline 
b Standard deviation of the mean as calculated in Microsoft Excel, 2003 
c IL-4 to IFN-γ ratio 
NA, Not applicable as pooled blood was used 
* Significant difference at 0.05 p value 
‡ No significant difference between groups 
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The qualitative nature of the immune response generated following BCG vaccination of 
mice was also reflected in the isotype of antibodies produced. Low dose vaccination 
resulted in either antibody levels below the detection limit when assessed with a serum 
dilution of 1 in 100 (represented by *** in Figure 5), or predominantly IgG2a antibodies 
for intermediate doses (data not shown). In contrast, vaccination with the highest dose of 
BCG induces a mixed IgG1 and IgG2a antibody response (Figure 5). Our findings agree 
with a recently published report, which concluded that the BCG antigen-specific antibody 
response was dose dependent (Horwitz et al., 2006). Extraordinarily few (10 cfu) of BCG 
was used in this study to vaccinate guinea pigs and only cell-mediated response was 
induced. In contrast, the highest vaccine dose used in the study induced both cell-
mediated and humoral responses, with significant antibody titers.  
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Figure 5. Low dose BCG vaccination in 5-7 day old BALB/c mice induces a 
predominantly cell-mediated response with no detectable BCG-specific IgG1 and 
IgG2a antibodies.  
Blood taken from the tail vein was spun at 12000 rpm for 3-5 minutes in a Microspin 
centrifuge to obtain serum; then assessed by ELISA for BCG-specific IgG1 and IgG2a 
antibodies. Numbers in the abscissa represent the dose of BCG vaccine. AMC indicates 
pooled serum sample from 3 age matched control mice given saline at the time of 
vaccination. * stands for a titer < 100. Results shown are from one of three replicate 
experiments with data presented for individual mice in each group (n=3-4 mice). 
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5.1.2.2. Pre-exposure of Newborn BALB/c Mice to Low Doses of BCG 
Leads to Th1-Imprinting as Assessed by a High Dose BCG iv 
Challenge 
 
To examine whether exposure of newborn mice to BCG could result in effective Th1 
imprinting, as assessed by high dose BCG challenge, and whether such imprinting 
resulted in decreased splenic mycobacterial burden following BCG challenge, mice were 
vaccinated sc with either saline (control group) or different doses of BCG (33, 330, 3300, 
and 3.3x107 cfu in 20 µl of saline) at 5-7 days after birth. Mice were followed 
longitudinally for up to a year to monitor the antibody and T-cell responses by ELISA 
and ELISPOT assays, respectively. As reported in section 5.1.2.1, mice vaccinated with 
low doses of BCG consistently mounted exclusive Th1-type responses, whereas mice in 
the high dose vaccinated group (3.3x107 cfu) generated mixed Th1/Th2 responses. The 
Th1/Th2 nature of the response in the vaccinated mice was stable for at least 9-12 months 
(data not shown); a time corresponding to half of the mouse’s expected life span. 
However, the critical question was whether this stable response was associated with a 
stable Th1 imprint? We wanted to address this issue by high dose challenge of vaccinated 
mice and assessing the IgG isotypes of the anti-BCG antibody response and the Th1/Th2 
nature of the immune response by ELISA and ELISPOT assays, respectively.  
 
Before challenge of vaccinated mice with a high dose of BCG, we wished to determine 
the highest dose that could be administered without affecting the health of the mice. 
Several experiments were required to determine an effective challenge dose. We first 
challenged both vaccinated and naïve mice with ~3.3x107cfu of BCG iv, but some mice, 
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particularly in the high dose vaccinated and challenged group demonstrated neurological 
symptoms, such as loss of balance and head tilting to one side at around six weeks post-
challenge. Although ear infection was first suspected, necropsy and histopathological 
examination performed on representative mice by Dr. O’Connor, (Prairie Diagnostic 
Service, Western College of Vet. Medicine, University of Saskatchewan) excluded ear 
infection. This examination revealed severe inflammatory lesions in multiple organs 
(lung, liver, spleen, kidney, brain, and adrenal glands) with lymphocytic infiltration and a 
non-suppurative encephalitis in the mid-brain. The lesions were particularly severe in the 
lung and spleen with severe perivascular and peribronchiolar lymphocytic infiltration and 
granulomatous inflammation. Numerous acid-fast bacilli were detected inside foamy 
macrophages in the lung and prominent follicles with similar histopathology were 
observed in the spleen. Following high dose iv challenge, an increase in the size of the 
spleen was also observed, with a maximum increase of 2-to-5 fold in the high dose 
vaccinated and unvaccinated groups when compared to vaccinated but unchallenged mice 
(Figure 6).  
 
We suspected the gross and microscopic lesions were due to the extremely high challenge 
dose for various reasons. Since the iv route is more immunogenic than id/sc routes, the 
challenge dose used here (~3.3x107 cfu) might be high enough to induce a mixed 
Th1/Th2 response when given id/sc, but so high that when administered as an intravenous 
challenge a potential pathogenic capacity of BCG was revealed. The greater effectiveness 
of antigen given intravenously over that given subcutaneously is not surprising, as in the 
former case the antigen is expected to reach secondary lymphoid organs more effectively. 
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In addition, the BCG will likely reach more locations in the body when given iv than sc 
or id. Our observations are consistent with other reports indicating antigen given iv was 
more immunogenic than when given sc (Lagrange et al., 1974). Furthermore, re-
assessment of the number of bacteria in the challenge dose by plating on agar showed 
around 1.1x108 cfu, considerably higher than the original estimate of 3.3x107. After a few 
preliminary challenge experiments, we determined that doses between 2x106 and 1x107 
cfu were safe for challenge. All challenges were made iv based on previous protocols 
employed in M. tuberculosis challenge studies. North and Jung have reported that 
infecting mice with 105 cfu virulent M. tuberculosis iv can result in similar pathological 
lesions in the lung and other organs as mice infected with 100 cfu intranasally, which 
corresponds to the natural mode of infection (North and Jung, 2004). The ultimate goal of 
our studies was to carry out such M. tuberculosis challenges, but these could not be 
realized due to unavailability of appropriate facilities at our university. The same study 
by North and Jung has reported that, next to the liver, the bulk of an iv inoculum implants 
in the spleen. It is, therefore, appropriate to assess the splenic response following iv 
challenge of mice.  
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Figure 6. A very high dose of BCG (1.1x108 cfu) given iv following sc vaccination 
with different doses of BCG induces pathological lesions in the spleen and lung of 
BALB/c mice.  
Gross and histopathology studies of spleen and lung were conducted on BALB/c mice 
vaccinated with different doses of BCG sc and challenged iv with ~1.1 x108 cfu of BCG 
12 weeks post-vaccination. Mice were sacrificed between 6 and 9 weeks following high 
dose iv challenge. A) Gross size of spleen from vaccinated but unchallenged mice (first 
two tubes) as well as in mice vaccinated with 3.3 x107 cfu of BCG and then challenged 
with a high dose BCG (last two tubes). B) Acid-fast bacilli inside a macrophage from 
spleen lesions. C) Lymphocyte infiltration with giant foamy macrophages in the lung. D) 
Acid-fast bacilli in one of these macrophages from the lung lesion. 
A C
B D
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We tried different doses to find a dose of BCG that can induce a mixed Th1/Th2 response 
in naïve mice, and with little or no complication in vaccinated mice when given 
intravenously. By using a dose of BCG that induces a mixed Th1/Th2 response in naïve 
mice as a challenge dose, we are trying to mimic the type of response observed in human 
tuberculosis patients with a significant Th2 component. Accordingly, doses between 
2x106 and 1x107 cfu were found to be safe for our purpose and naïve mice as well as 
mice vaccinated with different doses of BCG were challenged with a dose of BCG within 
this range, injected iv in 250 µl of saline. Each group contained 9-12 mice and mice in 
each group were challenged between 3 to 6 months after vaccination. Three to five mice 
from each group were bled for assessment of the BCG-specific antibody response by 
ELISA and sacrificed for an assessment of the Th1/Th2 nature of the splenic immune 
response by ELISPOT, and splenic bacterial burden by colony formation, at a time 
between 12 and 18 weeks post-challenge. ELISA results indicated that all challenged 
mice had high titers of both BCG-specific IgG1 and IgG2a antibodies (Figure 7). On 
average, the ratio of IgG2a to IgG1 was between 5 and 15 in the low dose vaccinated 
group, between 2 to 4 in the high dose vaccinated group, and around 1 for the non-
vaccinated but high dose challenged group. Similarly, results from the ELISPOT assay 
revealed that low dose BCG (33, 330, 3300 cfu) vaccinated mice mounted a Th1-type 
response upon high dose iv challenge, with IFN-γ to IL-4 ratio ranging between 15 to 60. 
In contrast, the high dose (3,3x107 cfu) vaccinated and non-vaccinated group when 
challenged iv with a high dose of BCG generated mixed Th1/Th2 responses, with IFN-γ 
to IL-4 ratios of around 1 and < 1, respectively (Figure 8). No significant differences 
were found in the level of IFN-γ secreting cells when comparing among groups. 
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Furthermore, the level of IL-4 was not different among mice from the low dose (33, 330, 
3300 cfu) vaccinated groups. Accordingly, the IFN-γ to IL-4 ratios of the low dose 
vaccinated groups were not statistically different. Similarly, there was no significant 
difference in IL-4 levels between the high dose (3.3x107 cfu) vaccinated and non-
vaccinated groups after challenge. However, a significantly higher (p<0.05) level of IL-4 
in the high dose vaccinated and non-vaccinated mice after high dose iv challenge was 
noted when compared to the low dose vaccinated groups. Accordingly, the IFN-γ to IL-4 
ratios from all low dose vaccinated groups were significantly different (p<0.05) than the 
high dose vaccinated and non-vaccinated groups. These results confirm that low dose 
BCG vaccination in the newborn can induce the appropriate type of response, with a 
subsequent lock of the response into a Th1 mode as seen upon high dose iv challenge. It 
is tempting, when comparing Figures 4 and 8, to summarize these observations by saying 
that long term infection of newborn BALB/c mice with 33, 330 and 3300 cfu led to Th1 
responses and Th1 imprints, and with 3.3x107 to balanced Th1/Th2 responses and 
Th1/Th2 imprints.  
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Figure 7. The BCG-specific IgG2a to IgG1 ratio following iv challenge with high dose 
BCG was higher in the sera of mice vaccinated with low dose of BCG than mice 
vaccinated with a high dose of BCG or naïve mice.  
Newborn BALB/c mice vaccinated with different doses of BCG were challenged iv with 
6x106 cfu of BCG at 16 weeks post-vaccination. A) Titers of BCG-specific IgG1 and 
IgG2a antibodies present in serum at 12 weeks post-challenge were assessed in ELISA. 
The ratio of IgG2a to IgG1 antibodies for each group is also shown (B). These data 
represent mean antibody titers of 3-5 mice per group with SD and is representative of one 
of at least three replicate experiments. AMC (age matched control) refers to the 
unvaccinated but challenged group. CNT (control) refers to pooled sera from 
unvaccinated and unchallenged mice. * represents titers <100 
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Figure 8. Low dose BCG vaccination induces Th1 type response and Th1-imprinting 
in newborn ( 5-7 days old) BALB/c mice.  
Newborn BALB/c mice were vaccinated with different doses of BCG, and were 
challenged iv 16 weeks post-vaccination with ~6x106 cfu of BCG. BCG-specific IFN-γ 
and IL-4-producing T-cells present in the spleen were measured by the ELISPOT assay at 
(A) 12 and (B) 18 weeks post-challenge. AMC (age matched control) refers to naïve mice 
challenged with high dose of BCG. The results shown are from one of three replicate 
experiments with data presented from individual mice within each group (n= 3). 
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We also determined if the Th1 imprint seen in the low dose vaccinated mice was 
accompanied by a more efficient clearance of BCG and hence a lower bacterial burden in 
the spleen. Spleens were removed from each mouse at the indicated time points following 
BCG challenge and processed to generate single cell suspensions at 107 cells/ml. Half the 
spleen was used for ELISPOT assay and the remaining half processed for assessing 
bacterial burden as described in the Materials and Methods section (see also Figure 9).  
 
Figure 10 summarizes our findings from four independent experiments determining how 
the mycobacterial burden in the spleen, following an intravenous challenge of BALB/c 
mice with a high dose of BCG, depends on the dose of BCG vaccine given to them sc as 
newborn mice. The scale for the bacterial burden is different for the different 
experiments; however, in all cases greater bacterial burdens were seen in mice given 
higher doses of BCG challenge. The exact conditions of these experiments are slightly 
different, as described in the legend. However, the overall pattern is very clear. 
Vaccination with the lowest dose (33 cfu) is the most consistent and reliable means of 
reducing the mycobacterial burden following the high dose BCG challenge, with a 
reduction ranging from around 50 to about 200 fold. In general, no statistically significant 
difference was observed among the low dose vaccinated groups. However, non-
vaccinated and high dose vaccinated mice were significantly different (p<0.05); both 
these groups were also significantly different than the entire low dose vaccinated groups. 
In some experiments, no difference was found between high dose vaccinated mice and 
low dose vaccinated mice in the efficacy of clearing mycobacteria from the spleen 
(Figure 10C and D). The reason for this could be due to the technical difficulty of trying 
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to deliver 3.3x107 cfu of BCG in a very small inoculum (10-20 μl) administered sc to 
newborn mice. An assessment of the bacterial suspension after vaccination led on one 
occasion to an estimate of only 106 cfu of BCG in each aliquot of the high dose, which is 
10-fold lower than the intended dose. Such a dose generates a mixed Th1/Th2 response 
with relatively higher levels of IFN-γ than IL-4 (data not shown). Even after high dose 
challenge there is a tendency for mice vaccinated with a high dose of BCG to show a 
slight bending of response generated to the high dose challenge towards the Th1 pole. It 
is interesting to examine the situation represented in Figure 8A that comes from the same 
experiment that provided the observations recorded in Figure 10B. Vaccination of 
newborn mice with high dose of BCG resulted in a slight but significant bending of the 
response to the Th1 pole, a bending associated with about a 5-fold drop in mycobacterial 
burden. The greater the modulation of the immune response towards the Th1 pole, caused 
by vaccination of mice with lower doses of BCG, the greater are the reductions in the 
mycobacterial burden.  
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Figure 9. Pictures of plates used to measure mycobacterial burden in the spleen of 
BALB/c mice following high dose BCG challenge.  
Spleen cells were pooled from 3 mice in each group vaccinated with different doses of 
BCG and challenged iv with a high dose of BCG. Mice vaccinated with low doses of 
BCG had a lower bacterial burden than non-vaccinated mice or those vaccinated with a 
high dose of BCG following a high dose BCG iv challenge. Numbers represent dose of 
BCG used to vaccinate newborn mice sc before high dose iv challenge. Result represents 
one of more than 4 replicate experiments.  
33cfu 330cfu 3300cfu
3.3x107cfu unvaccinated
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Figure 10. Th1 imprinting as a result of vaccination of newborn BALB/c mice with 
low doses of BCG was associated with more efficient BCG clearance from the spleen 
following iv challenge of mice with high dose of BCG.  
BALB/c mice were vaccinated with different doses of BCG and challenged iv with 
~3.3x107 (A), ~6x106 (B) and 2x106 (C and D) cfu of BCG at 12 weeks post-vaccination. 
Mice were then sacrificed between 12 and 18 weeks after challenge and spleen cells 
processed for assessment of bacterial burden. Results shown represent mean of 4-6 mice 
per group with error bars (SD). AMC (age matched control) refers to naïve mice 
challenged with high dose of BCG. 
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Table 2. Results of statistical analysis for data shown on Figure 10A-D 
BALB/c mice vaccinated and challenged as described in the legend for Figure 10 were 
sacrificed at (A) 14 weeks, (B) 12 weeks, (C) 16 weeks, and (D) 18 weeks post-
challenge. Spleens were removed from each mouse and processed for assessment of 
bacterial burden. Data presented show average bacterial burden x103 cfu per spleen of 4-6 
mice in each group. Statistical analysis was done to compare bacterial burden among 
groups following high dose BCG iv challenge. Groups with the same p value letters 
indicate no statistical difference in bacterial burden at p=0.05. 
 
A‡ B‡ C‡ D‡  
BCG 
vaccine 
dose (cfu) 
Mean  p* 
value 
Mean  p* 
value 
Mean  p* 
value 
Mean  p* 
value 
33 32.8 a 26.8 a 7.7 a 2.7 a 
330 47.0 a 39.2 a 7.8 a 6.0 a 
3300 58.7 a 163.4 b 11.2 a 9.7 a 
3.3 x107 285.4 b 275.2 c 52.1 a 22 a 
AMC 4936.7 c 1248.4 d 384.2 b 297.7 b 
‡ Stands for the four different experiments described in Figure 10 
*Vaccination groups with the same letter (p value) indicates no significant difference in 
bacterial burden at p=0.05 
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5.1.3. Discussion 
 
The major aim of this study was to develop a mouse model of human neonatal BCG 
vaccination. Such vaccination is most often administered intradermally. Reliable 
intradermal delivery of BCG to neonatal mice was difficult, so we adopted subcutaneous 
administration. We made this compromise under the premise that the Th1/Th2 phenotype 
of the immune response in adult mice depends on the dose of BCG independently of the 
route of administration (Power et al., 1998). We also initially attempted to vaccinate mice 
within two days of birth and obtained relatively inconsistent immune responses. For 
reasons discussed in section 5.1.1, we chose to inject mice at the age of 5-7 days, and 
obtained very consistent responses.  
 
The immune response in neonates is generally believed to be intrinsically biased towards 
Th2-type responses. Antigen administration during the neonatal period is also thought to 
often result in antibody-dominated responses later in life, contributing to the poor 
capacity of neonates to mount an effective cell-mediated response against intracellular 
pathogens (Barrios et al., 1996; Adkins and Du, 1998; Adkins, 2000; Siegrist, 2000). 
However, evidence indicates that neonates can generate effective cell-mediated immunity 
(CTL) that can clear viral infections (Sarzotti et al., 1996), supporting the possibility that  
whether antigens generate specific Th1 or Th2 cells in neonates depends on the dose and 
mode of vaccination (Forsthuber et al., 1996; Sarzotti et al., 1996). Our observations 
reinforce conclusions made by Forsthuber and Sarzotti, which indicate that neonatal mice 
can produce cell-mediated and antibody responses upon exposure to low and higher doses 
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of antigen, respectively. We employed the ratio of the number of BCG-specific IFN-γ to 
IL-4-producing cells per million spleen cells in vaccinated mice as a measure of the 
relative magnitude of the Th1 and Th2 components of the immune response. This ratio is 
referred to as the index of the Th1/Th2 phenotype of the response. A high Th1/Th2 index 
thus corresponds to a predominantly Th1 response, and a low index, below 1, to a 
predominantly Th2 response. This ratio was > 10 with spleen cells derived from mice 
vaccinated 12 weeks previously with lower doses of BCG, whereas the corresponding 
ratio was around 1 for mice vaccinated with 3.3x107 BCG. Goriely and colleagues 
suggested that the Th1 response in human neonates may be defective as cord blood 
derived dendritic cells are unable to produce the pro-Th1 cytokine, IL-12, in response to 
stimulation with LPS or CD40L (Goriely et al., 2001). In contrast, and in agreement with 
our results, BCG vaccination of infants at birth induced a potent Th1 response with levels 
of IFN-γ similar to that achieved with vaccination of adults (Marchant et al., 1999; 
Vekemans et al., 2001), suggesting our findings are pertinent to vaccination strategies of 
human neonates. 
 
We also demonstrated that the generation of a Th1 response by low dose BCG 
vaccination of newborn mice led not only to a predominantly Th1 response, but also to a 
modulation of the Th1/Th2 phenotype of the response towards the Th1 pole following a 
high dose BCG iv challenge. This dose generated a mixed Th1/Th2 response in adult 
naïve mice. Moreover, this Th1 biased response was associated with a decreased 
mycobacterial burden in the spleen. The observations of Figures 8 and 10 clearly indicate 
that the greater the modulation of the response to the Th1 pole, the greater was the 
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decrease in mycobacterial burden. Furthermore, the most consistent and greatest Th1 bias 
and bacterial clearance was achieved by vaccination of newborn mice with the lowest 
dose of BCG (33 cfu) injected sc. This has been supported by statistical analysis as 
described in the corresponding text for each figure and also shown in Table 2. Our 
finding that robust Th1 responses and efficient Th1 imprinting can be achieved by 
administering as low a dose of BCG as 33 cfu to newborn BALB/c mice is in agreement 
with a very recent finding in which 10 cfu of live rBCG vaccine induced strong 
protective immunity against tuberculosis in guinea pigs (Horwitz et al., 2006a). Our 
results, therefore, support the possibility that an ultra-low dose BCG vaccination strategy 
in neonates may be used to achieve Th1 imprinting in a genetically diverse population. 
Ultra-low dose of BCG is defined as a dose of BCG that initially induces either no 
immune response at all or induces only a cell-mediated immune response in every 
individual of a heterogeneous population. In the former case, as BCG is a live replicating 
organism, we expect it to replicate and reach the threshold level over a certain period of 
time and induce a cell-mediated response in all individuals. These observations may have 
implications for a vaccination strategy in humans, a strategy that can induce protective 
immunity against infections with M. tuberculosis in all individuals. 
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5.2. BCG Vaccination Studies in Adult Mice 
 
5.2.1. Introduction 
The aim of this study was to determine if our neonatal low dose BCG vaccination 
strategy was also effective in adult mice and if the results obtained after sc vaccination 
were consistent for other routes of BCG administration. The rationale for this study was 
that our planned study with virulent M. tuberculosis would be done with adult mice and 
all challenges with the virulent strain would be best done intravenously. Previous studies 
demonstrated that iv challenge with 105 cfu of a virulent strain of M. tuberculosis was 
equivalent in inducing disease to aerosol challenge with 102 cfu (North and Jung, 2004). 
In addition, we wanted to determine if our low dose BCG vaccination strategy would 
work on a genetically heterogeneous population, as the ultimate goal of such studies is to 
establish a universally efficacious vaccination protocol that can be applied to humans. 
The dose of BCG that is low enough to induce a Th1-type response in one individual may 
be high enough to induce a mixed Th1/Th2 response in another individual, as the genetic 
diversity of the host may have an impact on the outcome of our vaccination protocol. We 
hypothesized that giving an ultra-low dose of BCG that would not induce a mixed 
Th1/Th2 type response in any individual of the population could solve this problem. This 
dose will either induce an exclusively Th1-type response initially or be too low to induce 
a detectable immune response. In the latter case, as BCG is a slow replicating live 
vaccine, it should in time reach levels sufficient to induce a Th1-type response. 
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5.2.2. Results 
 
5.2.2.1. Low Dose BCG Vaccination Induces Th1 Type Responses and 
Th1 Imprints in Adult BALB/c Mice Independently of Whether 
BCG is Administered Intravenously or Subcutaneously 
 
In an attempt to examine the type of response generated following subcutaneous and 
intravenous vaccination in adult mice, 6-8 week old BALB/c mice were vaccinated sc 
and iv with different doses of BCG, ranging from 102 to 108 cfu. To determine the type of 
the primary response generated, mice were bled and sacrificed at different times starting 
from week 9 post-vaccination, and antibody and T-cell responses were measured in 
ELISA and ELISPOT assays, respectively. Similar to our findings in the newborn mice, 
as well as previous report from studies in adult mice (Power et al., 1998), mice given  
relatively lower doses of BCG either iv or sc generated a predominantly cell-mediated 
response, with IFN-γ-secreting cells dominant over IL-4-secreting cells. In contrast, mice 
given higher doses (>106 cfu) of BCG mounted a mixed Th1/Th2 response (Figure 11). 
As clearly shown in Figures 11 and 13, spleen cells from all vaccinated mice produced 
significantly higher (p<0.05) levels of IFN-γ than the non-vaccinated group, with no 
significant difference among groups at 12 and 24 weeks post-vaccination. However, the 
level of IL-4 differs significantly among groups. Mice given less than 106 cfu of BCG did 
not produced detectable levels of IL-4. In contrast, the spleen cells of mice vaccinated 
with BCG doses higher than 106 cfu had significantly higher (p<0.05) levels of IL-4 
when compared to low dose vaccinated mice. Consequently, the IFN-γ to IL-4 ratio was 
significantly lower in the high dose vaccinated (~1) than the low dose vaccinated group 
(usually > 10).  
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Figure 11. Low dose BCG vaccination induces a predominantly Th1-type response 
in adult BALB/c mice independently of whether the vaccine is administered by the 
intravenous or subcutaneous route.  
Adult BALB/c mice were vaccinated with different doses of BCG, shown along the 
abscissa, via the intravenous (A) or subcutaneous (B) routes. Mice were sacrificed 12 
weeks post-vaccination and their spleen cells assessed for BCG-specific cytokine 
producing T-cells. Results shown are one of three replicate experiments, each with 2-4 
mice per group. Data presented are for individual mice within each group. AMC (age 
matched control) refers to naive control mice. 
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A comparison of Figures 11A and B suggests that the transition number – the number of 
BCG cfu above which a mixed Th1/Th2 response was induced in naïve mice – is 10 fold 
higher for sc vaccination as compared to iv vaccination on the same strain of mice. As 
discussed above, this may not be surprising as the iv route of antigen administration was 
more immunogenic than sc immunization (Lagrange et al., 1974). Even though the 
transition numbers seems to vary between iv and sc routes of BCG administration, in 
both cases relatively lower doses induced Th1-type responses, while higher doses 
induced mixed Th1/Th2 responses. Figure 13 represents ELISPOT results 24 weeks after 
sc vaccination of mice and confirms that the response generated after low dose 
vaccination remained stable for as long as 6 months, which is almost 1/3 of the life span 
of the mouse. Again, the Th1/Th2 index (IFN-γ to IL-4 ratio) is significantly higher (p< 
0.05) in the low dose vaccinated groups when compared to mice vaccinated with high 
dose of BCG. The index ranges between 6 and 17 in mice vaccinated with 106 and 102 
cfu of BCG, respectively. In contrast, the index was close to 1 in mice vaccinated with108 
cfu, and between 1 and 2 in mice vaccinated with 107 cfu of BCG sc. As discussed in our 
neonatal vaccination studies, this stable cytokine level probably only occurs several 
weeks post-vaccination, as the lower doses probably require time to replicate and induce 
response comparable in magnitude to that induced by higher doses of BCG. As assessed 
by ELISA, the low dose vaccinated groups produced either no detectable antibody 
response or an IgG2a antibody response, which was dominant over the IgG1 antibody 
response. A mixed Th1/Th2 response associated with higher levels of both IgG1 and 
IgG2a antibodies was seen in the high dose vaccinated mice (Figure 12). The ELISA 
results presented here came from mice vaccinated subcutaneously, but similar results 
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were also obtained when mice were vaccinated intravenously (data not shown). The only 
observed difference following iv vaccination was that mice started to seroconvert at a 
lower dose of BCG, between 104 and 105 cfu, versus to between 105 and 106 following 
subcutaneously vaccination. 
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Figure 12. Relatively lower doses of BCG induced immune responses with no 
detectable level of antibody or with a relatively higher IgG2a than IgG1 antibody 
production as assessed by the ELISA assay. 
Blood was taken from the tail vein of BALB/c mice vaccinated subcutaneously with 
different doses of BCG, and serum was assessed by ELISA 12 weeks after vaccination 
for the level of BCG-specific IgG1 and IgG2a antibody titers. Results represent mean 
antibody titer of 3-5 mice per group and are from one of three replicate experiments. 
Numbers in the abscissa represent dose of BCG vaccine in cfu. AMC (age matched 
control) refers to pooled sera from control mice injected with saline only. * indicate titers 
below detection level. 
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Figure 13. The Th1/Th2 nature of the anti-BCG response remains stable six months 
after BCG vaccination.  
Adult BALB/c mice were vaccinated subcutaneously with different doses of BCG, as 
shown on the abscissa. Mice were sacrificed 24 weeks post-vaccination. BCG antigen-
specific cytokine production by spleen cells was assessed in the ELISPOT assay. Results 
represent one of two replicate experiments with 3-5 mice per group. Data presented are 
values for individual mice in each group (n=3 per group). AMC (age matched control) 
refers to non-vaccinated control mice. 
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To determine if the cell-mediated response generated following low dose BCG 
vaccination in adult BALB/c mice was associated with a Th1 imprint, mice vaccinated iv 
and sc with different doses of BCG were challenged iv, between 12 to 16 weeks post-
vaccination, with a high dose of BCG, which induced a mixed Th1/Th2 response in naïve 
mice. Representative mice from each group were sacrificed between 12 to 24 weeks after 
challenge. Spleen cells were used for ELISPOT assay to determine the type of response 
generated and for the assessment of bacterial burden in the spleen. We wished to 
determine whether low but not high dose BCG vaccination had generated a Th1 imprint 
as assessed by a high dose BCG iv challenge and examine if this Th1 imprinting is 
associated with more efficient clearance of mycobacteria from the spleens of mice. 
Vaccination of mice with doses <106 cfu for iv vaccinated mice (Figure 14) and <106 for 
sc vaccinated mice (Figure 15) abrogated the generation of Th2 cells following BCG iv 
challenge, whereas vaccination with saline or higher doses of BCG could not prevent the 
generation of Th2 cells following high dose BCG iv challenge. This clearly shows that, 
similar to the situations in newborn mice, low dose BCG vaccination generated a Th1-
type response and a Th1 imprint that predisposed adult mice to a Th1 biased response 
following exposure to a high dose challenge. This may imply that low dose BCG 
vaccination is more efficacious in generating effective immune response against 
mycobacterial infections than the standared dose of BCG commonly used to vaccinate 
humans and animals against M. tuberculosis. 
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Figure 14. Evaluation of how vaccination of adult mice with different doses of BCG 
affects the response to a subsequent high dose iv challenge with BCG.  
Adult BALB/c mice were vaccinated iv with different doses of BCG and challenged iv 
with ~5x106 cfu of BCG 16 weeks post-vaccination. Mice were sacrificed 12 weeks post-
challenge and spleen cells processed to assess the level of antigen-specific cytokine 
producing T-cells in the ELISPOT assay. Results shown are representative of one of three 
replicate experiments and data presented are values for individual mice in each group 
with 4 mice per group. Numbers in the abscissa represents dose of BCG vaccine in cfu. 
AMC (age matched control) refers to naive control mice. 
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Figure 15. Low dose BCG vaccination of adult BALB/c mice induces a Th1 imprint 
as assessed by a high dose intravenous BCG challenge.  
Adult BALB/c mice were vaccinated sc with different doses of BCG and challenged iv, 
16 weeks after vaccination, with ~1.1x107 cfu of BCG. Mice were sacrificed 12 weeks 
post-challenge and spleen cells processed for ELISPOT assay to enumerate the type of 
antigen-specific cytokine producing cells generated. Results shown are representative of 
one of three replicate experiments and data represent values for individual mice with 3 
mice per group. Numbers in the abscissa indicate dose of BCG used for vaccination. 
AMC (age matched control) refers to naïve mice challenged with a high dose BCG. 
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The Th1 and mixed Th1/Th2 imprinting, respectively following vaccination of adult mice 
with low and high doses of BCG leads to a stable Th1 and mixed Th1/Th2 responses, 
with a similar responses generated at 12 weeks (Figure 14) and 20 weeks (Figure 16) 
post-challenge for iv vaccinated mice, as well as 12 weeks (Figure 15) and 24 weeks 
(Figure 17) post-challenge for sc vaccinated mice. Even though there were some 
variations in the level of IFN-γ produced by spleen cells of mice in different vaccination 
groups, particularly at 12 weeks post-challenge, the over all picture is that there was no 
statistically significant difference at the p value of 0.05 in the levels of IFN-γ among 
groups. Similarly there was no significant difference in the level of IL-4 produced by 
spleen cells from mice vaccinated with <106 cfu of BCG for iv and < 106 cfu for sc 
vaccinated mice. In contrast, the level of IL-4 was significantly higher (p<0.05) in all 
mice vaccinated with higher doses of BCG as well as in naïve mice following high dose 
BCG iv challenge. This is reflected in a lower IFN-γ to IL-4 ratio observed following 
high dose BCG challenge in mice vaccinated with higher doses of BCG as well as in 
naïve mice than in mice vaccinated with lower doses, independently of whether BCG was 
administered by the sc or iv route. Table 3 shows the results of a statistical analysis done 
on data obtained 20 weeks post-challenge for iv vaccinated mice and 24 weeks after 
challenge for sc vaccinated mice. 
.
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Figure 16. The Th1 imprinting induced by low dose BCG iv vaccination ensures 
stable, long-term Th1 responses following high dose BCG iv challenge in adult mice.  
Adult BALB/c mice vaccinated with different doses of BCG iv were challenged with 
~5x106 cfu of BCG 16 weeks post-vaccination. Mice were sacrificed 20 weeks post-
challenge and splenic antigen-specific T-cell responses assessed by the ELISPOT assay. 
Results shown represent one of three replicate experiments with 3 mice per group and 
data presented are for individual mice in each group. Numbers on the abscissa indicate 
dose of BCG in cfu used for vaccination. AMC-challenged (age matched control) refers 
to naive mice challenged iv with the high dose of BCG. 
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Figure 17. The Th1 imprinting induced by low dose sc BCG vaccination of adult 
BALB/c mice ensures stable, long-term Th1 responses following high dose BCG iv 
challenge. 
Adult BALB/c mice vaccinated subcutaneously with different doses of BCG were 
challenged intravenously, 16 weeks later, with ~1.1x107 cfu of BCG. Mice were 
sacrificed 24 weeks post-challenge and spleen cells used in the ELISPOT assay to assess 
antigen-specific responses. Representative results from one of three replicate experiments 
are shown. Data presented are values for individual mice in each group with 3-4 mice per 
group. Numbers on the abscissa represent the dose of BCG used for vaccination. AMC-
challenged (age matched control) refers to naïve mice that were challenged iv with the 
high dose of BCG.  
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Table 3. Results of a statistical analysis on cytokine levels produced by spleen cells 
from adult mice vaccinated with different doses of BCG and challenged iv with a 
high dose BCG. 
Mice vaccinated with different doses of BCG and challenged with high doses of BCG as 
described in the legend for Figures 16 and 17, were sacrificed at 20 weeks post-challenge 
for iv vaccinated mice and 24 weeks for sc vaccinated mice. Spleens were removed from 
each mouse and antigen-specific cytokine producing cells enumerated by the ELISPOT 
assay. Data presented show average number of cytokine producing cells per million 
spleen cells for 3-4 mice per group following high dose iv challenge. The Th1/Th2 index 
is presented as the ratio of the number of IFN-γ to IL-4 producing cells. Statistical 
analysis was done to compare the number of cytokine producing cells as well as the 
Th1/Th2 index among groups. Groups with the same letter along each column indicate no 
statistical difference. 
 
Subcutaneously vaccinated mice* Intravenously vaccinated mice** 
Mean value Ratio Mean value Ratio 
 
 
Vaccination 
groups*** 
IFN-γ IL-4 IFN-γ/ IL-4 IFN-γ IL-4 IFN-γ/ IL-4 
Group 1 594a 120a 5a 624a 88a 8a 
Group 2 664b 146a 4.6a 970b 38a 26b 
Group 3 846b 140a 6a 913b 91a 14a 
Group 4 841b 566b 1.5b 861bc 377b 2c 
Group 5 827b 674bc 1.2b 675a 531c 1c 
Group 6 663b 727c 0.9b 691ac 782d 0.89 c 
*Assay done 24 weeks post-challenge 
**Assay done 20 weeks post-challenge 
*** Refers to vaccination dose of BCG as described, respectively, in Figures 16 and 17 
for iv and sc vaccinated mice  
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The nature of the response after challenge was also reflected in the IgG isotypes of BCG 
specific antibodies (Figure 18A). Vaccination with doses of BCG less than or equal to 
106 cfu resulted in significantly higher (p<0.05) levels of IgG2a than IgG1 antibodies 
following high dose BCG iv challenge, indicating a Th1 biased response. On the other 
hand higher doses of BCG vaccination generated a mixed Th1/Th2 response with 
comparable levels of IgG2a and IgG1 antibodies following high dose BCG iv challenge. 
Vaccination with a low dose of BCG clearly favored a type of response, on challenge, 
that can more efficiently clear BCG from the spleen than in naïve mice or mice 
vaccinated with a high dose of BCG (Figure 18B). All mice vaccinated iv with doses less 
than or equal to 106 cfu of BCG were able to substantially reduce the bacterial load in 
their spleen after high dose challenge, with no statistically significant difference between 
groups. However, mice vaccinated with the highest dose of BCG (108 cfu) and naïve 
mice had significantly higher (p<0.05) levels of bacterial load in their spleen after high 
dose challenge than mice vaccinated with less or equal to 106 cfu.  Similar findings were 
also observed in mice vaccinated sc (data not shown). Therefore, from these observations 
we conclude that Th1 imprinting was essential for immune-mediated protection against 
BCG infection, and vaccination of mice with relatively low doses of BCG, independently 
of the route of BCG administration, can best generate this type of imprint.  
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Figure 18. Low dose BCG vaccinated adult BALB/c mice have higher levels of IgG2a 
than IgG1 antibodies in their sera and more effectively reduced the bacterial burden 
in the spleen than high dose vaccinated or naive mice following high dose iv 
challenge.  
Adult BALB/c mice vaccinated subcutaneously (A) or intravenously (B) with different 
doses of BCG were challenged iv with ~1.1x107 cfu and 5x106 cfu of BCG, respectively. 
Mice were bled to determine the isotypes of antigen-specific IgG antibodies in serum 
samples (A) and sacrificed to assess the splenic bacterial burden (B) 12 weeks after 
challenge. Result show mean and SD of values for 3-5 mice per group and are 
representatives of at least two replicate experiments each. AMC (age matched control 
refers to naive control mice challenged iv with a high dose of BCG.  
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5.2.2.2. Low Dose BCG Vaccination Induces Th1 Type Responses and 
Th1 Imprints in Genetically Heterogeneous Mice 
 
The objective of this study was to explore if low dose BCG vaccination will induce 
predominantly cell-mediated immunity and Th1 imprints in a genetically heterogeneous 
population. To address this objective we used three different strains of mice: CBA (H-2k), 
BALB/c (H-2d), and CD1. The first two mouse strains were chosen based on a previous 
report, which claimed that these two strains of mice differ considerably in their 
susceptibility/resistant phenotype to M. tuberculosis challenge (Medina and North 1998). 
We wanted to compare the efficacy of BCG vaccination in these two different strains of 
mice. The CD1 mice are an out-bred strain of mice derived from Swiss mice, and are 
believed to be genetically heterogeneous. These mice may represent the genetic 
heterogeneousity of humans and animals. All mice were injected intravenously with 
different doses of BCG (102 to 108 cfu). Starting from nine weeks after vaccination, cell-
mediated and antibody responses were evaluated using ELISPOT and ELISA assays, 
respectively. Results in BALB/C mice were similar to results obtained in our previous 
studies presented in section 5.2.2.1. The value of the transition number (tn), defined as the 
dose of BCG below which, when given to mice, induces predominantly cell-mediated 
response was determined to be between 105 and 106 cfu for adult BALB/c vaccinated 
intravenously. All mice vaccinated with doses < 104 cfu responded with an exclusively 
cell-mediated response with either no detectable antibody production or only a low titer 
of IgG2a. These responses were consistent with a predominantly Th1 type response. On 
the other hand, doses of BCG between 105 and 106 cfu induced BCG-specific antibody 
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responses dominated by IgG2a isotype (IgG2a /IgG1 ratio ~4), and doses > 107 cfu of BCG 
induced higher titers of both IgG1 and IgG2a antibodies with a ratio close to 1 (Figure 
19A). The ratio of BCG specific IFN-γ to IL-4-producing T-cells for the low dose 
vaccinated group (<106 cfu) was large but not ascertainable as the number of IL-4-
producing cells is usually insignificant. However, significant numbers of IL-4-producing 
T-cells were detected following injection with BCG doses >106 cfu, with the IFN-γ/IL-4 
ratio approaching 1 at a dose of 106 cfu (Figure 19B). Statistical analysis of the number 
of BCG specific IFN-γ and IL-4-producing T-cells was similar to those described in 
section 5.2.2.1 for adult BALB/c mice vaccinated iv. The value of tn for BCG given iv 
was found to be 100 fold higher in CBA mice than BALB/c mice. All doses < 108 cfu 
induced exclusively cell-mediated immune responses with higher levels of BCG-specific 
IFN-γ and few or no detectable IL-4-producing T-cells. In contrast the highest BCG dose 
used (108 cfu) induced a mixed Th1/Th2 response, with comparable levels of antigen-
specific IFN-γ and IL-4 cytokine producing T-cells (Fig 20B). Determining the exact 
ratio of IFN-γ to IL-4-producing T-cells was some times difficult due to indeterminate 
levels of IL-4 secreting cells in some of the low dose vaccinated CBA mice, but in 
general it was > 10 for mice vaccinated with BCG doses < 106, around 5 for a dose of 
107, and significantly lower (p< 0.05) with a ratio approaching 1 for the highest dose (108 
cfu). All doses < 106 cfu induced undetectable antibody, as assessed by ELISA, 
indicating an exclusively cell-mediated immune response, while a dose of 107 cfu 
induced either predominantly IgG2a antibodies or undetectable BCG-specific antibody 
levels. The highest dose used, 108 cfu, induced a mixed Th1/Th2 type of response with 
comparable titers of IgG2a to IgG1 antibodies (Figure 20A).  
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Figure 19. The Th1/Th2 nature of the splenic immune response, as well as the 
isotypes of BCG-specific IgG antibodies produced in adult BALB/c mice depend on 
the dose of BCG employed for immunization.  
Adult BALB/c mice were vaccinated intravenously with different doses of BCG or 
saline. Mice were bled and antibody titers assayed with ELISA at 9 weeks post-
vaccination (A). Mice were also sacrificed at 12 weeks post-vaccination to determine 
antigen-dependent immune responses by ELISPOT assay (B). ELISA results represent 
mean antibody titer of 4 mice per group with SD. Results shown are representative of at 
least three replicate experiments. Numbers in the abscissa represent dose of BCG vaccine 
in cfu. AMC (age matched control) refers to naive control mice. 
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Figure 20. The Th1/Th2 nature of the splenic immune response and the IgG isotypes 
of serum antibodies in adult CBA mice depend on the dose of BCG used for 
vaccination.  
Adult CBA mice vaccinated iv with different doses of BCG were bled to determine 
antigen-specific serum antibody levels (A) and sacrificed to assess the levels of antigen-
specific cytokine producing T-cells in the spleen (B), 12 and 16 weeks post-vaccination, 
respectively. ELISA results represent average antibody titer of 3-5 mice/group and 
*stands for titers below detection level. Results are representative of three replicate 
experiments. Numbers in the abscissa represent the dose of BCG vaccine. AMC (age 
matched control) refers to naive control mice. 
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Observations made with CD1 mice were contrary to our expectations. As CD1 mice are 
said to be out-bred and believed to be genetically heterogeneous, we expected the 
transition number, tn, might vary by ten-fold or more between individual mice within a 
group. However, results indicate that the CD1 mice behave roughly like a homogenous 
population with a similar tn of close to 106 cfu among individual mice (Fig. 21A and B). 
Data from 9 and 16 weeks post-vaccination demonstrate that the response was stable over 
time except that the tn appears to shift towards 107 cfu at later time period after 
vaccination. However, results from other similar experiments and data from post-
challenge experiments (Figure 26) show that the tn in CD1 mice is ~106 cfu. Therefore, 
similar to adult BALB/c mice vaccinated iv, all CD1 mice that received a dose of BCG 
<106 cfu demonstrated a predominantly Th1-type response with high levels of BCG-
specific IFN-γ and no or few detectable IL-4-producing T-cells. In contrast, higher BCG 
doses induced significantly higher (p<0.05) numbers of IL-4-producing cells, with an 
IFN-γ/IL-4 ratio of close to 1, representing a mixed Th1/Th2 response. Data from all 
these studies can be summarized as supporting the concept that relatively low doses of 
BCG vaccination can efficiently induce predominantly Th1-type responses in all mice 
strains following iv or sc routes of vaccine administration. Furthermore, the values of tn 
can vary by up to 100-fold among different mouse strains and by up to 10-fold between 
sc and iv routes of vaccination.  
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Figure 21. Enumeration of BCG-specific IFN-γ and IL-4-producing cells in the 
spleen of adult CD1 mice vaccinated with different doses of BCG.  
Adult CD1 mice were vaccinated iv with different dose of BCG and levels of antigen- 
specific cytokine producing T-cells in the spleen assessed in the ELISPOT assay 9 weeks 
(A) and 16 weeks (B) post-vaccination. Data presented are average + SD of values of 4 
mice per group. Results shown represent two of the four replicate experiments done at 
different time points after immunization. Numbers in the abscissa indicate doses of BCG 
vaccine in cfu. AMC (age matched control) refers to naïve control mice.  
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The next step in testing the validity of our strategy was to challenge a subset of mice 
from each group with a high dose of BCG iv to determine if the immune response was 
locked into a Th1 mode in mice vaccinated with low doses of BCG. To this end mice 
vaccinated with different doses of BCG were injected iv at 12-16 weeks post-vaccination 
with a BCG dose that induced a mixed Th1/Th2 type response in naïve mice. Based on 
our previous results, we chose to use ~5x106 cfu in CD1 and BALB/c mice and ~2x108 
cfu in CBA mice as our challenge doses. 
 
Similar to previous findings, the immune response in all low dose vaccinated adult 
BALB/c mice was found to be locked into a Th1-type following a high dose BCG iv 
challenge. The mean values for antigen-specific cytokine producing cells, as well as the 
ratio of the number of IFN-γ to IL-4-secreting T-cells (Table 4), demonstrate that 
vaccination with low doses of BCG resulted in a Th1 imprint. In Figure 22, the data for 
individual mice are presented to demonstrate the consistency of the responses. In all 
cases, vaccination with BCG doses >106 cfu resulted in a mixed Th1/Th2 response with 
comparable levels of IFN-γ and IL-4 cytokine producing cells following high dose iv 
challenge. However, BCG challenge of mice vaccinated with doses of BCG less than 106 
cfu induced a predominantly Th1-type response with high numbers of IFN-γ and 
significantly lower numbers of IL-4-producing cells. These data confirm that the immune 
responses are locked into a Th1 mode. This deviation of the response was also reflected 
in the isotype of BCG-specific antibodies detected in serum (Figure 23A), and was 
significant with respect to the protection offered, as indicated by the level of bacteria 
isolated from the spleen of the mice after high dose BCG challenge (Figure 23B and C). 
  
155 
 
 
 
Assessment of bacterial burden shows mice vaccinated with doses <106 were able to 
more effectively reduce the bacterial load in spleens when compared with the naive 
group. At 106 cfu, the transition number, mice had significantly higher (p<0.05) bacterial 
burden in the spleens than in the spleens of mice vaccinated with lower doses at 12 weeks 
post-challenge (Figure 23B), but this difference was not significant at 18 weeks post-
challenge (Figure 23C). This may suggest that immune mediated BCG clearance is 
influenced by BCG vaccine dose only during the early period post-challenge. However, 
as shown in several other experiments (Figure 18B), higher doses (107 and 108 cfu) had 
shown significantly higher bacterial burden in the spleen when compared to the low dose 
vaccinated groups at all time points post-challenge. One such data is shown in Figure 
18B. 
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Table 4. BCG-specific IFN-γ and IL-4 cytokine production by spleen cells isolated 
from mice vaccinated with different doses of BCG and challenged iv with a high 
dose of BCG.  
Adult BALB/c mice were vaccinated iv with different doses of BCG and then challenged 
intravenously with ~5x106 cfu at 12 weeks post-vaccination. Four mice from each group 
were sacrificed at 12 weeks post-challenge and splenic immune response assessed by 
ELISPOT as described previously. Mean numbers of antigen-specific cytokine producing 
spleen cells with standard deviation and the ratio of the numbers of IFN-γ and IL-4-
producing cells are presented. Statistical analysis was done to compare the level of 
cytokines as well as the Th1/Th2 index (IFN-γ/IL-4 ratio) among groups. The same 
letters along each column indicate no statistical difference among groups and two letters 
in one group show an overlap. 
 
 
 
Antigen-specific cytokine secreting cells per 
million spleen cells as detected in the 
ELISPOT assay 
 
 IFN-γ IL-4 IFN-γ/IL-4* 
BCG dose (cfu) Mean SD Mean SD Ratio 
104 593.3ab 152.6 72.7a 18.2 8.2a 
105 543.7ab 172.9 132.3a 68.9 4.1b 
106 478.7b 20.6 290.7b 17.4 1.6 c 
107 655.8a 17.8 605.8c 88.2  1.1c 
108 607.5ab 88.9 756.3d 96.5  0.8c 
AMC 488.5b 82.0 494.0e 30.7  1.0c 
AMC refers to naive mice challenged iv with a high dose of BCG 
SD stands for standard deviation of the mean as calculated in Microsoft Excel, 2003 
* refers to ratio of IFN-γ to IL-4-producing cells 
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Figure 22. Low dose BCG vaccination predisposes adult BALB/c mice to a 
predominantly Th1 response following high dose BCG iv challenge.  
Adult BALB/c mice were vaccinated iv with different doses of BCG and then challenged 
intravenously with ~5x106 cfu of BCG at 12 weeks post-vaccination. Three mice from 
each group were sacrificed around 18 weeks post-challenge to assess, in the ELISPOT 
assay, the type of antigen-specific response generated by spleen cells. Data represent 
values of individual mice in each group and are from one of at least two replicate 
experiments. Numbers in the abscissa represent dose of BCG used for vaccination. AMC 
(age matched control) refers to naïve control mice. 
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Figure 23. Antibody levels and bacterial burden assessment in adult BALB/c mice 
vaccinated with different doses of BCG and subsequently challenged with a high 
dose of BCG.   
BALB/c mice vaccinated iv with different doses of BCG were challenged iv with 5x106 
cfu 12 weeks post-vaccination. Mice were bled 18 weeks after challenge to determine the 
isotypes of BCG-specific serum antibodies (A), and sacrificed 12 weeks (B) or 18 weeks 
(C) post-challenge to assess the splenic bacterial burden. Data represent average antibody 
titer of 3-5 mice per group (A) or average numbers of bacteria (cfu) per spleen of 5 mice 
per group (B and C) with error bars (SD). Results shown are from one of at least 2 
replicate experiments each. AMC refers to naive control mice. 
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Figure 24 presents the immune responses generated in CBA mice at 12 weeks post-
challenge. The BCG challenge was given iv at 16 weeks following iv vaccination of mice 
with different doses of BCG or an equal volume of saline. The responses in CBA mice 
were similar to those observed in BALB/c mice, except the tn in CBA mice was between 
107 and 108 cfu. Thus the tn for CBA mice is 100 fold higher than BALB/c. In general, 
the amount of IFN-γ produced following high dose BCG iv challenge was not 
significantly different among all groups. However, the number of antigen-specific IL-4-
producing spleen cells in the spleen from the high dose (>107 cfu) vaccinated and 
unvaccinated groups are significantly (p<0.05) higher than in the low dose vaccinated 
groups. Accordingly, the ratios of antigen-specific IFN-γ to IL-4-producing spleen cells 
in the high dose vaccinated and naive mice, following high dose challenge, were both 
significantly lower than the low dose vaccinated groups. Table 5 shows results of 
statistical analysis on data obtained 18 weeks after high dose BCG challenge. Even 
though there is some overlap at 107 cfu, which is the tn, it is clear that all groups of mice 
vaccinated with low dose of BCG had significantly (p< 0.05) lower numbers of IL-4-
secreting cells in the spleen than mice in the high dose vaccinated groups. Therefore, we 
can conclude that CBA mice, vaccinated with BCG doses >107 cfu respond with mixed 
Th1/Th2 responses, while vaccination with doses <107 induced primarily Th1 responses 
and Th1 imprints. For doses close to the tn (107 cfu), the lock into a Th1 mode became 
clear at a later time after challenge (Figure 25B). The Th1 imprint generated following 
low dose BCG vaccination in CBA mice was also associated with high titers of IgG2a 
antibody following high dose BCG iv challenge, while mice vaccinated with high dose or 
naïve mice produced higher levels of both IgG1 and IgG2a antibodies (Figure 25A).  
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Figure 24. BCG-specific IFN-γ and IL-4 production by spleen cells from adult CBA 
mice immunized with different doses of BCG and subsequently challenged iv with a 
high dose of BCG.  
Adult CBA mice vaccinated iv with different doses of BCG were challenged iv 16 weeks 
post-vaccination with 2x108 cfu of BCG and sacrificed 12 weeks post-challenge to assess 
the immune response generated by spleen cells. Results shown represent one of two 
replicate experiments with 4 mice per group and data represent values of individual mice 
in each group. Numbers along the abscissa refer to dose of BCG vaccine. AMC (age 
matched control) stands for naïve control mice. 
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Figure 25. The Th1 imprinting induced by low dose BCG vaccination ensures stable, 
long-term Th1 responses following high dose BCG iv challenge in adult CBA mice. 
Adult CBA mice vaccinated and challenged as described in the legend of Figure 24 were 
bled at 18 weeks post-challenge to assess BCG-specific serum antibody levels in ELISA 
(A). Mice were also sacrificed 24 weeks post-challenge and their splenic immune 
response assessed by ELISPOT assay (B). ELISA data represent average antibody tiers of 
4-6 mice per group + SD and ELISPOT data are values from individual mice in each 
group. Numbers in the abscissa refer to dose of BCG vaccination. AMC (age matched 
control) refers to naive control mice. CNT stands for a naïve control mice used as source 
of APC.  
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Table 5. Results of a statistical analysis on the number of cytokine producing spleen 
cells from adult CBA mice vaccinated with different doses of BCG following high 
dose BCG iv challenge. 
Adult CBA mice vaccinated with different doses of BCG iv and challenged with 2x108 
cfu of BCG were sacrificed at 24 weeks post-challenge. Spleens were removed from each 
mouse and processed for ELISPOT assay as described in Figure 25. Data presented show 
average cytokine levels secreted by spleen cells following high dose iv challenge. The 
Th1/Th2 index is presented as IFN-γ to IL-4 ratio and statistical analysis was done to 
compare the level of cytokines as well as the Th1/Th2 index among groups. The same 
letters along each column indicate no statistical difference among groups and two letters 
in one group show an overlap. 
 
Average number of cytokine secreting 
spleen cells  
 
BCG vaccine 
dose (cfu) 
IFN-γ IL-4 IFN-γ/IL-4 
102 372a 54a 8.3a 
103 523b 36a 14.5b 
104 338a 33a 10.2a 
106 372a 42a 8.9a 
107 426ab 93ab 4.6ac 
108 192c 191b 1.1c 
AMC 151c 190b 0.8c 
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Another important question addressed here was whether the transition number (tn) for the 
BCG dose, and hence the type of immune response generated, was affected by changing 
the route of antigen administration in CBA mice. To this end, adult CBA mice were 
vaccinated subcutaneously with different doses of BCG and the immune responses 
assessed following both primary vaccination and a subsequent high dose BCG 
intravenous challenge. As shown in Figures 26B, BCG doses <108 cfu given sc induced 
primarily a Th1-type response with exclusive IFN-γ production by spleen cells. There 
was variation in the number of IFN-γ-producing splenocytes among vaccination groups 
but all vaccinated mice respond with significantly higher levels of IFN-γ than naïve mice. 
In contrast, there was no significant difference (p<0.05) in the level of IL-4-secreting 
cells in mice vaccinated with lower dose of BCG and naïve mice. However, mice 
vaccinated with the highest BCG dose (2x108 cfu) had significantly higher (p<0.05) 
numbers of IL-4-secreting splenocytes when compared to mice in all the low dose 
vaccination groups and naive mice. Consequently the IFN-γ/IL-4 ratio is significantly 
higher in the low dose vaccinated groups when compared to mice in the high dose 
vaccinated group, which is close to 1. There was no detectable BCG-specific antibody in 
the sera from all the low dose BCG vaccinated mice. In contrast, the high dose BCG 
vaccinated mice had high titers of both IgG1 and IgG2a antibodies (Figure 26A). 
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Figure 26. Low dose sc vaccination with BCG induces an exclusively Th1 response 
with undetectable levels of serum antibodies in adult CBA mice.  
Adult CBA mice were vaccinated sc with different doses of BCG and bled at 20 weeks 
post-vaccination to determine the levels of BCG-specific IgG1 and IgG2a antibody titers 
(A). Mice were also sacrificed at 24 weeks post-vaccination to assess the type of BCG-
specific immune response generated by spleen cells (B). Antibody levels represent mean 
titer of 3 mice per group with error bars (SD); * denotes titers below detection level. 
ELISPOT data represent values for individual mice in each group (n=3). Results shown 
are representative of three replicate experiments. Numbers on the abscissa represent the 
dose of BCG vaccine. AMC (age matched control mice) refers to naive control mice. 
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Following high dose challenge, adult CBA mice vaccinated sc with BCG doses < 107 cfu 
still generated a predominantly Th1 response, whereas mice vaccinated with the highest 
dose (2x108 cfu) or naïve mice generated a mixed Th1/Th2 response (Table 6). There is 
no significance difference in the amount of IL-4 produced among mice vaccinated with 
dose of BCG < 107 cfu after high dose BCG iv challenge. However, the high dose 
vaccinated group and naive mice had significantly higher (p<0.05) numbers of IL-4- 
producing spleen cells than the other groups. Consequently, mice vaccinated with BCG 
doses < 107 cfu had significantly higher IFN-γ/IL-4 ratios when compared to mice 
vaccinated with the highest dose (2x108 cfu) or naïve mice following high dose BCG iv 
challenge. Again, the IgG isotype of the anti-BCG antibody response correlated well with 
the type of the T-cell response in the spleen (Figure 27). Mice vaccinated with doses of 
BCG <107 cfu induce no detectable levels of IgG antibodies suggesting an exclusively 
cell-mediated immune response, while 107 cfu of BCG induced only the IgG2a isotype. In 
contrast, mice vaccinated with the highest dose and naïve mice had higher titers of both 
IgG1 and IgG2a antibodies following high dose BCG iv challenge suggesting a mixed 
Th1/Th2 response. These observations support the conclusion that the route of BCG 
administration did not alter the Th1/Th2 nature of BCG-specific immune response. This 
is consistent with observation made with adult BALB/c mice. Echoing the results 
following intravenous administration, vaccination of mice with BCG by subcutaneous 
administration caused a Th1 imprint in CBA mice in a dose dependent manner, as 
assessed by a high dose BCG iv challenge. In addition, comparing Figures 24 and Table 
6, it appears that the tn is 10 fold higher in sc vaccinated than iv vaccinated CBA mice, 
which parallels findings in BALB/c mice. 
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Table 6. Th1 imprinting in adult CBA mice following sc vaccination with low doses 
of BCG and high dose BCG iv challenge.  
Adult CBA mice vaccinated sc with different doses of BCG were challenged iv with 
2x108 cfu of BCG at 16 weeks post-vaccination. BCG-specific immune responses 
generated by spleen cells were assessed by ELISPOT assay 12 weeks post-challenge. 
Results show mean number + SD of cytokine producing cells per million spleen cells 
from 3 mice per group and the ratio of the numbers of IFN-γ to IL-4-secreting cells for 
each group. Results of statistical analysis are also presented. The same letters in each 
column show no statistical difference among groups at a p level of 0.05. Data are from 
one of two similar experiments. 
 
 
Antigen-specific cytokine secreting cells per 
million spleen cells as detected in the 
ELISPOT assay 
 
 
 IFN-γ IL-4 IFN-γ/IL-4
 
BCG dose (cfu) Mean SD Mean SD Ratio 
103 900.0a 117.5 59.7a 9.9 15.1a 
105 770.3a 93.3 49.0a 3.0 15.7a 
107 1017.0b 78.0 75.0a 25.5 13.6a 
2x108 410.0c 16.6 339.3b 28.9 1.2b 
AMC 308.0c 36.8 348.0b 37.6 0.9b 
AMC stands for naïve control mice challenged iv with high dose of BCG 
SD represents standard deviation of the mean  
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Figure 27. Vaccination of adult CBA mice with lower doses of BCG induced a Th1 
imprint as assessed by the amount and isotype of IgG antibodies produced following 
a high dose BCG iv challenge. 
Adult CBA mice vaccinated sc with different doses of BCG were challenged iv with 
2x108 cfu of BCG at 16 weeks post-vaccination. Mice were bled 12 weeks post-challenge 
to determine the amount and isotype of BCG-specific IgG antibodies in serum. Data 
shown represent mean titer of 3-5 mice per group and * denotes titers below the detection 
level. Results shown came from one of at least three replicate experiments. Numbers on 
the abscissa represent dose of BCG vaccine. AMC (age matched control) refers to naive 
control mice. 
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Experiments with CD1 mice yielded results nearly identical to results from BALB/c mice 
both during primary exposure to BCG (Figure 19 and 21) and after high dose iv challenge 
(Table 4 and Figure 28). Similar to data from adult BALB/c mice, there was no statistical 
difference in the number of BCG-specific IFN-γ-secreting splenocytes among all groups. 
However, the number of IL-4-secreting splenocytes was significantly higher (p<0.05) in 
mice vaccinated with doses of BCG >106 cfu. Consequently the IFN-γ/IL-4 ratio is 
significantly lower (p<0.05) in all mice vaccinated with doses of BCG > 106 cfu. Results 
from CD1 mice were contrary to our expectations in that CD1 mice, claimed to be 
genetically heterogeneous, would display a more heterogeneous response. Thus, we did 
not pursue further experiments with CD1 mice, as they did not prove to be a useful model 
to assess the validity of a general vaccination strategy in a heterogeneous population. 
Nonetheless, our hypothesis that ultra-low dose of BCG, as low as 33 cfu as shown in the 
newborn mice, can induce a protective immune response against mycobacterial 
infections, is still compelling since all the lower doses used in this study, in all the three 
different strains of mice, induced Th1-type responses and Th1 imprints following a high 
dose BCG iv challenge. 
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Figure 28.  Low dose BCG vaccination induces Th1 imprinting in CD1 mice.  
Adult CD1 mice were vaccinated iv with different doses of BCG and then challenged 
intravenously 12 weeks post-vaccination with ~5x106 cfu of BCG iv. Four mice from 
each group were sacrificed 12 weeks post-challenge to assess the BCG-specific immune 
response generated by spleen cells. Results represent one of at least two similar 
experiments and show the average number of cytokine producing cells per group with 
error bars (SD). Numbers on the abscissa are dose of BCG vaccine in cfu. AMC (age 
matched control) refers to naive control mice. 
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5.2.3. Discussion 
 
In agreement with a previous finding in adult mice (Power et al., 1998), we show here 
that the dose of BCG given to adult BALB/c mice determined the Th1/Th2 phenotype of 
the response, with relatively lower doses inducing predominantly Th1-type responses and 
higher doses inducing mixed Th1/Th2 responses. This pattern was seen independently of 
whether BCG is given iv or sc. We have also shown that a similar relationship holds true 
between the dose of BCG and the Th1/Th2 phenotype of the ensuing response in 
newborn BALB/c mice when BCG was administered sc (section 5.1.2.2.). The main 
difference was that higher doses of BCG (>3.3x107 cfu) were required to induce a 
significant Th2 component to the immune response when BCG was given to newborn 
than to adult mice, where a mixed Th1/Th2 response began to appear at doses >106 cfu of 
BCG injected sc. This is surprising in view of the generally accepted concept that the 
neonatal immune system is inherently biased to mount antibody, Th2, responses (Barrios 
et al., 1996; Adkins, 2000). Similarly, the vaccination dose of BCG given to adult CBA 
mice determined the Th1/Th2 nature of the ensuing immune response independently of 
whether BCG is administered by the iv or sc route of vaccination. However, the transition 
number, tn, was 100-fold different between BALB/c and CBA mice when BCG was 
given iv. In agreement with this, the transition number for another intracellular pathogen, 
the L. major parasite, was found to vary by almost a million fold among different strains 
of mice (Menon and Bretscher, 1998). Additionally, the tn seems to vary by about 10-fold 
between sc and iv routes of vaccination both in BALB/c and CBA mice; this is not 
surprising due to reasons discussed in section 5.1.2.2.  
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Our finding that low doses of BCG induce Th1 biased responses in adult mice is in 
agreement with a recent report of a study in guinea pigs (Horwitz et al., 2006). In this 
study, extraordinarily small amounts (10 cfu) of BCG vaccine induced an exclusively 
cell-mediated response with no detectable levels of antibody, which protected the host 
against lethal challenge with M. tuberculosis given by the aerosol route of infection. This 
is in direct agreement with our finding that the lowest dose BCG vaccine (33 cfu) was the 
most consistent and effective in terms of inducing an exclusively Th1 response and 
reducing the bacterial burden from the spleen after a subsequent high dose BCG iv 
challenge. Horwitz et al also reported that, despite the presence of high antibody titers, 
the highest dose used (106 cfu) was able to induce cell-mediated immunity to the same 
level as that of the lower doses used, and was as efficient as the lower doses in protecting 
the host against challenge with virulent M. tuberculosis. Based on these results, the 
authors conclude that the BCG-specific humoral response was dose-dependent, but the 
cell-mediated response was dose-independent. All the doses they used induced a cell-
mediated response of comparable magnitude, as assessed by BCG-specific proliferation 
and expression of DTH, as well as equal efficacy in reducing the bacterial burden from 
lung and spleen of guinea pigs following aerosol challenge with M. tuberculosis. While 
the results reported by Horwitz and colleagues, as well as our findings, are fundamentally 
the same, their conclusion implies that dose of antigen may not have an effect on the 
efficacy of BCG vaccination, as both their lowest and highest doses reduced bacterial 
burden with comparable efficacy. We contend this conclusion is misleading for several 
reasons. First, we believe the highest dose they used (106 cfu) was not high enough to 
induce a Th2 biased response. In our studies, equal doses were found to induce pure Th1 
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responses in CBA mice and a mixed Th1/Th2 response, with a bias towards the Th1 pole 
in BALB/c as well as in CD1 mice. Therefore, the highest dose they used might have 
induced mixed Th1/Th2 response with a bias towards the Th1 pole similar to our findings 
in BALB/c and CD1 mice or a predominantly Th1 response as in CBA mice. Second, 
their conclusion that cell-mediated immunity was dose-independent was based on 
lymphocyte proliferative response and DTH assays, which cannot distinguish between 
Th1 and mixed Th1/Th2 responses. However, the presence of high levels of BCG 
specific IgG antibodies they reported may be an indication of the presence of Th2 helper 
cells. This suggests that the immune response generated following vaccination with 106 
cfu may have a Th2 component, differentiating it from the response of the low dose 
vaccinated group, which was exclusively a Th1 response. Thus, concluding the type of 
cell-mediated response generated following BCG vaccination was dose-independent is 
questionable, as we have shown in our studies that doses higher than >107 and >108 in 
adult BALB/c and CBA mice, respectively, induce qualitatively different immune 
responses than those generated following immunization with lower doses. The responses 
generated following relatively higher doses of BCG in each mouse strains had a 
significant Th2 component, which we think may counteract the effect of a protective Th1 
response. Third, as discussed in the Introduction, the standard dose of BCG (>108 cfu) 
administered to school children showed variable efficacy ranging from no effect at all in 
India to 80% efficacy in England. Therefore, these results may suggest that the guinea pig 
model in this study is not an appropriate model for determining why BCG failed to 
protect against tuberculosis in tropical areas like India and Africa, but presents an 
appropriate model for the English trial. There can be several factors to explain the failure 
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of BCG on these areas, but we believe that one of the most important variables was the 
dose of BCG used during these vaccination trials. The reason why high dose of BCG was 
effective in England and not in India or Africa could be due to the fact that there is 
genetic variation in susceptibility/resistance to tuberculosis between these different 
populations used in the studies. Tuberculosis is an old disease in Europe when compared 
to Asia or Africa and hence the population may have developed better resistance to 
tuberculosis than the population in areas where tuberculosis became a public health 
problem in the late 19th and early 20th century, following colonization of these areas by 
European settlers. As a result the transition number (tn) for M. tuberculosis and the BCG 
vaccine may be higher in the European population, resulting in a better efficacy of high 
dose BCG vaccination as reported in England. This is consistent with our finding that the 
tn can vary by several folds between different mouse strains. These comments are clearly 
of a speculative nature, but it is this kind of consideration that might explain the diversity 
of results from BCG trails and the dramatic results of Buddle and colleagues (Buddle et 
al., 1995) on the efficacy of low dose BCG vaccination in cattle. 
 
We have also shown the Th1 responses generated following vaccination with relatively 
low doses BCG are associated with a Th1 imprint in both adult and newborn BALB/c 
mice, as demonstrated by the more efficient clearance of BCG from the spleen following 
high dose iv challenge of low dose vaccinated mice. Based on the present results, one can 
conclude that low dose BCG vaccination induced a predominantly Th1-type response and 
Th1 imprinting in mice independent of, to the limited extent we examined, the age or 
strain of mice used, as well as the route of antigen administration. Similarly, 5x108 cfu of 
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BCG vaccine was reported to be inferior as compared to lower (5x104 cfu) and 
intermediate (5x107 cfu) doses in protecting deer against challenge with M. bovis 
independent of the route of administration (Griffin et al., 1999). In their recent review 
article, Griffin and colleagues have discussed in detail the summary of results they 
obtained from several vaccination studies in deer (Griffin et al., 2001). Based on these 
results, they conclude that BCG doses in the range of 104 to 107 cfu were able to induce 
responses dominated with type 1 cytokines that provided better protection against 
infection with M. bovis. In contrast, the high dose (108 cfu) induced type 2 cytokines 
dominated with high level of IL-4 and strong antibody responses, which was less efficient 
in protecting deer against M. bovis infection. The response generated following 
vaccination with high dose BCG seems to be a mixed Th1/Th2 response as they reported 
both strong DHT responses and high antibody titers in those animals. In another study, 
low dose BCG vaccination (6x104 and 6x106 cfu), which was 10,000 to 100,000 lower 
than the commonly used dose (1010 cfu), induced immune response with higher levels of 
mycobacterial antigen-specific IFN-γ and IL-2 cytokines that protected calves from lethal 
M. bovis challenge (Buddle et al., 1995). These observations, made in various animal 
species including mice, guinea pigs, deer and cattle, imply that low dose BCG 
vaccination is sufficient to generate Th1 type responses and Th1 imprints that can 
effectively control infection with pathogenic mycobacteria. The consistency of this 
response among species argues strongly that this may also be applicable to human 
vaccination protocols against M. tuberculosis infections. 
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5.3. Isolation and Identification of T-cell Subsets Responsible for 
the Secretion of BCG-Specific Cytokines 
 
5.3.1. Introduction 
Knowledge of the nature of the primary immune response generated following infection 
with chronic intracellular pathogens, such as mycobacteria, and identifying the T-cell 
subsets responsible for protection, is very important in designing an improved anti-
tuberculosis vaccine. Evidence in the literature, discussed in detail in section 2.6, has 
unequivocally shown that anti-tuberculosis immunity is mediated by cytokines, mainly 
IFN-γ from antigen-specific CD4+ Th1 cells and CD8+ cytotoxic T-cells. On the other 
hand, cytokines from antigen specific CD4+ Th2 cells, mainly IL-4 may play a role in the 
failure of immunity to tuberculosis infection (Sanchez et al., 1994; Surcel et al., 1994; 
Baliko et al., 1998). We therefore wished to determine the subset of lymphocytes 
responsible for the production of cytokines (IFN-γ and IL-4) during BCG infection. To 
this end, BALB/c mice vaccinated sc with low and high doses of BCG were subsequently 
challenged intravenously with a high dose of BCG and sacrificed between 12 to 16 weeks 
post-challenge. Single cell suspensions of spleen cells were depleted of particular T-cell 
subsets by antibody dependent complement mediated lysis. In addition, positive and 
negative selection using magnet assisted cell sorting (MACS) was used to obtain specific 
cell populations. Positive and negative fractions isolated from the spleen cells using the 
MACS beads, as well as the population recovered following complement mediated lysis, 
were washed and re-suspended in the original (pre-depletion) volume in complete RPMI 
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media. Cells were counted and whenever the number is less than 106 per 100 μl, the 
amount dispensed per well, feeder cells from naïve mice were added so that each well in 
the ELISPOT assay would have 106 cells in 100 μl media. A 100 μl aliquot, containing 
around 106 cells, was also taken from each tube and processed for flow cytometric 
analysis to determine the level of expression of the respective markers in comparison to 
stained normal spleen cells.  
 
5.3.2. Results 
 
Our results clearly show that purifying T-cell subsets using MACS is an efficient method 
of sorting T-cell subsets when compared to the complement dependent depletion of a 
particular subset of T-cells (data not shown). In addition, cells treated by complement-
mediated lysis appear unhealthy under the microscope, which may have a detrimental 
effect on the survival of cells and their ability to produce cytokines in the ELISPOT 
assay. For this reason, all our remaining cell-sorting experiments were carried out using 
the MACS procedure despite the greater cost of this method. Figure 29 shows FACS 
analysis of cell surface markers following MACS depletion of a given T-cell subset from 
the spleen cells of BCG infected mice. Both the negative and positive fractions obtained 
from MACS were processed for ELISPOT assay as described in Materials and Methods. 
Results from ELISPOT assays show both IFN-γ and IL-4 cytokines produced during 
BCG infection come from lymphocytes that express the surface markers of Thy1.2 and 
CD4, which confirms that the source of BCG-specific IFN-γ and IL-4 cytokines are 
CD4+ T-cell subsets or cells dependent on CD4+ T cells.  
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Figure 29. Expression of markers on MACS depleted or enriched cells as compared 
to normal spleen cells.   
Adult BALB/c mice vaccinated with 107 cfu of BCG subcutaneously and then challenged 
intravenously with 5x106 cfu of BCG were sacrificed 12 weeks post-challenge. Pooled 
spleen cells from 3 mice were sorted using MACS beads and samples taken for FACS 
analysis as described in Materials and Methods. Expression of Thy1.2, CD4 and CD8 
markers are shown in comparison to un-depleted stained spleen cells.  
CD8 
CD4 
Stained control 
CD8 depleted 
CD4 depleted 
Thy 1.2 depleted 
CD4 enriched 
CD8 enriched 
CD4 CD8 
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Figure 30 is a picture of an ELISPOT plate illustrating the number of IFN-γ and IL-4 
spots per million spleen cells plated. Even though counting the number of spots in each 
well was difficult, comparable numbers of spots can easily be seen both in the un-
depleted and CD8 depleted spleen cells, suggesting few, if any, of the cytokines are 
secreted by CD8 cells (compare row 3 with row 4). However, Thy1.2 and CD4 depleted 
cells secrete almost no IFN-γ and very little IL-4 as compared to un-depleted (control) 
spleen cells, which indicates that the source of BCG-specific IFN-γ and the majority of 
the BCG-specific IL-4 cytokines in the spleen are Th1.2+CD4+ cells. Similarly, Table 7 
clearly shows >90% of the BCG-antigen dependent IFN-γ-secreting cells, as well as 70-
80% of the IL-4-producing cells were Thy1.2+ CD4+ cells. The level of cytokines 
produced by CD8 depleted spleen cells was not significantly different than the control 
group. However, depletion of Thy1.2+ or CD4+ T-cells reduced the levels of both IFN-γ 
and IL-4 cytokines. 
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Figure 30.  A picture of an ELISPOT plate with spots formed by antigen-specific 
cytokine secreting T-cell subsets of spleen cells sorted using magnetic beads.  
Pooled spleen cells from 3 BALB/c mice vaccinated sc with 107 cfu of BCG and 
challenged iv with a high dose BCG were sorted using MACS. Cells depleted of specific 
T-cell subsets were used in the ELISPOT assay to determine the source of cytokines 
during BCG infection. Numerous antigen-specific IFN-γ and IL-4 spots were observed in 
wells with un-depleted spleen cells as well as CD8 depleted cells. In contrast, almost no 
IFN-γ spots and only a few IL-4 spots were observed in wells with Thy1.2 depleted and 
CD4 depleted spleen cells.  
Thy1.2 depleted
CD4 depleted
CD8 depleted
Control
IFN-γ IL-4
 Ag- Ag+  Ag- Ag+
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Table 7. BCG-specific IFN-γ and IL-4 cytokine production by T-cell subsets of the 
spleen following MACS depletion. 
Spleen cells from 3 BLAB/c mice vaccinated with 107 cfu of BCG sc and challenged 
with high dose of BCG iv were pooled together and sorted into specific subsets using 
MACS. Both the positive and negative fractions were re-suspended in the original 
volume and 100 μl aliquots added per well in the ELISPOT assay to assess the level 
BCG-specific cytokines produced. Feeder cells from naïve mice were added to bring the 
total number of cells per well to 106. Results represent the average of three different 
ELISPOT assays. 
 
 Antigen-specific cytokine secreting cells per million 
spleen cells as detected in the ELISPOT assay 
 IFN-γ IL-4 
 
Treatment group Mean SDb Mean SDb 
Control cellsa 1308 334 551 91 
CD8+ cells depleted 1285 305 453 61 
CD4+ cells depleted 56 27 155 33 
Thy1.2+ cells depleted 43 14 96 11 
Thy1.2+ 1396 173 349 60 
CD4+ 1199 168 221 149 
CD8+ 89 61 25 16 
APCc 29 14 22 6 
a  Undepleted control cells  
b Standard deviation of the mean as calculated in Microsoft Excel, 2003 
c Antigen presenting cells from naive mice 
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5.3.3. Discussion 
The results from the depletion experiments clearly show that the majority of the BCG-
specific IFN-γ-producing cells, detected by the ELSPOT assay and present in immune 
spleen, are CD4+ T-cells. This suggests that BCG vaccination, if administered under 
optimal conditions, can induce mycobacterial-specific CD4+ T-cells capable of secreting 
cytokines responsible for the activation of macrophages. Activated macrophages in turn 
are responsible for the destruction of the mycobacteria. Our findings are in agreement 
with previous reports where in vivo depletion of αβ T-cells or MHC class II-/- was 
associated with progressive disease and rapid death of tuberculosis infected mice. In 
contrast, normal mice were able to contain infection at a stationary level from day 20, 
associated with increased levels of IFN-γ in the lung, resulting in a relatively longer 
survival time (Mogues et al., 2001). Observations in human HIV patients have also 
shown that CD4+ T-cells secreting IFN-γ are very important in maintaining M. 
tuberculosis infection in a latent state and prevent reactivation disease (Scanga et al., 
2000). These observations are clear evidence in support of the hypothesis that CD4+ cells 
and their cytokines are very important in controlling tuberculosis disease progression in 
both humans and animals. Our results also show that BCG-specific IL-4-producing cells, 
present in immune spleen, are mainly CD4+ cells, suggesting that the same populations 
of T-cells (probably a different subset) are responsible for the down regulation of the 
protective immune response in mice vaccinated with high dose of BCG. This is consistent 
with our hypothesis that a low dose BCG vaccine induces Th1 cells, which secrete IFN-γ 
that activates macrophages, whereas a high dose of BCG induces mixed Th1/Th2 cells 
with a substantial level of IL-4 that may counteract the effect of Th1 cells. 
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5.4. Examining whether Anti-IL-4 Therapy can Modifying an 
Ongoing, Mixed Th1/Th2, anti-BCG Response into a Th1-
type response 
 
5.4.1. Introduction 
In situations where no effective vaccine is available that can prevent infection, or no 
appropriate chemotherapy exists to control disease, immunotherapy may become a 
feasible approach in fighting chronic diseases. Evidence in the literature and results from 
our laboratory indicate treatment with appropriate cytokines or anti-cytokine antibodies 
can redirect the immune response from a non-protective response to one that can control 
infection. Partial depletion of CD4+ T-cells, administration of pro-Th1 cytokines, such as 
rIL-12 or neutralizing Th2 cytokines, such as IL-4 prior to and/or during the time of 
infection with L. major, resulted in a Th1 response that protected BALB/c mice from a 
high dose challenge (Titus et al., 1985; Sadick et al., 1990; Heinzel et al., 1993; Nabors et 
al., 1995; Heinzel and Rerko, 1999). Interestingly enough, anti-IL-4 therapy also cured 
mice with a stable “border-line leishmaniasis” associated with a mixed Th1/Th2 response 
several months post-infection (Uzonna and Bretscher, 2001). These results prompted us 
to explore whether treatment of BCG infected mice, with a stable mixed Th1/Th2 anti-
BCG response, using anti-IL-4 or anti-CD4 antibody, could switch the BCG specific 
response into a Th1 mode. If this could be achieved, we would examine whether such a 
modulation led to increased clearance of the bacteria as reflected in a reduced bacterial 
burden in the spleen. The specific objective of this study was to determine if anti-IL-4 
treatment could shift an ongoing mixed Th1/Th2 anti-BCG response into an exclusive 
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Th1 mode in BCG infected mice. To determine the minimum dose of anti-IL-4 antibody 
that produced the desired effect, BALB/c mice vaccinated with 107 and 108 cfu BCG 
were divided into three groups. Starting at week 12 post-vaccination, groups were treated 
intraperitoneally (ip) with ascites fluid that contained either 1 mg/mouse/wk (G1) or 0.25 
mg/mouse/wk (G2) of anti-IL-4 monoclonal antibody (11B11), or 1 mg/mouse/week of 
isotype-matched control antibody (G3), for four weeks. We could not ascertain any effect 
of these treatments on the Th1/Th2 nature of the response in two different experiments; a 
third experiment was conducted to specifically address variables we suspected might be 
responsible for the failure of anti-IL-4 treatment to have an effect. In the third 
experiment, the dose of BCG used to create a mixed Th1/Th2 response was 6x106 cfu, 
and the biological activity of the ascites fluid in terms of ability to neutralize IL4, was 
determined using the CT4S assay as described in section 4.11. In addition, CBA mice, 
with a predominant Th1-type response, but also with a readily detectable level of BCG-
specific IL-4-producing cells, were also used as a positive control, to help determine if 
the lack of effect observed in the previous experiments was due to an excessive 
polarization of the response towards the Th2 pole. Evidence in the leishmania system 
showed that highly polarized Th2 responses could not be easily modulated to the Th1 
mode by anti-IL-4 treatment. The treatment groups in BALB/c mice were: 1 mg/week 
(G1), 0.5 mg twice a week (G2), 1 mg/week isotype control antibody (G3). Parallel 
experiments were conducted with CBA mice, but with only two groups: G1 receiving 1 
mg/week anti-IL-4 monoclonal antibody (11B11), and G2 receiving an equal amount of 
control antibody. All treatments were given ip for 4 consecutive weeks. 
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5.4.2. Results 
Adult BALB/c and CBA mice were injected with 6x106 and 5x107 cfu of BCG iv, 
respectively. Three mice from each group were sacrificed 12 weeks post-vaccination to 
determine the type of response generated. As shown in Table 8, BALB/c mice mounted a 
mixed Th1/Th2 response with IFN-γ/IL-4 and IgG2a/IgG1 ratios close to 1, with no 
significant difference in the level of cytokines and antibodies in each mouse. In contrast, 
CBA mice generated a predominantly Th1 response with significantly higher levels of 
IFN-γ-secreting cells associated with higher BCG-specific IgG2a than IgG1 antibody 
titers. However, the spleen cells of CBA mice also had a considerable number of IL-4-
secreting T-cells. This allowed us to determine whether anti-IL-4 treatment could 
eliminate or reduce the frequency of these cells and modulate the BCG-specific immune 
response into an exclusively Th1 mode. Mice were treated with ascites fluid containing 
anti-IL-4 antibody as described above. Starting from week 6 after the last treatment, 3 
mice per group were bled to assess antibody titers and isotypes in serum and then 
sacrificed to assess the Th1/Th2 nature of the BCG-specific cells present in the spleen. 
Figure 31A shows results from both BALB/c and CBA mice after anti-IL-4 treatment. 
These results clearly show that anti-IL-4 treatment did not significantly alter the mixed 
Th1/Th2 response in BALB/c mice. Similarly, treatment did not have a significant effect 
on reducing the frequency of IL-4-secreting cells in CBA mice. We conclude that our 
anti-IL-4 treatment protocol does not significantly modulate a mixed Th1/Th2 response 
towards the Th1 pole during BCG infection. Parallel results were also obtained when the 
isotype of BCG-specific IgG antibodies was assessed by ELISA 18 weeks after the last 
treatment of BALB/c mice, with no detectable effect observed (Figure 31B).  
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Table 8. Effect of anti-IL4 antibody treatment in modulating an ongoing mixed 
Th1/Th2 anti-BCG response into a Th1 mode, as assessed by determining BCG-
specific IL-4 and IFN-γ-producing spleen cells and levels of BCG-specific IgG2a and 
IgG1 serum antibodies.  
Adult BALB/c and CBA mice were injected iv with a dose of BCG that induced a mixed 
Th1/Th2 response. 12 weeks after infection, representative mice from each strain were 
bled to determine the isotype of BCG-specific IgG antibodies and sacrificed to assess the 
nature of antigen-specific cytokine response by splenocytes. Results are from one of two 
replicate experiments. 
 
 Cytokine secreting cells per million 
spleen cells as detected in ELISPOT 
Log10 titer of Serum Antibodies  
as detected in the ELISA assay 
 
 
 
IFN-γ 
 
IL-4 
 
IFN-γ/IL-4b 
 
IgG2a 
 
IgG1 
 
IgG2a/IgG1c 
BALB/c       
a M1 446 502 0.88 5.9 5.6 1.1 
M2 480 470 1.02 5.3 5.3 1.0 
M3 397 508 0.78 5.7 5.5 1.0 
APCd 47 9 NA    
CBA       
M1 387 96 4.03 4.4 3.2 1.4 
M2 406 93 4.37 4.7 2.6 1.8 
APCe 35 19 NA    
a M refers to mouse 1, 2, 3   
b Ratio of IFN-γ to IL-4   
c Ratio of IgG2a to IgG1 
d Spleen cells taken from naïve BALB/c mice  
e Spleen cells taken from naïve CBA mice  
NA; not applicable 
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Figure 31. Treatment with anti IL-4 antibody does not modulate BCG-specific 
immune response in either BALB/c or CBA mice.  
Mice were injected iv with a dose of BCG that can induce a mixed Th1/Th2 response. 
Starting from week 12 post-infection, mice were treated with anti-IL-4 antibody for 4 
consecutive weeks as described in the text. Starting from week 6 after the last anti-IL-4 
treatment, the isotypes of the anti-BCG IgG antibodies and the nature of the splenic 
cytokine response were assessed. (A) Shows the results of treatment on the splenic anti-
BCG response at 12 weeks post-treatment and (B) is the isotypes of anti-BCG serum 
antibodies 18 weeks post last treatment of the BALB/c mice. Results shown are 
representative of three replicate experiments carried out at weeks 6, 12 and 18 after the 
last anti-IL-4 treatment. Labeling in the abscissa represents treatment groups. In BALB/c 
mice, G1 refers to administration of (1 mg Ab/week), G2 (0.5 mg twice a week), G3 (1 
mg/week control antibody). In CBA mice, G1 is (1 mg/week), G2 (1 mg/week control 
antibody). APC stands for spleen cells from naïve mice used as feeder cells in the 
ELISPOT assay. 
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5.4.3. Discussion 
 
Contrary to our hypothesis, anti-IL-4 therapy did not modulate an ongoing mixed 
Th1/Th2 anti-BCG response towards the Th1 pole in BALB/c mice. This was not due to 
the pro-IL-4 nature of the BALB/c mice, as a similar lack of effect was seen with CBA 
mice. This may suggest that the fine balance between Th1 and Th2 cells is differently 
regulated in mycobacterial and L. major infections. A possible mechanism could be via 
IL-10, as it was shown in vitro that IL-10 inhibits the activation of macrophages to 
destroy intracellular pathogens. IL-10 inhibits macrophage activation either by 
suppressing the transcription of pro-inflammatory cytokines (mainly IL-1, TNFα, IFN-γ) 
and/or by down-regulating surface molecules such as the B7.1 and B7.2 co-stimulatory as 
well as MHC class II molecules (Moore et al., 2001). It also suppresses the production of 
reactive oxygen and nitrogen intermediates in activated macrophages (Redpath et al., 
2001). Thus, IL-10 is sometimes known as a macrophage deactivation factor; 
mycobacteria may cause IL-10 production in order to ensure their survival within the 
macrophages. In line with this, the excessive level of IL-10 seen in active tuberculosis 
patients, as compared to healthy contacts, is believed to be the cause for the depressed 
mycobacterial antigen-specific immunity during pulmonary tuberculosis infections 
(Hirsch et al., 1999) and for the immunosuppression exhibited during trypanosome 
infections (Uzonna et al., 1998). A recent study reports patients with active tuberculosis 
have higher levels of IL-10 and CD4+CD25+ T-cells in their PBMC than PPD positive 
healthy contacts, suggesting a possible role of the Treg cells and their primary cytokines, 
IL-10, in the regulation or suppression of immune response during tuberculosis infection 
(Ribeiro-Rodrigues et al., 2006). Therefore, inhibiting the effect of IL-10 either by 
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neutralizing the cytokine using monoclonal antibodies or by blocking its effect using anti 
IL-10R monoclonal antibody is worth considering. However, in direct contrast to 
previous findings that report a direct role for IL-10 in suppressing mouse immunity 
against M. avium (Denis and Ghadirian, 1993) and BCG (Murray et al., 1997) infections, 
a recent study by North and colleagues reported increased IL-10 expression is not 
responsible for the failure of Th1-type response to resolve airborne infection with virulent 
M. tuberculosis in mice (Jung et al., 2003). Therefore, the idea of treating mice with a 
mixed Th1/Th2 response following BCG infection, using anti-IL-10 or anti-IL-10R 
monoclonal antibody would be interesting in view of these conflicting reports. Anti-IL-
4R therapy is also worth investigating, as BALB/c mice deficient in IL-4R are more 
effective in controlling leishmaniasis than mice that lack the IL-4 cytokine (Noben-
Trauth et al., 1999). In addition, healthy contacts in tuberculosis endemic areas are found 
to express high levels of type one cytokines and a considerable amount of the IL-4 
antagonist, IL-4δ2, that functionally competes with IL-4 by binding to the α chain of the 
IL-4R (Demissie et al., 2004). These results suggest inhibiting the function of IL-4 by 
blocking its receptor with anti IL-4R monoclonal antibody may more effectively down-
regulate the effect of type two cytokines than directly neutralizing the cytokines with 
anti-cytokine monoclonal antibody. It would also be interesting to try partial depletion of 
CD4+ cells as this was found to be effective in modulating the immune response from 
mixed Th1/Th2 into a Th1 polarized response in the leishmania model (Uzonna and 
Bretscher, 2001).  
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5.5. Modeling in Mice the Effect of Environmental Mycobacteria 
on BCG Vaccination 
 
5.5.1. Introduction 
Reasons for the low efficacy of BCG vaccination and/or variation in its efficacy between 
different vaccination trials have been debated for a long time. One compelling 
explanation is the interference or masking of a BCG specific immune response due to 
prior exposure to environmental mycobacteria. Such interference might explain the 
reduced efficacy of BCG vaccination in tropical countries, such as India and Africa, 
where exposure to environmental mycobacteria is more common when compared to 
temperate regions, for example England, where efficacy rates as high as 80% were 
reported (Fine, 1995).  
 
The effect of environmental mycobacteria may well be of a different nature in different 
people exposed to different species of environmental mycobacteria. Reports from 
decades ago (Palmer and Long, 1966; Edwards et al., 1982) indicate exposure to 
environmental mycobacteria can induce partial protection against tuberculosis infection. 
Therefore, the observed lower efficacy of vaccination due to prior exposure to 
environmental mycobacteria could be due to the induction of a protected state by cross-
reacting antigens prior to BCG vaccination. The potential effect of BCG vaccination in 
naïve individuals would therefore be masked, which would hinder differentiation of the 
response when comparing vaccinated and placebo groups, as both groups will have a 
similar state of protection (Edwards et al., 1982). Immune responses due to 
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environmental mycobacteria may also interfere with the ability of BCG to generate a 
protected state. Prior exposure to environmental mycobacteria can induce an immune 
response which may prematurely eliminate the BCG vaccine from the host before it 
induces a sustainable immune response against M. tuberculosis (Andersen and Doherty, 
2005). Experimental observations support this hypothesis in the sense that environmental 
mycobacteria, cross-reactive with BCG, induced a transient immune response too weak 
to protect against infection by M. tuberculosis, but strong enough to block replication of 
the BCG vaccine and hence abrogating its capacity to induce protective immunity against 
tuberculosis infection (Brandt et al., 2002). On the other hand, depending on the timing or 
dose of exposure, oral exposure of mice to M. vaccae was found to either enhance, mask, 
or interfere with a subsequent immune response generated following BCG vaccination 
(Brown et al., 1985).  
 
The aim of our present study is to see if exposure of mice to M. gordonea (saprophytic 
mycobacterium frequently isolated from tap water), in a way that can induce a mixed 
Th1/Th2 response, will abrogate the generation of Th1 responses and Th1 imprints 
normally generated upon low dose BCG vaccination. We anticipated this prior 
mycobacterium exposure would interfere with the efficacy of BCG vaccination. We will 
also examine if early vaccination of mice, before exposure to environmental 
mycobacteria, can avoid this potential interference. These experiments test critical 
aspects of the neonatal low dose BCG vaccination strategy against tuberculosis. 
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5.5.2. Results 
 
5.5.2.1. Determining the Dose of M. gordonea that Induces a Mixed 
Th1/Th2 Response, as Measured Against BCG Antigens, in 
BALB/c Mice 
 
As we had neonatally vaccinated and age matched control BALB/c mice at our disposal, 
we exposed these groups to 106 cfu M. gordonea bacilli per ml of drinking water for 4 
weeks. We chose the oral route of exposure to mimic the natural route of infection with 
this environmental mycobacterium (commonly called tap water bacilli). We changed the 
water every week based on preliminary results indicating that the bacteria could survive 
in water at room temperature for at least 15 days. To roughly estimate the bacterial dose 
taken by each mouse, water consumption data was collected for four weeks and found to 
be between 3 and 4 ml per mouse/day. We, therefore, estimate each mouse was getting 
~3x106 cfu every day, which we considered might be a dose sufficient to seroconvert 
naïve mice and induce a mixed Th1/Th2 response. However, 12 weeks after the last 
challenge, no mice from the unvaccinated or low dose vaccinated group serconverted as 
assessed by ELISA. All mice had mounted a Th1-type response as determined in the 
ELISPOT assay (data not presented). We therefore chose another route of challenge to 
determine the dose of M. gordonea that could induce a mixed type of response in naïve 
mice. To this end, we injected mice (5-7 mice/group) subcutaneously at the base of the 
tail with different doses (105 to 109 cfu) of live M. gordonea. Serum antibody levels were 
assessed in ELISA at ~14 weeks post-infection. The lower doses used (105 and 106 cfu) 
induced only IgG2a antibodies, while all higher doses induced both IgG1 and IgG2a 
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isotype antibodies with IgG1/IgG2a ratio of <1 for 107 cfu, ~1 for 108 cfu and >1 for 109 
cfu. Similarly, the Th1/Th2 nature of the response as assessed by ELISPOT assay 
revealed that doses <107 cfu induced predominantly Th1 responses, while doses >108 
induced mixed Th1/Th2 responses with an increasing bias towards Th2 as the doses 
increased (Table 9). No significant difference in the number of IFN-γ-producing spleen 
cells was found between mice belonging to the different groups. However, the number of 
IL-4-producing cells was significantly higher for mice immunized with doses >108 cfu 
than for mice immunized with lower doses. Therefore, based on these results, a dose >108 
cfu of M. gordonea was chosen as the dose that would induce a mixed Th1/Th2 response 
for the subsequent experiments. 
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Table 9. Determination of a dose of M. gordonea that induces a mixed Th1/Th2 
response in naïve mice. 
Adult BALB/c mice were injected subcutaneously at the base of the tail with different 
doses of live M. gordonea and were bled and sacrificed between 12-16 weeks post-
infection. BCG-specific cytokine secreting spleen cells and serum antibody titers were 
determined by the ELISPOT and ELISA assays, respectively. Numbers under the Group 
heading refer to the number, in cfu, of M. gordonea injected. Data shown are an average 
+ SD of values from 5-7 mice per group, and are from one of two replicate experiments.  
 
 Cytokine secreting cells/ 106 cells Serum antibodies titers 
  
IFN-γ 
 
IL-4 
 
Ratiod 
 
IgG2a 
 
IgG1 
 
Ratiod 
Group Mean SDc Mean  SDc  Mean SDc Mean  SDc  
105 190.3 140 28.3 24 6.8 949 607 *** NA __ 
106 199 63 64.3 38 3.1 1166 1435 *** NA __ 
107 226 44 71 15 3.2 975 1725 327 281 3 
*108 195.3 26 183 27 1.1 8138 6034 4287 2733 1.9 
109 232 43 218 28 1.1 6453 4762 13163 7741 0.5 
AMCa 72.7 34 19 4.6 NA 461 88 109 95 NA 
CNTb 15 NA 17 NA 0.9 *** NA *** NA __ 
aAMC refers to age matched control mice  vaccinated with an equal volume of saline. 
bCNT refers to naïve control mice used as source of APC in the ELISPOT assay. 
cStandard deviation of the mean as calculated in Microsoft Excel, 2003 
dIFN-γ to IL-4 and IgG2a to IgG1 ratio 
NA applies when value is not applicable. 
*** titer less than 100. 
* Dose of M. Gordonea used for subsequent experiments 
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5.5.2.2. Pre-exposure to M. gordonea Interferes with the Type of 
Immune Response Generated Following BCG Vaccination 
 
 We wanted to test the hypothesis that priming by environmental mycobacterium can 
abrogate the ability of low dose BCG vaccination to generate a predominantly Th1 
response and Th1 imprint. We also wanted to examine whether neonatal low dose BCG 
vaccination of mice, before exposure to environmental mycobacteria, could prevent the 
interference normally caused by the environmental mycobacterium. Young mice, around 
4 weeks of age, were divided into seven different groups (12 mice/group) and each group 
was treated as shown in Table 10. Mycobacterial doses used for exposure, vaccination 
and challenge were based on results from earlier experiments. To differentiate between 
mycobacteria used for vaccination (BCG) or for exposure (M. gordonea) from that used 
for challenge, mice were challenged with BCG expressing a vector with a kanamycin 
resistant gene, pMV261 (Connell et al., 1993). Thus, all bacterial burden assessments 
were carried out on agar plates without or with 20 μg/ml kanamycin. A preliminary 
experiment demonstrated that mice vaccinated intravenously with 107 cfu BCG pMV261 
still expressed the antibiotic resistant gene for as long as 12 weeks post-vaccination (data 
not shown). Unfortunately our attempt to grow bacteria from spleen cells of challenged 
mice on agar plates with kanamycin was not successful for reasons that we could not 
explain. In one experiment there was no growth at all in most of the plates both from 
vaccinated and non vaccinated mice. On another experiment, there was growth but the 
high variation between mice of the same group made it difficult to make comparison 
among groups. Therefore, bacterial burden assessment results are not presented. 
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Table 10. Treatment groups and plan of exposure for M. gordonea sensitization 
experiments. 
Young BALB/c mice were obtained immediately after weaning (3 weeks) and divided 
into seven groups with 12 mice in each group. Each group was vaccinated sc with BCG 
and exposed sc to live M. gordonea as shown, then challenged intravenously with a high 
dose of BCG. 
 
Age** 
 
Expos* 
 
Group 
4 weeks 
 
1st exposure 
(sc) 
13 weeks 
 
2nd exposure 
(sc) 
22 weeks 
 
3rd challenge   
(iv) 
34weeks 
 
Test to be done 
G1 Low (104cfu) 
BCG  
High (108cfu) 
M.gordonea  
High (2x106cfu) 
BCG 
Bleed= for Ab test 
 Sacrifice=to assess   
response & burden 
G2 Low (104cfu) 
BCG 
 
None High (2x106cfu) 
BCG 
,, ,, 
G3 None High (108cfu) 
M.gordonea 
High (2x106cfu) 
BCG 
 
,, ,, 
G4 High (108cfu) 
M.gordonea 
 
Low (104cfu) 
BCG 
High (2x106cfu) 
BCG 
,, ,, 
G5 None Low (104cfu) 
BCG 
 
High (2x106cfu) 
BCG 
,, ,, 
G6 None None High (2x106cfu) 
BCG 
 
,, ,, 
G7 None None None ,, ,, 
*Stands for exposure or/and vaccination of mice with M. gordonea or/and BCG  
**Refers to age of mice at each treatment/exposure 
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The observations presented on Figures 32A and B show that early exposure of mice to 
cross-reacting environmental mycobacteria, M. gordonea, interferes with low dose BCG 
vaccination and can alter the nature of the immune response generated following low 
dose BCG vaccination, compare Groups 4 and 5. Furthermore, vaccinating mice early in 
life, before they are exposed to environmental mycobacteria, can abrogate the negative 
impact of M. gordonea on the type of immune response generated following low dose 
BCG vaccination, see Groups 1 and 2. When challenged with high dose of BCG 
intravenously, Group 1, which had been exposed to a high dose of M. gordonea 
following low dose BCG vaccination, showed a similar response to Group 2, which 
received only the low dose BCG vaccine. This indicates that the Th1 imprint generated 
following low dose BCG vaccination was not altered by exposure to a high dose of 
environmental mycobacteria. In contrast, mice in Group 4, which were vaccinated with a 
low dose of BCG following exposure to a high dose of M. gordonea, generated a mixed 
Th1/Th2 response, indistinguishable from the responses of mice in Group 3, which 
received only a high dose of M. gordonea. This again suggests that pre-exposure to an 
environmental mycobacteria can abrogate the generation of the desired type of response 
achieved in naïve mice upon low dose BCG vaccination. Results from two different 
experiments performed 4 and 6 months after challenge with BCG expressing a vector 
with kanamycine resistant gene (pMV261) are presented to show the consistent nature of 
our observations. Statistical analysis of cytokine secreting cells revealed that the 
frequency of BCG-specific IFN-γ-secreting cells was similar in all groups. In contrast, 
the IL-4 levels differ significantly, which altered the IFN-γ/IL-4 ratio among groups. 
Table 11 summarizes the results of a statistical analysis demonstrating no difference 
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between groups 1, 2 and 5, as well as, between groups 3, 4 and 6. However the difference 
in the level of IL-4 and hence the IFN-γ/IL-4 ratio was significant (p<0.05) between these 
groups. An independent study carried out a few months later gave identical results to 
those obtained from the first study (Figure 33A and B), further strengthening evidence 
that pre-exposure to environmental mycobacterium can potentially interfere with low 
dose BCG vaccination. This in turn suggests the importance of vaccinating early in life 
with a low dose of BCG in order to avoid possible interference with Th1 imprinting that 
may result from pre-exposure to environmental mycobacteria. 
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Figure 32. Pre-exposure of mice to environmental mycobacteria, M. gordonea, alters 
the immune response to low dose BCG vaccination in mice.  
Young BALB/c mice, 3-4 weeks of age, were divided into seven different groups of 12 
mice each and treated as described in Table 10. At around 6 months of age, all mice in 
groups 1-6 were challenged with a high dose of BCG expressing kanamycin resistant 
gene intravenously. Results show BCG-specific IFN-γ and IL-4-secreting cells in the 
spleen 16 weeks (A) and 24 weeks (B) after challenge with the high dose of BCG261. 
Labels in abscissa represent treatment groups as shown on Table 10. APC (antigen 
presenting cells) stands for spleen cells from a naïve mouse. Data are average of values 
from 4 mice per group with error bars (SD) and represents one of two replicate 
experiments conducted at each time point. 
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Table 11.  Statistical analysis of the results shown in Figure 32. 
Young BALB/c mice treated as described in the legend for Table 10 were sacrificed for 
ELISPOT assay to determine the levels of BCG-specific cytokines produced. Levels of 
BCG-specific IL-4 and IFN-γ as well as ratio of both cytokines were compared 
statistically as described on the Materials and Methods section. Numbers refer to BCG-
specific spots per million spleen cells. 
 
  IFN-γ IL-4 IFN-γ/IL-4 
Group N** mean t – group* mean t – group* mean t – group* 
G1 4 797 A 286.8 A 3.08 A 
G2 4 716.8 A 270.8 A 3.18 A 
G3 4 644.5 AB 771.3 B 0.88 B 
G4 4 459 B 668.5 B 0.8 B 
G5 4 851.3 A 327.8 A 2.7 A 
G6 4 434.3 B 828.8 B 0.55 B 
 AMC 4 31.5 NA 35.5 NA 1.5 NA 
  
* t-group with the same letter indicates no significant difference in values of the indicated 
cytokines between the groups, while different letters indicate significant difference 
(p<0.05) between groups. t-group with more than one letter indicates overlap. 
** Number of mice per group 
NA= not applicable 
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Figure 33. Exposure of mice to environmental mycobacteria, M. gordonea, alters the 
immune response to low dose BCG vaccination in mice.  
Young BALB/c mice, 3-4 weeks of age, were divided into seven different groups of 12 
mice and treated as described in Table 10. At around 6 months of age all mice in groups 
1-6 were challenged with a high dose of BCG expressing kanamycin resistant gene 
intravenously. Results show BCG-specific IFN-γ and IL-4-secreting cells in the spleen 20 
weeks (A) and 30 weeks (B) after challenge with the high dose of BCG261. Labels in 
abscissa represent treatment groups as shown on Table 10. APC stands for spleen cells 
from a naïve mouse. Data presented are average of values from 4 mice in each group with 
error bars (SD) and represent one of two replicate experiments at each time point. 
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5.5.3. Discussion 
The impact of exposure to environmental mycobacterium on the host response to BCG 
vaccine remains controversial. The fact that BCG can give up to 80% protection in places 
with few or no environmental mycobacteria (Hart and Sutherland, 1977) and little or no 
protection in tropical countries where there is a plethora of environmental mycobacteria 
(Baily, 1980), suggests prior exposure to environmental mycobacteria may alter the 
protective efficacy of BCG vaccination.  
 
As discussed in the Introduction, neonates can be exposed to environmental mycobacteria 
within a few weeks after birth. Depending on the type of environmental mycobacterium 
present, their frequency in the environment, as well as the level of exposure of the host to 
one or a mixture of mycobacteria, newborns may generate either a Th1-type response or a 
mixed Th1/Th2 response, and BCG vaccination can enhance each of these responses 
(Rook, 1981; Standford, 1981). Therefore, BCG vaccination can either increase the Th1-
type response and hence enhance protection, or increase the non-protective mixed 
Th1/Th2 response, leading to interference and failure of protection. Rook and Stanford 
claim different species of environmental mycobacteria have an inherent capacity to 
induce either one of these two types of responses. Furthermore, they suggested that pre-
exposure to a given species that can induce one type of response can inhibit the 
subsequent induction of the other response by another species of mycobacteria (Rook, 
1981; Standford, 1981). On the other hand, the same species of environmental 
mycobacterium that Rook and Stanford used was reported to induce either of these two 
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types of responses depending on the dose of exposure, suggesting that the dose is rather 
important in determining the type of response generated following exposure to any cross-
reacting environmental mycobacteria. High doses of environmental mycobacterium 
induce a mixed Th1/Th2 response while lower doses of the same species induce Th1-type 
response (Hernandez-Pando et al., 1997). In our studies, prior injection of mice with high 
dose of M. gordonea induces a mixed Th1/Th2 response and abrogated the generation of 
a predominantly Th1-type response following low dose BCG vaccination, which induced 
exclusive cell-mediated response in naïve mice. A similar finding was reported from 
cattle vaccination studies in which pre-exposure of calves to environmental 
mycobacterium reduced the protective efficacy of a subsequent BCG vaccine (Buddle et 
al., 2002). Furthermore, our observation shows the generation of the M. gordonea 
specific mixed Th1/Th2 response can be inhibited by early vaccination of mice with low 
doses of BCG, which induced a Th1-type response. This finding is also in agreement with 
a previous report in which the non-protective response, usually induced after infections of 
mice with M. kansai, was completely inhibited as a result of pre-exposure of mice to a 
cross-reacting bacteria that induces the protective type of response (Rook, 1981). These 
findings support our hypothesis that neonatal vaccination of humans with appropriate 
doses of BCG, before exposure to cross-reacting pathogens, can induce a protective 
immune response against tuberculosis infections. These observations lend a support to 
our strategy of low dose BCG vaccination of newborns in an attempt to generate Th1 
imprint before significant and detrimental exposure to environmental mycobacteria. The 
Th1 imprinting following low dose vaccination in our first study on environmental 
mycobacteria, see Figure 32, seems to be rather weak when compared to our previous 
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findings both in newborn and adult mice. This could be due to the very high dose of BCG 
used for challenge, which was determined to be 10-fold higher than intended. When 
corrected in our second study, Th1 responses and imprints were similar to our previous 
findings. Overall, our results show pre-exposure of mice to a high dose of environmental 
mycobacteria abrogates the efficacy of the low dose BCG vaccination strategy to induce 
a Th1 imprint. Moreover, we confirmed here that early vaccination of mice before 
exposure to environmental mycobacteria may circumvent the deleterious effect of 
exposure to environmental mycobacteria 
.
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6. General discussion 
 
6.1. Dose of Antigen Determines the Th1/ Th2 Nature of the 
Immune Response Generated Following BCG Vaccination 
 
The studies described here test in both adult and newborn mice two propositions central 
to a vaccination strategy against tuberculosis. They support the hypothesis that BCG dose 
is crucial in determining the Th1/Th2 nature of the immune response, with relatively 
lower doses favoring an exclusive cell-mediated, Th1 response, independently of the 
route of antigen administration or strain of mice used. They also support the hypothesis 
that the generation of a relatively exclusive cell-mediated, Th1, response results in the 
generation of a Th1 imprint, such that the immune response to a subsequent BCG iv 
challenge remained biased towards a cell-mediated, Th1-type response; administration of 
higher doses of BCG did not produce such an imprint. This inclination of the immune 
response to the cell-mediated, Th1 pole, was also associated with more efficient clearance 
of mycobacteria from the spleen following a high dose BCG iv challenge. In addition, our 
observations from vaccination of newborn BALB/c mice with low dose BCG show the 
immune response in newborn mice is not inherently biased towards a Th2 response; 
newborn mice can produce a predominantly Th1 response if an appropriate vaccination 
protocol is applied. Our observations support the general conclusion of an earlier study in 
which neonatal mice produced cell-mediated and antibody responses, respectively, upon 
infection with low and higher doses of a retrovirus (Sarzotti et al., 1996). Similar 
observations were also reported from human studies in which BCG vaccination of 
neonates induced a Th1 response against tuberculosis of similar magnitude seen in adults 
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(Marchant et al., 1999; Vekemans et al., 2001; Davids et al., 2006). In line with this, we 
found that robust Th1 responses and most efficient Th1 imprinting can be achieved in 
newborn mice by administering lower doses of BCG (33, 330 and 3300 cfu). We also 
found that relatively low doses always induce a Th1-type response in all strains of adult 
mice used independently of the route of administration. In all cases, the lowest doses of 
BCG vaccine used were as efficient as the other doses in the low dose category, both in 
inducing a Th1-type response and generating Th1 imprints, as well as ensuring clearance 
of BCG from the spleen following high dose iv BCG challenge. Even though a broad 
range of doses within the low dose category show similar efficacy, we strongly argue for 
the use of the lowest possible dose in a genetically heterogeneous population, as the 
higher doses in this category may induce Th2 biased response in some individuals, and 
fail to protect the host against natural infections with virulent M. tuberculosis. Therefore, 
our findings lend a support to the proposition that an ultra-low dose vaccination strategy 
to achieve Th1 imprinting in a genetically diverse population is realizable (Bretscher et 
al., 2001). In addition to our findings, a recent report from studies in guinea pigs supports 
our ultra-low dose vaccination strategy (Horwitz et al., 2006b).  
 
Our observations naturally lead to the question of why the dose of BCG determines the 
Th1/Th2 phenotype of the ensuing response. This dose dependence has been observed 
with many antigens administered to different species by different routes. How this dose-
dependence might be accounted for in terms of the requirements for inducing the 
generation of Th1 and Th2 cells has been discussed in detail in this thesis (see section 
2.9). However, there are two considerations that make the relevance of our studies to 
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achieving efficacious vaccination in mice against M. tuberculosis uncertain. The first 
question is whether intradermal and/or subcutaneous vaccination can protect against 
infection with M. tuberculosis that usually occurs through inhalation of the pathogen, the 
usual route of infection in man. The second point worthy of consideration is whether the 
"protection" achieved against BCG is also applicable to M. tuberculosis. Observations 
suggest, for example, that mycobacterium specific CD8+ T-cells play some role in 
protection against the virulent M. tuberculosis but not in the clearance of BCG (Flynn et 
al., 1992; Xing et al., 1998; Mogues et al., 2001). This could be due to the presence of 
some virulence factors in M. tuberculosis that can lyse and form pores on the 
phagolysosome membrane thereby facilitating the release of mycobacterial proteins into 
the cytosol or allowing the escape of the pathogen into the cytoplasm. This in turn 
facilitates the processing and presentation of antigens via the MHC class I pathway and 
activates CD8+ T-cells (Mazzaccaro et al., 1996). These virulence factors are the 
immunodominant antigens expressed by virulent strains of M. tuberculosis and M. bovis, 
but the genes that encode these proteins are deleted in BCG. Therefore, the potential 
efficacy of BCG vaccination against tuberculosis might be compromised. However, 
immunization with the immunodominant protein antigens or a DNA vaccine that encodes 
these proteins did not generate any protection which was superior to BCG (Britton and 
Palendira, 2003). Nonetheless, reports still claim the efficacy of BCG vaccination can be 
improved by expressing genes that encode the virulence factors, ESAT-6 and CFP-10 
proteins, in BCG (Pym et al., 2003). Both of these questions can be decisively addressed 
by determining whether low dose BCG vaccination given via the systemic route will 
protect mice against an intrapulmonary challenge with virulent strains of M. tuberculosis. 
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However, the very high degree of protection provided to humans by intradermal BCG 
vaccination, as seen in some trials, suggests that the issues surrounding these two kinds of 
considerations do not provide over-riding impediments to the achievement of effective 
BCG vaccination against tuberculosis.  
 
Another important consideration is the duration of immunity induced following neonatal 
BCG vaccination. Previous studies indicate immunity against tuberculosis, generated 
following BCG vaccination, is on average not more than 15 years (Sterne et al., 1998). 
This may suggest that our neonatal low dose BCG vaccination strategy, if found to be 
effective against M. tuberculosis infection, may lose its efficacy in humans during 
adolescence and thus may not provide protection against adult pulmonary tuberculosis. 
One way of overcoming this problem would be a heterologous prime-boost vaccination 
strategy whereby neonates receive a low dose BCG pre-exposure vaccine and then are 
boosted as adults with another vaccine that contain antigens predominantly expressed in 
virulent strains of mycobacteria. Viral based recombinant live vaccines are good 
candidates for this approach. One such vaccine – the MVA-85A, which expresses the 
strong immunogenic antigen (Ag85A) from the virulent M. tuberculosis strain in a 
replication deficient vaccinia virus Ankara – is found to be effective as a booster vaccine 
against tuberculosis in BCG vaccinated animal models (Goonetilleke et al., 2003) and is 
also safe to use in man (McShane et al., 2004). Adenoviruses, with a natural tropism to 
the respiratory tract and good Th1 adjuvant properties, are also good candidates for the 
development of recombinant vaccines for a prime-boost vaccination strategy (Wang et 
al., 2004). Despite promising results from a prime-boost vaccination protocol using 
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rBCG, boosting the cell-mediated response generated following vaccination with a 
second dose of the same BCG strain is controversial. While results from human studies 
show no increase in level of protection (Fine, 1995), studies in calves indicate reduced 
levels of protection (Buddle et al., 2003). In contrast, BCG vaccination studies in deer 
show two subsequent low dose vaccinations given at an interval of 8 weeks induce a 
better Th1 response and better protection against infection with M. bovis than a single 
low dose BCG vaccination (Griffin et al., 1999). Due to these conflicting reports, a 
prime-boost vaccination protocol using the same strains of BCG is not recommended. 
 
The correlates of a protective immune response against M. tuberculosis are disputed, 
particularly in conditions where both sick and healthy individuals display mycobacterial-
specific DTH reactivity, proposed to be protective, as assessed by a positive PPD-skin 
test. Sometimes people with active tuberculosis can express stronger skin sensitivity than 
infected healthy contacts. Such findings have generated the suggestion that this immune 
state does not correlate with the expression of protective immunity (Comstock, 1988). 
However, recent observations in ill and healthy individuals who are both skin test 
positive indicate both groups have similar numbers of mycobacterial-specific cells able to 
produce IFN-γ upon appropriate stimulation in their peripheral blood lymphocyte (PBL) 
cells, but the PBL of tuberculosis patients appear to have a higher number of 
mycobacterial-specific IL-4-producing cells (Surcel et al., 1994; van Crevel et al., 2000). 
Similar observations from other tuberculosis patients and healthy contacts (controls) 
support the view that a cell-mediated, Th1-type response is protective, since all the 
healthy controls show high tuberculin reactivity, an increased proliferation index, and 
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higher levels of IL-2 and IFN-γ secretion (Sanchez et al., 1994). In contrast, tuberculosis 
patients exhibited low reactivity to tuberculin and had high percentage of IL-4 and IL-10 
producing cells in the peripheral blood associated with higher titers of IgG antibodies in 
their sera (Baliko et al., 1998). This suggests that the immune response of tuberculosis 
patients is biased towards Th2, which may contribute to disease progression by 
counteracting the effect of Th1 cells. The possible mechanism by which Th2 cells can be 
so detrimental to the health of the individual during chronic intracellular infections can be 
explained by the fact that pathogens like M. tuberculosis and L. major are obligate 
intracellular parasites that productively infect macrophages. Th1 cells (CD4+) as well as 
mycobacterial-specific CD8+ T cells, which produce IFN-γ and other Th1-associated 
cytokines, are responsible for activating macrophages in a variety of ways to become 
bacteriocidal or to limit mycobacterial replication (Kaufmann, 1988; Bloom et al., 1994; 
Scanga et al., 2001). The delivery of cytokines such as IL-4 and IL-10 by Th2 cells and 
possibly regulatory T-cells may counteract the activation signals delivered to the 
macrophage (Lehn et al., 1989; Hernandez-Pando et al., 1996; Redpath et al., 2001). 
However, recent reports suggest Th2 cells or their cytokines may not be responsible for 
the failure of immunity in tuberculosis infected mice (Jung et al., 2002; Jung et al., 2003). 
Therefore, the above presumption, however plausible, will only become convincing when 
it is demonstrated that ensuring a greater Th1-like component of the anti-mycobacterial 
immune response, at the expense of the Th2 component, prevents tuberculosis or results 
in a cure of this disease. We believe the experimental system developed here for low dose 
vaccination should be useful in testing this possibility in the mouse model.  
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A recent study attempted to explore whether secondary anti-mycobacterial Th1 responses 
were more effective than primary Th1 responses in protecting mice against a lethal 
challenge of M. tuberculosis (Jung et al., 2005). This study involved infecting mice with 
a normally lethal dose of M. tuberculosis, followed by antibiotic treatment from day 30 to 
day 100 post-infection, at which time mycobacteria could no longer be detected in the 
spleen. These primed as well as control mice were then given a lethal challenge (200 cfu) 
of virulent M. tuberculosis via the airborne route. The priming had a small effect on the 
size and kinetics of the ensuing Th1 response, and led to only a 10-fold reduction in 
mycobacterial burden. The authors concluded that a secondary immune response to M. 
tuberculosis infection to be neither qualitatively nor quantitatively superior to the primary 
response. This inference, as a general conclusion, is questionable for several reasons: 
(i) This pessimistic conclusion was based on results from one trial that used only one 
mode of vaccination (dose, route, strain of M. tuberculosis and strain of mice). This 
group of investigators did not consider that the Th1/Th2 nature of the immune response 
can be affected by various variables, as discussed in section 2.8.3 of this thesis. 
 
(ii) As few as 1-3 bacilli can induce diseases in susceptible individuals. In their 
experiment, 100 cfu of a virulent strain of M. tuberculosis (H37Rv) was used as a vaccine 
to prime the mice. This dose, according to their previous work (North and Jung 2004), is 
equivalent to 105 M. tuberculosis given intravenously. This is a very high dose that may 
induce the undesired type of immune response, leading to chronic disease upon future 
challenge. Our studies on BALB/c mice using BCG show doses as low as 33 cfu can 
reliably induce cell-mediated response and a Th1 imprint; a dose of 105 cfu of BCG given 
iv is a critical dose above which responses with a substantial Th2 component are 
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generated, likely rendering the mice susceptible to a subsequent challenge with virulent 
M. tuberculosis. Besides, considering the high in vivo replication rate of virulent strains 
of M. tuberculosis as compared to non-virulent BCG (North and Izzo, 1993), the 100 cfu 
(equivalent to 105 cfu given i.v.) of M. tuberculosis used to vaccinate the mice will be 
several hundred folds higher at week 3 post-vaccination when the adaptive immune 
response starts to become apparent. This extremely high dose may not generate 
predominantly cell-mediated responses. Importantly, the authors did not look at the type 
of response generated after vaccination. If the immune response generated after the 
primary challenge (vaccination) was a mixed Th1/Th2 or predominantly Th2 response, 
the secondary response would not be expected to be any more protective than the primary 
response in a naive mouse upon high dose challenge. According to our results from BCG 
vaccination, we might even expect the secondary response to be worse than the response 
in the naïve mice, at least as far as a protective Th1 dominated response is concerned. 
 
(iii) As stated in point (ii) above, only a few bacilli of virulent M. tuberculosis are 
required to induce disease. The dose the authors used to challenge the mice (200 cfu) is 
arguably so high that any beneficial response induced by the vaccine (primary exposure) 
would have been minimal. In our studies, we observed that low dose BCG vaccination 
can induce predominantly cell-mediated response and hence Th1 imprint as assessed by a 
challenge of 2x106 cfu iv; however, this Th1 imprint was broken with a massive 
challenge of 108 cfu iv. Thus, Th1-imprints are not absolute and their stability depends 
upon the nature of the challenge. 
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(iv) The authors looked at the generation of Th1 cells and their production of cytokines 
both in the vaccinated and non-vaccinated mice after a virulent challenge, and reported a 
relatively rapid and heighten Th1 type response in the vaccinated group. This response 
was associated with a reduced (~10-fold) bacterial burden in the lung, and was a good 
indication of an effect of vaccination, even though not to the extent of their expectation. 
However, they did not consider the role of Th2 cells and their cytokines, which are very 
important, since cytokines from Th2 cells, as previously discussed, are reported to have a 
down-regulatory function on the effect of Th1 cells. While they might have dismissed the 
influence of Th2 cells and their cytokines based on their previous reports which conclude 
no negative influence of Th2 cells (Jung et al., 2002) or their cytokines (Jung et al., 2003) 
on the protective ability of Th1 cells against tuberculosis, unequivocally accepting this 
line of reasoning is difficult for various reasons. First, several reports both from mouse 
and human studies indicate the role of Th2 cytokines on the severity of tuberculosis 
infection (Hernandez-Pando et al., 1996; Baliko et al., 1998; Seah et al., 2000; van Crevel 
et al., 2000). Second, the study was carried out employing Th2 cell/cytokine gene knock 
out mice with a genetic background the authors characterized as an M. tuberculosis 
resistant phenotype. Deleting Th2 cells or their cytokines in resistant strains of mice may 
not further increase their resistance to infection with M. tuberculosis, but may affect the 
immune response to M. tuberculosis in susceptible mice. This deletion can considerably 
increase the generation of Th1 cells and hence increase the resistance of susceptible mice, 
provided that deletion of these genes does not have any other unwanted effect on the 
mouse. Ample evidence in the literature indicates that partial depletion of CD4+ cells or 
neutralization of their cytokines and/or blocking their cytokine receptors by treating with 
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appropriate monoclonal antibodies in the leishmania system can render susceptible mice 
resistant (see 5.4.1). Thus, the 10-fold decrease in bacterial burden demonstrated in their 
study and reports from human and cattle studies on the efficacy of BCG vaccination are 
reasons to be optimistic that vaccination against tuberculosis under optimal conditions 
can generate a protective response.  
 
In summary, type 1 cytokines, such as IFN-γ secreted mainly by CD4+ Th1 cells, are 
protective against mycobacterial infection, whereas type 2 cytokines, mainly IL-4, IL-10, 
secreted by Th2 cells, can dampen the anti-mycobacterial response. Our results and 
several other reports indicate that low doses and high doses of antigen can induce the 
generation of CD4+ T-cells producing these two groups of cytokines, respectively. In our 
studies, doses around the transition number (tn) were found to induce a mixed Th1/Th2 
response with an increasing bias towards the Th1 pole as the dose is lowered in all mouse 
strains tested. In some of our experiments mixed Th1/Th2 response with a bias towards 
the Th1 pole, generated following vaccination with BCG numbers close to the tn, was 
found to be more efficient than the Th2 biased response seen in naïve mice or mice 
vaccinated with doses much higher than the tn in clearing the bacteria from the spleen 
following high dose BCG iv challenge. This may seem to contradict our hypothesis that 
cytokines from Th2 cells may dampen the protective effect of Th1 cells. We argue 
against this for two possible reasons. Firstly, the mixed Th1/Th2 response observed in 
most of our experiments was biased towards Th1 pole with more IFN-γ than IL-4-
secreting cells in the spleen as well as more IgG2a than IgG1 antibodies in the serum. This 
might have contributed to the efficient clearance of BCG from the spleen, which was not 
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observed in mice with more Th2 biased response. Secondly, a mixed Th1/Th2 response 
may be better than predominantly Th2 response in controlling the replication of the non-
virulent BCG. However, this might not be true in controlling the virulent M. tuberculosis, 
and thus the protection against BCG challenge observed in mice with mixed Th1/Th2 
primary response may not work against challenges with virulent strains of mycobacteria.  
 
6.2. Source of Cytokines during BCG Infection 
Our results clearly show that the majority of the cytokines produced by BCG specific 
cells during BCG infection are secreted by Thy1.2+CD4+ cells. Our findings are in 
agreement with previous reports both from human and animal studies (section 2.6.2.1) 
that show depletion of CD4+ cells or their cytokines ultimately increases susceptibility to 
tuberculosis or increases the chances of reactivation disease from latent infection. Spleen 
cells depleted of Thy1.2+ or CD4+ cells secreted very little IFN-γ but still produce ~30% 
of the total IL-4 detected in ELISPOT assays (see Figure 30; Table 7). This could be due 
to the presence of cells that express Th1.2 (7.3%) and CD4 (10%) markers at very low 
levels even after depletion of cells expressing these markers (Figure 29). Therefore, cells 
that express low levels of Th1.2 and CD4 markers after depletion might be responsible 
for the presence of few IL-4 spots in Thy1.2 and CD4 depleted spleen cells. Furthermore, 
there is evidence in the literature that cells other than T-cells can also produce IL-4. For 
example, mast cells are capable of interacting with mycobacteria, whose secreted 
antigens can directly bind to CD48 (a mannose rich, GPI-anchored protein) on the lipid 
raft of the mast cells (Munoz et al., 2003). As a result of this interaction, mast cells 
respond by releasing the pre-stored mediators and de novo synthesized cytokines. This 
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may suggest mast cells are capable of secreting mycobacterial specific IL-4 that may play 
a role in the activation of BCG specific Th2 responses. However, as IL-4 is produced 
only in high dose BCG vaccinated mice in all our experiments, and since it could not be 
detected in the low dose vaccinated group or in normal mice, the possibility that IL-4 
could have been produced by mast cells in response to BCG antigen stimulation is 
remote. On the other hand, it is also possible that high dose of BCG induces the 
production of very low level of BCG-specific IgE antibody, which in turn induces mast 
cell de-granulation and release of IL-4 from mast cells contributing to the presence of IL-
4-secreting cells in the Th1.2 and CD4 depleted population.  
 
The mechanism by which Th1 cells constitute protective immunity against tuberculosis 
infection is believed to be related to their ability to secrete high level of IFN-γ, which in 
turn activates macrophages to secrete reactive oxygen and nitrogen intermediates that 
destroy or inhibit multiplication of mycobacteria in the animal body. Reactive nitrogen 
intermediates (RNI) - nitrite (NO2-) and nitrate (NO3-) - are the most potent anti-microbial 
compounds. Measuring the level of total nitric oxide (NO) produced upon stimulation 
with BCG antigens of spleen cells obtained from mice vaccinated with high and low dose 
of BCG could be informative, as low dose BCG primed cells might produce more NO 
than cells from high dose primed mice. To this end, mouse peritoneal macrophages were 
cultured with nylon wool purified T-cells from low and high dose BCG vaccinated mice 
and the level of NO measured using the Griess reaction as described previously (Stuehr 
and Marletta, 1987; Ding et al., 1988). Despite repeated experiments, our findings were 
not conclusive and thus not included in this thesis.  
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6.3. Environmental Mycobacterium can interfere with the 
Protective Efficacy of BCG Vaccination  
 
BCG vaccination in humans is usually given neonatally within a few days of birth. A 
logical reason for this could be to minimize the effect of priming by environmental 
mycobacteria, which might prevent Th1 imprinting by causing a mixed Th1/Th2 or Th2 
imprint. There are reports in the literature claiming that neonates can be easily primed by 
environmental mycobacteria in the first few weeks of their life and that this pre-
sensitization can induce an immune response, which either masks or interferes with the 
efficacy of BCG vaccination (Palmer and Long, 1966; Edwards et al., 1982). Evidence 
supporting this explanation has been recently reported in human studies, in which BCG 
vaccination in PPD positive adults resulted in a very low BCG specific IFN-γ production 
(Black et al., 2001). Similar results were also reported from cattle, where calves which 
were PPD test positive before vaccination with BCG were found to be less protected than 
the PPD negative counterparts when challenged with virulent M. bovis (Buddle et al., 
2002). Our findings that mice pre-sensitized with a high dose of cross-reacting 
environmental bacilli, M. gordonea, were resistant to Th1 imprinting by low dose BCG 
vaccination as assessed by a subsequent high dose BCG challenge, support these prior 
observations. The exact mechanism of interference is not well understood, but it could be 
due to either: (i) inappropriate bias of the immune response as a result of priming by a 
high dose of the environmental mycobacterium, leading to the generation of Th2 or 
mixed Th1/Th2 type response upon BCG vaccination (Hernandez-Pando et al., 1997); or 
(ii) cross-reactive immune responses to BCG generated after exposure to the 
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environmental mycobacteria, which interferes with the replication of the BCG vaccine. 
Rapid clearance of BCG due to this cross-reacting immune response could inhibit the 
generation of protective immune response and memory T-cells against a subsequent 
infection with M. tuberculosis (Brandt et al., 2002). Therefore, in both cases, vaccination 
may not have any beneficial effect. The generation of the non-protective type response 
following exposure to environmental mycobacteria can inhibit the generation of 
protective immunity upon BCG vaccination by swaying the response to BCG into a Th2 
or mixed Th1/Th2 mode, and the protective/Th1-type response can be too weak to 
prevent infection by a virulent strain of M. tuberculosis yet strong enough to block 
replication of the BCG vaccine before it induces any sort of immune response. Our 
results make it plausible that neonatal imprinting can minimize undesirable Th2 
imprinting by environmental mycobacteria. It is, therefore, imperative to consider the age 
at which vaccination is carried out, in addition to the dose of the antigen, in order to 
minimize the interfering effect of environmental mycobacteria on a potential effective 
strategy of vaccination. Findings in calves (Hope et al., 2005) and newborn humans 
(Vekemans et al., 2001) support our proposition that neonatal vaccination with BCG is 
able to induce a high level of IFN-γ and low level of IL-4, signifying Th1 and Th2 type 
responses, respectively. High efficacy of BCG vaccination (as high as 83%) in children 
against the most severe forms of tuberculosis, particularly TB meningitis and 
disseminated tuberculosis, is reported from a meta-analysis of data coming from several 
vaccination trials (Colditz et al., 1995). Such high efficacies may be partly explained by 
the fact that BCG was usually administered neonatally, before exposure of the host to 
environmental mycobacteria. The high efficacy of BCG vaccination against TB 
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meningitis and military tuberculosis could be also explained based on fact that these two 
forms of tuberculosis are usually associated with highly polarized Th2 type responses, 
and the mixed Th1/Th2 response induced by the standard dose of BCG vaccine may be 
effective in protecting against diseases due to Th2 response but not against pulmonary 
tuberculosis, which is associated with a mixed Th1/Th2 type response.  
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7. Conclusion 
One of the success stories of medicine in the last century is the development of effective 
vaccines against acute bacterial and viral infections that can induce rapid and heightened 
immunity upon exposure of the host to natural infection. However, there is no universally 
efficacious vaccination strategy against chronic diseases caused by slow growing 
intracellular pathogens such as mycobacteria, responsible for leprosy and tuberculosis. In 
this thesis, I have tried to identify and address four issues/problems, which I believe are 
impediments in the effort to develop a universally efficacious vaccination strategy against 
these chronic intracellular pathogens in general and M. tuberculosis in particular.  
 
First and foremost, identification of the immune correlates of protection is a pre-requisite 
in any effort to develop an effective vaccine against a given pathogen. Even though we 
could not conduct the envisaged M. tuberculosis challenge experiments for logistical 
reasons, our findings in both very young and adult mice from BCG vaccination and 
challenge studies have shown that protection is correlated with a predominantly cell-
mediated, Th1-type, response. The second problem is how to guarantee Th1-type 
response upon natural infection of the host by M. tuberculosis? The results presented in 
this thesis clearly demonstrate that vaccination dose is an important factor that determines 
the Th1/Th2 nature of the immune response to BCG. Relatively low doses always induce 
Th1-type responses and Th1 imprints that can efficiently clear BCG from the spleen of 
mice as assessed by high dose BCG iv challenge. Thirdly, our experiments in different 
strains of mice illustrate that an ultra-low dose of BCG vaccine can be employed to 
induce a Th1-type response in all individuals of a genetically divers population, 
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addressing the problem of finding a standard vaccination protocol in humans and 
animals, which are genetically heterogeneous. Finally, we have shown that neonatal BCG 
vaccination can overcome the problem of immune interference to BCG vaccine due to 
pre-exposure of the host to environmental mycobacteria. Our hope is that the models 
reported here for BCG induced Th1-imprinting will allow us to examine in the future 
whether Th1-imprinting is effective in modulating responses against the virulent species 
of mycobacteria, and to determine whether this strategy of vaccination will protect mice 
against infections with virulent M. tuberculosis. Our observations on mycobacterial 
burden assessment strongly support the notion that BCG is best contained by a Th1 
response and not by a Th2 biased mixed Th1/Th2 response or predominant Th2 
responses, and that in all cases relatively lower doses of BCG vaccine generate the most 
effective response against a subsequent BCG challenge. Whether similar findings would 
have been made if the challenges were with virulent species of mycobacteria is not clear. 
As discussed elsewhere in this thesis, studies in cattle and deer support the suggestion 
that low dose but not high dose BCG vaccination can protect against tuberculosis caused 
by virulent M. bovis. These studies give reason for optimism that a low dose BCG 
vaccination strategy might contribute towards the global effort of preventing tuberculosis 
in man. Some might argue against this optimistic vision due to the genetic difference 
between M. tuberculosis and BCG that may compromise the efficacy of BCG vaccination 
against infections with virulent strains of mycobacteria. Two options may solve this 
problem: (i) developing a new attenuated vaccine from M. tuberculosis by deleting some 
of the genes responsible for its virulence, or (ii) using the immunodominant antigens or 
DNA that encodes these proteins as subunit vaccines. However, the usefulness and 
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practicality of both these options is questionable, for the following reasons: (i) Investing 
in the development of a vaccine by attenuating the virulent strains of M. tuberculosis may 
not be prudent as the safety in immunocopromised individuals will be questionable; and 
(ii) The subunit vaccines need an adjuvant safe for human use that can guarantee a Th1 
type response. The only adjuvant licensed for human use is alum, which favors the 
generation of Th2 responses. Furthermore, the efficacies of subunit vaccines have not 
been found to be better than BCG, as discussed previously.  
 
Therefore, I believe that the best option to control infection by virulent species of 
mycobacteria is low dose BCG vaccination. If necessary, its efficacy and durability of 
protection can be improved by expression of the genes missing from BCG and by the use 
of a prime-boost vaccination protocol, respectively. Also worth considering in the search 
for effective control against tuberculosis is the development of immunotherapeutic 
vaccines that can prevent the progression into active disease in the >2 billion people 
already infected with tuberculosis. The use of proteins expressed by M. tuberculosis 
strains during the chronic phase of infection as candidate antigens in the development of 
therapeutic (post-exposure) vaccine is a promising area of research to prevent 
reactivation disease in individuals with latent tuberculosis infection. One study estimates 
a post-exposure vaccine with 50% efficacy could reduce the global burden of tuberculosis 
by up to 25% in 15 years (Lietman and Blower, 2000). In summary, we recommend 
vaccination of neonates with low doses of BCG, as low as 103 cfu in humans and 104 cfu 
in cattle, to induce an exclusive cell-mediated response and a Th1 imprint that can 
guarantee protection against natural infection with virulent mycobacteria. Vaccination of 
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human neonates with low dose of BCG vaccine followed by booster immunization with 
recombinant post-exposure vaccine can most likely substantially reduce the burden of 
tuberculosis in developing countries by preventing both primary childhood tuberculosis 
and pulmonary tuberculosis in adults, as well as preventing reactivation tuberculosis in 
immuno-compromised individuals who are already latently infected with M. tuberculosis. 
Therefore, since vaccine failure could be due to the way in which the vaccine is used 
rather than any inherent deficiency of the vaccine per se, improving protocols for BCG 
administration should be further explored before replacing BCG with a new-generation 
vaccine.  
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